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Chapter 1
General Introduction
Partly published as: 
Alexandra W.C. Einerhand, Ingrid B. Renes, Mireille K. Makkink, Maria van der Sluis, 
Hans A. Büller and Jan Dekker. Role of mucins in inflammatory bowel diseases: 
important lessons from experimental models. 
European Journal of Gastroenterology & Hepatology, Vol 14 (6); 1-8, 2002.
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Abbreviations used in this paper
CD, Crohn’s disease; HNF, hepatocyte nuclear factor; IBD, inflammatory bowel disease; 
IL, interleukin; MUC, Mucin; NF-κB, nuclear factor kappa B; STAT, signal transducers and 
activators of transcription; Tff3, trefoil factor 3; TNF-α, tumor necrosis factor alpha; TGF-β, 
transforming growth factor beta; UC, ulcerative colitis; vWF, von-Willebrand-factor 
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The intestinal tract
The small intestine is the major organ for the absorption of nutrients and also 
secretes enzymes to complete the digestive processes started in the stomach1-5. A 30-
50% loss (remaining length, <75 cm in children and <200 cm in adults) often leads to 
malabsorption, with resultant severe diarrhea, dehydration, electrolyte imbalances, 
nutrient deficiencies and weight loss6, 7. The small intestine from proximal to distal 
is divided into the duodenum, jejunum, and ileum. The lining of the small intestine 
is a single-layered epithelium. It covers the surface area of the villi that project into 
the lumen, and lines the crypts that descend into the underlying connective tissue. 
Dividing stem cells lie protected in the depth of the crypts. These stem cells generate 
four types of differentiated progeny: (i) enterocytes, with densely packed microvilli 
on their surfaces to increase their active area, are absorptive in function2; (ii) goblet 
cells, secreting the mucin Muc28-11 and peptides such as trefoil factor 3 (Tff3)12, both 
products which serve protective roles in the gut; (iii) Paneth cells, involved in the 
innate defense system by secreting cryptdins, proteins of the defensin family that 
kill bacteria13-15, and (iv) enteroendocrine cells, producing peptide hormones that act 
on neurons and other cell types in the gut wall and regulate growth, proliferation 
and digestive activities of cells of the gut and other tissues2, 6, 16. All of these cells 
stem from undifferentiated multipotent stem cells located near the bottoms of the 
crypts, above the Paneth cells (Fig. 1A). These multipotent stem cells cannot be 
conclusively identified as they can produce all cell types within the epithelium. The 
regulatory mechanism behind lineage specification has not yet been fully elucidated 
as it is complex and specific markers are lacking17. The large intestine, or colon, joins 
the small intestine at the ileum via a T-shaped junction. 
Figure 1. Cell types and structure of the intestine. Haematoxylin and Eosin staining and schematic 
representation, respectively of (A) the small intestine3 and (B) colon. The colonic epithelium is 
organized into crypts and surface cuffs instead of villi and is composed of the same cell types as the 
small intestine, with the exception of Paneth cells. 
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One short arm of the T is a blind-ended pouch called the cecum. The colonic 
epithelium is organized into crypts and surface cuffs instead of villi and is composed 
of the same cell types as the small intestine, with the exception of Paneth cells (Fig. 
1B). Small intestinal enterocytes are specialized in enzymatic digestion, absorption 
and transportation of dietary nutrients3-5. Colonic enterocytes are specialized in 
electrolyte and water absorption18-20. Furthermore, enterocytes of both the small 
intestine and colon are involved in the epithelial defense through expression of 
alkaline phosphatase, which acts as an antimicrobial peptide21, 22. The epithelium and 
mucus layer in the intestinal tract form a physical barrier protecting the underlying 
tissues from potentially toxic and noxious agents. Goblet cells exert a vital protective 
role by secreting molecules such as mucins and trefoil factors. Mucins are the 
building blocks of the mucus layer. Previous studies have shown that human, rat 
and mouse colonic epithelium share the characteristic of expressing mainly one 
secretory mucin in high amounts, i.e. MUC28-11. Stored in bulky apical granules of 
the goblet cells, Muc2 is crucial to goblet cell morphology23. Tff3 is another protein 
expressed by goblet cells in the intestine and plays an essential role in intestinal 
mucosa maintenance and repair12.
Mucins
Many organ systems, including the eyes, gastrointestinal tract, trachea, 
lungs, bladder, pancreatic duct, gallbladder and the reproductive tracts, protect 
their epithelium by producing mucins24. The mucosal surface throughout the 
gastrointestinal tract must resist aggressive elements from the external environment 
present in the diet and encountered during normal function. Mainly composed of 
secretory gel-forming mucin, more specifically MUC2, mucus in the intestine forms 
a semi-permeable barrier between the intestinal lumen and the underlying mucosal 
surface24.
Functionally, MUC-type mucins can be classified into: i) secretory, gel-forming 
mucins, ii) membrane-bound mucins, and iii) small soluble mucins.
Ad. i. Secretory, gel-forming mucins are widely acknowledged as important 
players in gastrointestinal epithelium defense, and are produced in specialized 
mucous cells of glandular tissues and goblet cells in the gastrointestinal tract24-27. 
These mucins are produced as disulfide-linked oligomers28, which proves essential 
for their ability to form viscoelastic mucus-gels. The four members to this group, 
MUC2, -5AC, -5B, and -6, have been well characterized29, 30. In the healthy human 
intestine, MUC2 is the predominant mucin produced by all goblet cells, and MUC5B is 
expressed in minor quantities in a subset of goblet cells in the lower colonic crypts 26, 
27, 31. MUC5AC and MUC6 are normally confined to gastric epithelium32, 33.
Ad. ii. The membrane-bound mucins are involved in epithelial cell-signaling, 
adhesion, growth, and modulation of the immune system25, 34-38, and may have a role 
in cellular behavior – i.e. during proliferation and differentiation – as reviewed by 
Hollingsworth and Swanson39. These mucins are made in serous glands or epithelial 
cells, like enterocytes37, 40. MUC1, MUC3A, MUC3B, MUC4 have been extensively 
studied41-43. Membrane-bound mucins can be released from cells in soluble form, when 
the transmembrane domain has been removed by either proteolysis or alternative 
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splicing44-47. However, they are not exclusively restricted to the cellular membrane. 
Muc3 and Muc4 are both expressed by the secretory granules of the goblet cells in 
the intestine48-50. Furthermore, Rong et al. recently reported that Muc4 in the colon 
is predominantly expressed by the goblet cells in both rats and humans and that the 
soluble form of Muc4 prevails49. 
Ad. iii. So far only one small soluble human mucin has been identified (MUC7), 
which is found in saliva51. 
Many of the known human mucin genes have been grouped into the MUC 
gene family. So far, seven Muc-type genes have been identified in the mouse 
(Table I), and these were named after their human orthologues as Muc1, -2, -3, 
-4, -5ac, -5b and 652-59. Members of the membrane-bound mucins (Muc1, -3, and 
-4) as well as of the secretory, gel-forming mucins (Muc2, -5ac, -5b and 6, which 
are clustered on mouse chromosome 7) have been identified, indicating that the 
mucosal defense and other functions of the mucins are preserved both among man 
and rodent. Recent research, however, indicates that the current mouse orthologue 
of the human MUC3 may still go undiscovered. Extensive characterization of the 
membrane-bound mucin MUC17 has revealed that its carboxyl-terminal sequence 
resembles both rat and mouse Muc3 more than any other known human protein60, 61. 
Because of the high degree of similarity between the two proteins, and their identical 
genomic organization, it has been suggested that rodent Muc3 should be referred to 
as rat/mouse Muc1761. Other genes have been assigned to the MUC family (MUC8, 
-11/12, -13, -16, -18, -19 and -20)62-69. Some of these (MUC-11/12, -13, and -16) are 
expressed in the intestine, but so far their characterization is limited63, 64, 70. 
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Peptide structure of mucins
Biochemically, mucins are usually very large, filamentous molecules. Mucin 
proteins each contain unique variable number of tandem repeats, with regions rich 
in serine, threonine and proline71. Linkage of carbohydrate side chains through O-
glycosidic bonds to serine and threonine means that these are the major sites of 
glycosylation in the mucins24, 40. The O-linked carbohydrates form up to 80% of the 
molecular weight of the mucins. These very numerous, yet relatively short carbohydrate 
chains (2-20 monosaccharides), are tightly packed along the polypeptide and are 
responsible for the overall filamentous structure of mucins. The oligosaccharides 
make the large central region of the mucin backbone highly resistant to breakdown 
by proteolyic enzymes24. The C- and N- terminal regions of the mucin are much 
less glycosylated, which renders them susceptible to degradation by proteases. 
The addition of very large numbers of sulfate and sialic acid residues to the O-
linked carbohydrates gives the mucins a highly negative surface charge. Figure 2 
shows a cartoon representing the most predominant mucin in the colon and colonic 
mucus layer, MUC28-11. In the secretory mucins Muc2, Muc5ac and Muc5b, the Von 
Willebrand factor (VWF) domains (C and D types), located in the C- and N-terminus, 
respectively, are responsible for dimerization and oligomerization71. In contrast to the 
other secretory mucins, Muc6 lacks VWF-type C domains in its C-terminus. A review 
by Dekker et al.71 gives an elaborate description on mucin sequences, composition 
and similarities. 
Mucins in disease: Inflammatory bowel disease 
The two forms of chronic human inflammatory bowel disease (IBD), Crohn’s 
disease (CD) and ulcerative colitis (UC), are primarily characterized by chronic 
inflammation of segments of the gastrointestinal tract. Active inflammation will 
alternate with remission periods. Both are complex diseases believed to result from 
the interplay of multiple environmental and genetic factors involving: i) the immune 
system, ii) microbial factors, and iii) the intestinal epithelial barrier.   
Mucins, as the primary constituents of extra cellular mucus and the cellular 
barrier, are intimately associated with each of these three possible etiological factors. 
Mucins are important epithelial products of the intestine, essential for a proper 
Figure 2. Schematic representation of the mucin MUC2. The schematic representation of MUC2 
was already published by Dekker et al71.
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epithelial barrier function. Moreover, mucins are crucial in the contacts between many 
microorganisms and the intestinal mucosa. Therefore a primary defect in mucins could 
breach the epithelial barrier or lead to altered mucosal-bacterial interactions. Alterations 
in mucin synthesis, maturation, secretion, and/or degradation are generally thought to 
be involved in the initiation or perpetuation of IBD symptoms70, 72, 73. These quantitative 
and/or qualitative alterations in mucin synthesis may be related to mutations within 
mucin genes or to changes in immunological or microbial factors that influence mucin 
expression or mucus layer maintenance. 
In active UC, numbers of goblet cells are reduced and the mucus layer is 
thinner74. In remission periods, numbers of goblet cells return to normal75, 76. 
Furthermore, MUC2 synthesis, secretion and sulfation is decreased in active UC77-
79. Normally, colonic mucins are highly sulfated, and considered to be more resistant 
to bacterial degradation in this state. A colonic mucus layer composed of less sulfated 
mucins is deemed less protective, and was found closely associated with IBD in 
humans31, 79-84. Furthermore, changes in glycosylation of mucins were found in UC75, 
85, and fecal anaerobic bacteria were found able to degrade mucus by producing 
extracellular glycosidases in vitro86, 87. Thus, MUC2, as the prominent secretory mucin 
in the intestine produced by goblet cells, seems to play a key role in maintenance of 
the mucus layer by protecting the epithelium against bacteria, bacterial products and 
other luminal substances; in patients with IBD, however, this mucin seems to exert 
less protective capacities. 
Immunological influence on mucins
Several rodent models of colitis were recently developed in which chronic 
intestinal inflammation occurs as a consequence of alterations in the immune system, 
leading to failure of normal immuno-regulation in the intestine88. These animal models 
are very suitable for identifying the effects of the immune system on mucin expression. 
One is the interleukin (IL)-10 deficient (IL10-/-) mouse89-91, which spontaneously 
develops chronic colitis when maintained in conventional conditions. Colitis severity 
in these mice depends on both strain background and environmental factors92, 93. 
Upon introduction of normal enteric bacteria, IL10-/- mice rapidly develop symptoms of 
colitis as evidenced by infiltration of immune cells and induction of pro-inflammatory 
mediators such as IL1294. 
Mucins and intestinal metabolism
 Integrity of the mucus layer depends on the nutritional status of the intestine. 
For example, malnutrition and starvation will alter the mucus layer by decreasing 
intestinal mucin synthesis95, 96. In addition, the intestine of piglets utilizes between 
80-90% of dietary threonine, mainly due to threonine incorporation into mucosal 
proteins97. Interestingly, additional data demonstrated a 60% reduction in whole-body 
threonine requirements in piglets receiving total parenteral nutrition, compared to 
orally fed control animals98. In this context, the intestinal demand for dietary threonine 
probably arises from incorporation of threonine into secretory mucins, mainly Muc2, 
which are rich in threonine residues. Further support for this hypothesis is a study by 
Faure et al.98 showing that dietary restriction of the essential amino acid threonine 
impairs intestinal mucin synthesis. 
C
h
ap
te
r 
1
16
Regulation of mucin expression
Mucin production and secretion by specialized epithelial cells is a common 
mechanism for mammals to protect and maintain normal cell homeostasis, as 
reviewed by Van Seuningen et al.99. The expression of mucin genes is cell- and tissue 
specific, yet subject to variations during cell differentiation, inflammatory processes 
and carcinogenesis. In addition, in vitro experiments with intestinal cell lines showed 
that bacteria and bacterial components may influence the expression of mucins99-103. 
Mucin gene transcription is subject to dynamic pathways involving multiple receptors 
and transcription factors99. There are two broad classes of regulatory transcription 
factors, as reviewed by Brivanlou et al.104. One of these, the developmental 
transcription factors, are not strictly cell-, tissue-, or region-specific. Arrangement 
of groups of these factors, in different cell types, helps direct cell determination 
(choice of cell fate) and differentiation (synthesis of cell-type specific proteins). The 
second class comprises the signal dependent transcription factors. These proteins 
may be either developmentally restricted in their expression pattern or are present 
in cells, but are inactive (or minimally active) until cells containing such proteins are 
exposed to the appropriate intracellular or extracellular signals. These signals can 
be mediated and influenced by a variety of molecules (i.e. hormones, cytokines) and 
external factors (i.e. bacteria).
Developmental transcription factors
 Intestinal development proceeds through orchestrated cell growth, 
differentiation, migration, interactions and apoptosis. Cdx, GATA and hepatocyte 
nuclear factor (HNF) are all transcription factors from different families, which play a 
key role in development and cell differentiation in the intestine. They are expressed 
in embryonic endoderm, the germ layer that gives rise to the digestive system, and 
in the adult intestine105-108. Intestine-specific gene expression, such as intestinal 
lactase-phlorizin hydrolase and sucrase isomaltase expression, is controlled at the 
transcriptional level and relies on the activity of multiple tissue-enriched transcription 
factors like Cdx-1/-2, HNF-1/-3 and GATA-4/-5/-6109-114. Interestingly, only Cdx2 has 
been identified as a regulator of goblet cell-specific Muc2 gene expression115, 116. 
The role of GATA or HNF transcription factors in mucus production, and thus in 
maintenance of a defense line and protective barrier in intestinal pathophysiology70, 
remains to be investigated. Evidence in favor of a regulatory role for these factors on 
Muc2 gene expression, is that during embryonic development GATA-4/-5/-6, HNF-
3α and HNF-3β mRNA are expressed in the primitive intestine in which Muc2 is also 
found106, 107, 117-122. Moreover, further computer analysis of the murine Muc2 promoter 
sequence123 indicates the presence of several putative HNF binding sites throughout 
the promoter region. 
Signal dependent transcription factors 
 General homeostasis of cells is determined by a broad spectrum of 
intracellular or extra cellular signals. Widely diverse factors – for example hormones, 
cell-cell interactions, bacteria and cytokines – can govern these signaling pathways. 
To add to the complexity, there is correlation and cross-talk between these individual 
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factors99, 104. Major pathways involve signaling via the nuclear factor kappa B (NF-κB) 
family, the Smad family and the signal transducers and activators of transcription 
(STAT) family of transcription factors104. Activation of the NF-κB family of transcription 
factors is influenced by many extracellular factors including tumor necrosis factor 
alpha (TNF-α), IL-1 and bacterial products. The Smad transcription factors are 
activated by ligands of the transforming growth factor beta (TGF-β) super family 
and the STAT signaling pathway is activated by a large number of ligands including 
cytokines (i.e. interferon gamma), growth factors and charged small molecules104. 
 There are various direct and indirect indications that synthesis and secretion 
of secretory mucins can be regulated by immune factors103, 124-128. Epithelial cell line 
studies showed that pro-inflammatory cytokines like TNF-α, IL-1β and IL-13 also 
induce gene expression of the secretory mucins Muc2 and Muc5ac126, 129-131. Likewise, 
lipopolysaccharide (LPS, a cell wall component of Gram-negative bacteria), which is 
potentially toxic for cells, and different species of bacteria generally used as probiotic 
treatment, are also able to up-regulate Muc2 and Muc5ac mucin gene expression 
in different epithelial cell lines132-135. In addition, IL-10 has been shown to induce 
Muc2 synthesis136, maybe indirectly by producing IL-13, in addition to facilitating 
TGF-β production137. In diverse epithelial cell lines, TFG-β in turn was found to induce 
Muc2 transcription via Smad signaling pathways127. All this implicates a general 
mechanism in improvement and maintenance of the protective mucus barrier in 
intestinal pathophysiology. 
Aim and outline of this thesis
 If we were to better understand the function and regulation of mucin genes 
in the intestine, we could identify future potential therapeutic targets in epithelial 
diseases. Therefore, the major aims of this thesis are:
1. To investigate the influence of changes in mucus production, more 
 specifically Muc2, on the intestinal protective barrier function and elementary 
 intestinal physiology. 
2. To gain insight into the complex transcription regulatory mechanisms of the 
 secretory mucins Muc2 and Muc5ac. 
Part I  Role of mucins in the intestine  
 The first part of this thesis explores the function of mucins, more specifically 
Muc2, in the intestine. As mentioned earlier, bacteria can influence mucin expression. 
In order to elucidate the influence of commensal enteric bacteria on Muc2 synthesis, 
secretion and sulfation and the role of Muc2 in the pathogenesis of chronic colitis, 
we first studied how the introduction of specified pathogen free commensal 
bacteria in germ free IL-10 deficient mice affected Muc2 synthesis (Chapter 2). We 
subsequently addressed the importance of Muc2 in epithelial protection. Thereto, 
Muc2 deficient mice were characterized, and challenged luminally with dextran 
sulfate sodium as a means to provide insight into the protective capacities of Muc2 
(Chapter 3). Thus, considering that the severity of chronic intestinal inflammation 
may be governed by environmental, immunoregulatory, and epithelial factors, we 
investigated the protective capacities of Muc2 and IL-10 in the intestine. To this aim 
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we created Muc2/IL10 double knockout (Muc2/IL10DKO) mice and determined whether 
combined defects in the immunoregulatory and epithelial factors could exacerbate 
the pathogenesis of inflammation (Chapter 4). These studies indicated that Muc2 
has protective capacities in the intestine, which led us to evaluate the role of Muc2 in 
epithelial protection during serosal challenging conditions (Chapter 5). Then, integrity 
of the mucus layer has been associated with nutritional status. Therefore, we also 
investigated mucin involvement in intestinal metabolism. As threonine is an essential 
amino acid we determined threonine utilization by the intestine of Muc2 deficient 
and wild type mice so as to gain insight into the elementary intestinal physiology 
(Chapter 6).
Part II Regulation of mucin gene expression
 As described above, mucin gene expression is subject to complex regulatory 
mechanisms influenced by developmental and signal dependent transcription factors. 
Therefore, the second part of thesis focuses on the signal transduction pathways 
involved in the regulation of intestinal mucin expression. To this aim we assessed the 
transcriptional regulation of the two secretory mucin genes, Muc2 and Muc5ac. We 
focused on transcription factors involved in intestinal development, more specifically 
GATA-4/-5/-6 and HNF-3α/-3β, as these factors are expressed in the primitive 
intestine in which Muc2 is also found (Chapter 7 and Chapter 8, respectively). 
Furthermore, mucin gene transcription was shown to be influenced by a broad range 
of cytokines. Analysis of the Muc5ac promoter showed a high density of binding 
sites for factors essential for TGF-β signaling. Muc5ac is aberrantly expressed in 
rectosigmoid villous adenomas and TGF-β was shown to be involved in gastritis and 
gastric cancer. This led us to study Muc5ac regulation by TGF-β (Chapter 9). 
This thesis concludes with a summarizing general discussion in which 
insights obtained from the different studies are combined and future perspectives 
are discussed (Chapter 10).
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Abstract
Germ-free (GF) interleukin 10 deficient (IL10-/-) mice develop chronic colitis after colonization 
by normal enteric bacteria. Mucin 2 (Muc2) is the major structural component of the protective 
colonic mucus. Our aim was to determine if primary or induced aberrations in Muc2 synthesis 
occur in GF IL10-/- mice that develop colitis after bacterial colonization. GF IL10-/- and wild type 
(WT) mice were colonized with commensal bacteria for various intervals up to 6 weeks. Colitis 
was quantified by histological score and IL-12 secretion. Muc2 synthesis, total level of Muc2, 
and Muc2 sulfation were measured quantitatively. GF IL10-/- mice showed 10-fold lower Muc2 
synthesis and Muc2 levels compared to GF WT mice, but Muc2 sulfation was not different. 
When bacteria were introduced, IL10-/- mice developed colitis, whereas WT mice remained 
healthy. Muc2 synthesis was unchanged in WT, but IL10-/- mice showed a peak increase in 
Muc2 synthesis 1 week after bacterial introduction, returning to baseline levels after 2 weeks. 
Total Muc2 levels decreased 2-fold in WT mice, but remained at stable low levels in IL10-
/- mice. Upon introducing bacteria, Muc2 sulfation increased 2-fold in WT mice, whereas in 
IL10-/- mice Muc2 sulfation decreased 10-fold. Conclusions: A primary defect in colonic Muc2 
synthesis is present in IL10-/- mice, whereas bacterial colonization and colitis in these mice 
led to reduced Muc2 sulfation. These quantitative and structural aberrations in Muc2 in IL10-/- 
mice likely reduce the ability of their mucosa to cope with non-pathogenic commensal bacteria 
and may contribute to their susceptibility to develop colitis.
Abbreviations used in this paper
GF, germ-free; IBD, inflammatory bowel disease; IL, interleukin; MUC, Mucin; Tff3, trefoil 
factor 3; SPF, specific pathogen free; WT, wild type 
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Introduction
Secretory mucins play cytoprotective roles by forming a protective mucus layer 
covering the underlying epithelium in the gastrointestinal tract1, 2. The large intestinal 
epithelium confronts a particularly hostile environment, containing very large amounts 
of predominantly anaerobic bacteria of many species. Breaching the protective 
epithelial barrier can lead to a chronic cycle of inflammation that progressively 
damages the epithelial barrier function, thereby initiating a self-perpetuating 
inflammatory process3. Many gastrointestinal diseases, particularly the chronic 
inflammatory bowel diseases (IBD), show escalation of mucosal inflammation due 
to transient or sustained damage to the epithelium4-6. Inflammation may flare despite 
immunosuppressive therapies. The causes of these exacerbations are generally not 
understood, and are most likely multifactorial, including genetic and environmental 
factors. However, accumulating evidence implicates commensal enteric bacteria 
in playing an important role in the initiation and perpetuation of chronic, immune-
mediated intestinal inflammation3, 7, 8. The most compelling evidence for a role for 
bacteria in the pathogenesis of intestinal inflammation comes from rodent models 
of IBD, in which both the host genetics and the micro-ecology can be precisely 
manipulated9, 10.
We have demonstrated previously that the human colonic epithelium expresses 
one secretory mucin in very high amounts: Mucin2 (MUC2). Importantly, we also have 
shown that in patients with ulcerative colitis the activity of the mucosal inflammation 
correlates significantly with a decrease in MUC2 synthesis and MUC2 secretion11-
13. Adjacent to ileal ulcers in Crohn’s disease MUC2 is absent and MUC5AC and 
MUC6 are induced14. Pullan and coworkers demonstrated that the mucus gel of the 
colon was significantly thinner during active inflammation implying that the thickness 
of the mucus gel is affected by IBD or perhaps contributes to the pathogenesis of 
inflammation15. Also the mucus layer of IBD patients is more easily penetrated and 
colonized by enteric bacteria16, 17. These results in human colonic tissue suggest that 
MUC2 plays an important role in colonic cytoprotection, but the limited availability of 
tissues during early stages of disease and the lack of information on the early, sub-
clinical stages of disease hamper further studies. There are however many colitis 
models in the mouse that are well suited to test the susceptibility of the colonic 
epithelium to luminal substances9, 18.
In this study we used a genetically engineered mouse strain deficient for 
interleukin 10 (IL-10), which constitutes a well-accepted model for human IBD4, 19, 
20. These mice develop Th1-mediated chronic colitis when housed under specific 
pathogen free (SPF) conditions, but under germ-free (GF, completely sterile) 
conditions these mice develop no signs of inflammation 21. Adult GF IL10-/- mice 
develop mild colonic inflammation within 1 week after colonization with specific 
pathogen free enteric bacteria; this colitis progresses to severe intensity by 5 
weeks of bacterial colonization21. Wild type (WT) mice, which were born and raised 
under GF conditions, do not develop colitis upon introduction of commensal enteric 
bacteria under SPF conditions21. These, and a wealth of similar data, indicate that 
the presence of bacteria in the colon is a prerequisite for the development of chronic, 
immune-mediated colitis in a genetically susceptible host3, 22-25.
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Previously, we established that Muc2 is the dominant colonic secretory mucin 
in mice26, 27 similar to humans and rats28, 29. To reveal the influence of commensal 
enteric bacteria on Muc2 synthesis, secretion and sulfation and the possible role of 
Muc2 in the pathogenesis of chronic colitis, we studied the effects of the introduction 
of SPF commensal bacteria in GF IL10-/- mice on mucin biosynthesis at different 
times after bacterial exposure. Following previously established procedures for 
measuring Muc2 levels in human, rat and murine tissues12, 13, 26, we quantified Muc2 
synthesis, total Muc2, Muc2 sulfation, Muc2 mRNA, and secretion of Muc2 in the 
colonic tissues of these mice.
First, we documented that no congenital differences existed in the Muc2 levels 
between 129 SvEv SPF WT mice, the genetic background of the IL10-/- mice, and 
the BALB/c WT mice. Having established that there were no significant differences 
between the various parameters of Muc2 synthesis among these two mice strains, 
we determined the levels of Muc2 in GF IL10-/- and GF WT mice. Thus, we were 
able to study any differences in Muc2 levels related to the lack of endogenous IL-
10 that could pre-dispose to epithelial and/or mucosal damage upon introduction of 
commensal bacteria. After colonization with SPF enteric bacteria for variable times, 
we correlated changes in Muc2 in the IL10-/- and WT mice with the development 
of colonic inflammation. Thus, we were able to detect changes in synthesis or 
sulfation of Muc2 that were induced by bacterial colonization or by inflammation. 
We established that aberrant levels in Muc2 occurred in IL10-/- mice during both 
the GF and SPF states and suggest that these abnormalities may contribute to the 
development of colitis in IL10-/- mice.
Materials and Methods
Animals
Animals used in this study were 12-16 weeks-old 129 SvEv mice carrying 
a homozygous null-mutation of the IL-10 gene, formally designated IL10tm1Cgn19, 
20. The latter mice were indicated as IL10-/- mice throughout this study. Since GF 
129 SvEv WT mice were unavailable, 12-13 weeks-old GF BALB/c mice served 
as WT controls. All GF mice were provided by the Gnotobiotic Rodent Facility of 
the College of Veterinary Medicine, North Carolina State University, Raleigh, N.C., 
where the mice were housed under GF conditions in Trexler flexible film isolators 
with autoclaved food and water ad libitum, as previously described21. GF mice were 
documented to be sterile by aerobic and anaerobic culture of fecal and Gram stain 
pellets every 2 weeks and at necropsy. For bacterial colonization, GF mice were 
moved to a SPF mouse facility, where they were initially housed in sterile micro-
isolators with sterile food and water. After three days, normal enteric bacteria were 
introduced by swabbing the mouths of GF mice with a homogenate of feces of SPF 
mice, and by placing bedding and feces from SPF mice into the cages. Mice were 
then on the same day placed in clean cages and from then on housed under SPF 
conditions until analysis. The SPF bacteria that were introduced in these mice were 
documented to be free of Helicobacter species21. For comparison purposes, male 
10-12 weeks-old SPF 129 SvEv and BALB/c mice were obtained from Charles River 
Nederland (Maastricht, the Netherlands). All mice were kept in the same facility 
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under SPF conditions, and were colonized with the same strains of normal enteric 
bacteria.
Experimental design
BALB/c mice and IL10-/- mice were born and raised in a GF environment. 
Groups of GF BALB/c mice and GF IL10-/- mice were sacrificed for study of Muc2 in 
the absence of bacterial stimulation. In other GF mice, SPF bacteria were introduced 
and mice were maintained in a strict SPF environment until necropsy for BALB/c 
mice at 1 (n=6) and 4 weeks (n=4) and for the IL10-/- mice at 1 (n=5), 2 (n=4) and 
6 weeks (n=4) after bacterial colonization. We studied three regions of the large 
intestine in each mouse: cecum, proximal colon, and distal colon. The mice were 
killed by cervical dislocation and large intestinal tissue explants were prepared 
immediately. Four explants were taken for metabolic labeling and immediately put 
in appropriate pre-warmed culture medium, as described below. Sections of the 
cecum were prepared for fragment cultures, as described below. Additionally, large 
intestinal segments were fixed in 4% (w/v) paraformaldehyde in PBS, or frozen in 
liquid nitrogen and stored at minus 80°C for RNA analysis.
Histology and immunohistochemistry of large intestinal sections
Large intestinal segments, fixed in paraformaldehyde, were embedded, 
sectioned (6-µm thick), and processed for either histochemical staining or 
immunohistochemical detection of proteins. Histochemical staining was performed 
with: i. hematoxylin and eosin (HE), ii. alcian blue (AB) at pH 2.5 followed by periodic 
acid/Schiff’s reagent (PAS), or iii. high iron diamine (HID) followed by alcian blue 
at pH 2.5. A gastrointestinal histological score ranging from 0 to 4 was used in a 
blinded fashion to evaluate intestinal inflammation, as validated for IL10-/- mice21. 
Expression of Muc2 was detected by immunohistochemistry using a polyclonal anti-
murine Muc2 antibody as we described earlier26, 27. 
Measurements of IL-12 secretion
IL-12 secretion by cecal fragments was measured as previously described21. 
Briefly, small sections of cecal tissue were washed with PBS to remove feces, and 
subsequently gently shaken in RPMI medium containing 1% (w/v) penicillin and 1% 
(w/v) streptomycin for 30 min. The tissue sections were cut into small fragments 
and cultured in wells in duplicate in 1000 μl of RPMI 1640 medium (Gibco-BRL, 
Gaithersburg MD, USA) containing 1% (w/v) of both penicillin and streptomycin, and 
5% (v/v) heat-inactivated fetal calf serum, at 37°C for 18 h. Culture supernatants 
were collected and stored at minus 20°C until analysis. IL-12 secretion in the culture 
supernatants was measured by enzyme-linked immunosorbent assay (ELISA), 
using anti-IL-12 antibodies C15.6 and C17.8 (Pharmingen, San Diego, CA, USA) 
for capture and detection, respectively, of the IL-12p40 subunit21, 25. The amount of 
binding of biotinylated antibodies was detected using horseradish peroxidase-labeled 
streptavidin (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA). IL-12p40 
concentrations were calculated using a standard curve with recombinant IL-12 p70 
(Pharmingen). IL-12 p40 secretion was measured in duplicate culture supernatants 
in each separate experiment.
C
h
ap
te
r 
2
34
Metabolic labeling of large intestinal explants
Of each region of each mouse large intestine, two explants were metabolically 
labeled ex vivo with [35S]methionine/cysteine to label proteins, including Muc2 
precursors, and two further explants were metabolically labeled with [35S]sulfate to 
label glycoproteins, particularly mature mucin. Metabolic labeling was performed as 
described previously12, 13, 26, 30. Briefly, two biopsies were placed separately in 100 
µl tissue culture medium devoid of either methionine/cysteine or sulfate and pulse-
labeled for 30 min by adding respectively 100 µCi [35S]methionine/cysteine (Translabel, 
ICN, Costa Mesa CA, USA) or 100 µCi Na[35S]sulfate (ICN). The [35S]methionine/
cysteine-labeled explants were homogenized immediately. The two [35S]sulfate-
labeled explants were chase-incubated separately for 4 h in 500 µl medium devoid 
of radiolabel, but containing a standard concentration of non-radiolabeled sulfate. 
All incubations took place in RPMI 1640 medium (Gibco-BRL) supplemented with 
antibiotics and glutamine (Sigma, St. Louis, USA) at 37oC under 95% O2/ 5% CO2. 
All explants were homogenized separately at 0oC in 1000 µl homogenization buffer 
containing Triton X-100 (BDH, Poole, UK) and various protease inhibitors. The media 
from chase-incubations were mixed with 500 µl of this buffer and thoroughly mixed. 
The homogenates and media were stored at minus 20oC until further analysis as 
described in the next paragraphs.
Measurement of protein synthesis
Protein content was measured in the homogenate of each explant, using a 
bicinchoninic acid protein assay kit and bovine serum albumin as a standard (Pierce, 
Rockford IL, USA). Total incorporation of radioactivity in proteins was determined 
using a PhosphorImager with ImageQuant software (Molecular Dynamics, B&L 
systems, Zoetermeer, the Netherlands) after trichloroacetic acid precipitation, as 
previously described12.
Quantitation of radiolabeled Muc2
We described the Muc2 quantitation protocol previously in studies on the 
quantification of human, rat and mouse Muc2 synthesis in colonic biopsies12, 13, 26, 30. 
In these studies, we showed that after pulse-labeling with [35S]methionine/cysteine 
for 30 min the Muc2 precursor could be identified on SDS-PAGE, which is detectable 
as a band at approximately 600 kDa. The [35S]sulfate-labeled mature Muc2 was 
detected on SDS-PAGE as a 550 kDa band. For the quantitation of [35S]sulfate- and 
[35S]methionine/cysteine-labeled mature Muc2, equal aliquots of each radiolabeled 
homogenate were analyzed on reducing SDS-PAGE (3% (w/v) stacking, 4% (w/v) 
running gel). Gels were fixed in 10% (v/v) methanol/10% (v/v) acetic acid, stained 
with PAS, dried and then the Muc2 bands were quantified (in arbitrary units, a.u.) 
by autoradiography using a PhosphorImager and ImageQuant software. In each 
sample the Muc2 precursor synthesis was corrected for the total protein synthesis, 
measured by trichloroacetic acid precipitation as described above. To determine 
[35S]sulfate-incorporation into Muc2, the amount of [35S]sulfate-labeled Muc2 in a 
tissue homogenate, as determined from the 550 kDa mature Muc2 band on SDS-
PAGE, was corrected for the total Muc2 contents in the respective homogenates, 
determined as described below. For each explant, the [35S]sulfate-incorporation into 
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Muc2 was also corrected for differences in protein content between the individual 
homogenates.
Quantitation of total Muc2
We described this quantitation protocol previously for human and murine 
Muc212, 13, 26, 30. In short, to analyze the total Muc2 (i.e. both radiolabeled and non-
radiolabeled Muc2, and Muc2 precursor as well as mature Muc2) Western-type 
dot blotting was performed, using an antibody that recognizes peptide epitopes 
of precursor as well as mature murine Muc2 26, 27. The linear range of the assay 
was determined by serial dilution of samples, and subsequently a sample size was 
chosen that allowed measurement of each sample within the linear range of the 
assay. Homogenates were diluted and 100 µl of 35S-labeled homogenate containing 
exactly 1 µg protein as measured using a BCA protein assay kit was dot blotted 
onto nitro-cellulose (Nitran, Schleier & Schuell, Dassel, Germany). Then the blot was 
incubated with anti-mouse Muc2 antibodies, washed and incubated for 2 h with 125I-
labeled protein A (specific activity 17.0 mCi/µg, Amersham, Buckinghamshire, UK). 
Binding of 125I-labeled protein A to the polyclonal anti-mouse Muc2 antiserum was 
detected by autoradiography using a PhosphorImager (expressed in a.u.), after the 
blot was covered by two sheets of 3MM Whatman filter paper in order to eliminate 
background radiation of intrinsic 35S-label as present in the homogenates. The 
percentage of secreted Muc2 was calculated as the amount of Muc2 in the medium 
divided by the sum of the amount of Muc2 in the tissue and in the medium. This was 
multiplied by 100 to give the percentage of secreted Muc2.
Quantitation of mRNA
RNA was isolated from the various regions of the murine large intestine, using 
Trizol reagent (Gibco-BRL) following the manufacturer’s protocol. The Northern blot 
analysis was essentially carried out as previously described11. Briefly, 2 µg total 
RNA derived from each tissue sample was separated on a 0.8% (w/v) agarose 
gel containing 10 mM HEPES (Sigma) pH 7.5 and 2.2 M formaldehyde (Merck, 
Darmstadt, Germany). Integrity of RNA was assessed by analysis of the 28 S and 
18 S ribosomal RNAs after electrophoresis and staining by ethidium bromide. Spot 
blotting of the RNA to Hybond N+ membrane (Amersham) was carried out using a 
vacuum-operated manifold (BioRad, Veenendaal, the Netherlands). The blot was 
hybridized to either a 32P-labeled 244 bp SalI-EcoRI fragment of the murine Muc2 
cDNA, or to a 32P-labeled 438 bp rat trefoil factor family peptide 3 (Tff3) probe, as 
we described previously29, 31, 32. After autoradiography by exposure of the membrane 
to a PhosphorImager plate, the probe was stripped from the blot. The membrane 
was re-probed with a 32P-labeled human glyceraldehydephosphate dehydrogenase 
(GAPDH) probe. The level of hybridization on the spot blots to the murine Muc2 
probe and the GAPDH probe were measured through autoradiography using a 
PhosphorImager and ImageQuant software, as described26.
Statistical analysis
Statistical significance was assessed by one-way analysis of variance test and 
Mann-Whitney U-test. Results were considered as statistically significant at P<.05.
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Results
Wild type mice: Comparison of the Muc2 synthesis in BALB/c and 129 SvEv mice
Since GF 129 SvEv WT mice were unavailable, GF BALB/c mice of the 
same age served as WT controls. It was however not known if these two strains 
of mice expressed the same levels of Muc2, or if these strains differed in any of 
the other parameters relevant to this study. Therefore, SPF mice of both strains, 
BALB/c (n = 7) and 129 SvEv (i.e. the parental strain of the IL10-/- mice, n = 6) were 
tested for their ability to synthesize Muc2 in their colonic epithelia. Following the 
previously established procedures, described in the Material and Methods section, 
we measured in the colonic tissue of these mice: (i). total protein synthesis, (ii). Muc2 
precursor protein synthesis, (iii) total Muc2 levels in colonic mucosa, (iv). sulfation 
levels of Muc2, (v). Muc2 mRNA levels, (vi) secretion of Muc2, (vii) secretion of 
sulfated Muc2, and (viii) Tff3 mRNA levels. As documented in Figure 1 and Table I, 
there were no statistically significant differences in these parameters as measured 
between these mouse strains. The only remarkable observation, in the comparison 
between these two WT strains, was that the 
degree of sulfation of Muc2, as produced 
by colonic explants of the 129 SvEv mice, 
was higher in each of the colonic regions 
than in the BALB/c mice. However, these 
differences are statistically significant only 
for the proximal colon. Collectively these 
data indicate that there are no differences in 
the parameters that are relevant to this study 
among these two mouse strains, when born 
and raised under SPF conditions.
Introduction of normal enteric bacteria
We investigated specific changes 
in the large intestine during onset and 
development of colitis in IL10-/- mice after 
the introduction of SPF bacteria into GF 
IL10-/- mice, versus BALB/c WT control 
mice. During these experiments, there were 
no significant changes in animal behavior, 
stool consistency or body weight within or 
between the groups (data not shown). Total 
protein synthesis in the BALB/c mice was 
Figure 1. Muc2 synthesis in wild-type BALB/c and 129 SvEv mice. Muc2 precursor synthesis 
(Panel A), total Muc2 levels (Panel B), and the sulfation of total Muc2 (Panel C) were measured in 
wild-type BALB/c (n = 7), and 129 SvEv (n = 6) mice in the cecum and the proximal and distal colon. 
All mice were kept in the same facility under SPF conditions, and were colonized with the same strains 
of normal enteric bacteria. SEMs are indicated. Asterisks denotes a statistically significant difference in 
sulfation level between Muc2 form the proximal colon of the 129 SvEv and BALB/c mice (P<.05).
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increased at day 7 after the introduction of enteric bacteria (Table II). At day 7 after 
the introduction of SPF bacteria the total protein synthesis was higher in all regions 
of the large intestine of the BALB/c mice, compared to the comparable region of the 
large intestine of the IL10-/- mice. At days 28-42 the protein synthesis levels of both 
strains returned to levels not significantly different from the respective levels on day 
0 after introduction of bacteria.
IL-10 normally plays an important role in the regulation of the immune responses 
by inhibiting innate immune cell production of the pro-inflammatory cytokine IL-12. We 
measured IL-12p40 secretion by cecal tissues from each group. IL10-/- and BALB/c 
mice revealed nearly undetectable levels of IL-12p40 in cecum culture supernatants 
under GF conditions. Upon introduction of commensal bacteria, the IL10-/- mice 
housed under SPF conditions for 42 days showed significantly increased levels of 
cecal IL-12 secretion, whereas BALB/c mice revealed no significant changes in IL-12 
levels over the 28-day period of observation (Fig. 2).
Large intestinal morphology
The cecum and proximal and distal colon of IL10-/- and BALB/c mice showed 
similar histology with no evidence of inflammation under GF conditions (not shown). 
BALB/c mice revealed no significant morphological alterations by HE staining after 
the introduction of SPF bacteria in all large intestinal regions, as exemplified for 
proximal colon in Figure 3A, B. In contrast, the large intestines of the IL10-/- mice 
displayed major differences in each colonic region after inoculation with commensal 
bacteria, primarily characterized by epithelial hyperplasia and mononuclear infiltrates 
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Tables
Table I. Protein synthesis, Muc2 and trefoil family factor 3 (Tff3) mRNA levels and secretion of total and
35
SO3-labeled Muc2 in wild-type BALB/c and 129 SvEv mice.
Region Strain*
Total protein
synthesis
(a.u./mg) †
Muc2 mRNA
(a.u.)
Tff3 mRNA
(a.u.)
Secretion
total Muc2
(%)
Secretion
35
S03-labeled
Muc2 (%)
BALB/c 209.1 [50.4]
 ‡
442.5 [61.7] 342.2 [57.8] 52.8 [5.4] 64.0 [8.6]
Cecum
129 SvEv 470.2 [154.1] 405.4 [45.2] 286.0 [53.2] 64.1 [9.4] 52.0 [5.8]
BALB/c 413.0 [91.8] 5142.8 [919.9] 479.0 [86.2] 25.9 [5.0] 21.6 [7.0]
Proximal
Colon
129 SvEv 287.8 [48.5] 5898.3 [836.5] 496.6 [90.3] 34.3 [5.6] 22.5 [5.2]
BALB/c 328.1 [64.4] 459.9 [37.4] 381.9 [44.7] 44.6 [6.2] 32.1 [4.5]
Distal
Colon
129 SvEv 411.9 [114.7] 579.9 [94.1] 333.8 [118.4] 38.8 [8.2] 34.2 [5.8]
NOTE. * Normal SPF BALB/c (n = 7) and 129 SvEv (n = 6) mice were analyzed as indicated in the legends of Figure
1.
† a.u., arbitrary units
‡
 SEMs are indicated between brackets.
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(Fig. 3C, D). The inflammation was quantified in a blinded fashion using a standardized 
histological score ranging from 0 (no inflammation) to 4 (severe inflammation)21. 
The GF IL10-/- tissue showed only a very low grade of inflammation (inflammation 
score, 0.58 [SEM, 0.05]). The inflammation scores did not change significantly in the 
BALB/c mice after the introduction of SPF bacteria. However, after the introduction 
of commensal bacteria in the IL10-/- mice the histologic inflammatory score increased 
significantly (P<.05) to 2.50 [SEM, 0.34], 2.56 [SEM, 0.54], and 2.31 [SEM, 0.40], 
after 7, 14 and 42 days of bacterial exposure, respectively.
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Table II. Total protein synthesis in BALB/c and IL10
-/-
 mice.
Region Strain* Day 0 Day 7 Day 14 Day 28 Day 42
BALB/c 62.5 [12.7]
 §
237.3 [60.5] 
‡
n.d.
_
95.3 [34.2] n.d.
Cecum
IL10
-/-
194.0 [60.5]
 †
171.6 [51.7] 90.5 [30.2] n.d. 282.0 [32.7]
BALB/c 80.0 [10.7] 272.0 [66.9] 
‡
n.d. 188.8 [81.4] n.d.
Proximal
colon
IL10
-/-
189.8 [75.6] 161.4 [74.4] 103.8 [36.3] n.d. 205.0 [63.0]
BALB/c 129.5 [77.5] 295.5 [70.9]
‡
n.d. 167.9 [109.4] n.d.Distal
colon
IL10
-/-
237.4 [121.9] 85.6 [28.8] 118.5 [39.1] n.d. 142.0 [38.3]
NOTE. * On day 0, GF mice from either strain were colonized with normal enteric bacteria under SPF conditions.
Days after inoculation with bacteria are indicated, day 0 indicates the GF status. Total protein synthesis was
measured as explained in the Methods section, and is expressed as a.u./mg.
†
 The protein synthesis in the cecum of the IL10
-/-
 was significantly higher than in the cecum of GF BALB/c mice
(P<.05).
‡
 The protein synthesis in each region of the large intestine of the BALB/c mice was higher on day 7, than in the
cognate regions of the IL10
-/-
 mice (P<.05).
_
 n.d., not determined.
§
 SEMs are indicated between brackets.
Figure 2. Cecal IL-12 secretion 
in BALB/c and IL10-/- mice. IL-12 
secretion was measured from cecum 
explants, which were cultured in vitro for 
24 h (measured as pg IL-12 per 0.025 
g tissue protein). Days after inoculation 
of the germ-free mice (GF) with normal 
enteric bacteria are indicated, day 0 
indicates the GF status. Asterisks, 
indicates a significant increase in IL-12 
production in tissue from IL10-/- mice 
on day 7, relative to BALB/c mice on 
day 7 (P<.02). a Indicates a significant 
increase in the IL-12 production by 
explants from the IL10-/- on these 
respective days, relative to IL10-/- mice 
on day 0 (P<.02). SEMs are indicated.
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Goblet cells, the source of secretory mucins like Muc2, were numerous in 
each large intestinal region of the GF as well as the bacteria-colonized mice of both 
strains, as detected by AB/PAS and HID/AB staining (Fig. 3E-L). Interestingly, the 
IL10-/- mice revealed altered PAS and HID staining patterns upon introduction of SPF 
bacteria. GF IL10-/- mice, like BALB/c mice, displayed PAS- and HID-positive goblet 
cells in the upper half of the colonic crypts. Remarkably these PAS- and HID-positive 
cells were absent in crypts of the bacteria-colonized IL10-/- mice, shown in Figure 
3H and 3L, respectively. This is indicative of structural changes in the glycosylation 
of the mucins in these cells of the upper crypts. In particular, the absence of HID-
staining indicated that the IL10-/- mice colonized by enteric bacteria have a lower 
level of sulfation of the mucins within these goblet cells, relative to the GF situation.
Immunohistological staining revealed that the goblet cells in both GF and 
bacteria-colonized BALB/c mice stained positive for Muc2 (Fig. 3M, N). Also in IL10-
/- mice, both in GF status and after colonization with enteric bacteria, all goblet cells 
were stained for Muc2 (Fig. 3O, P), indicating that Muc2 was still produced by goblet 
cells after bacterial colonization.
Figure 3. Histochemistry of BALB/c and IL10-/- proximal colon. Tissue sections were prepared 
from the proximal colon of BALB/c and IL10-/- mice in germ-free (GF) conditions and at 7 days 
after the introduction of SPF normal enteric bacteria (Bacteria). The tissue sections were stained 
histochemically with hematoxylin and eosin (Panels A-D), AB/PAS (Panels E-H), or HID/AB (Panels 
I-L). The arrows in Panels E-G indicate PAS-positive goblet cells in the upper half of the crypts. The 
arrowheads in Panels I-K indicate HID-positive goblet cells in the upper half of the crypts. Sections 
were stained immunohistochemically for the presence of Muc2 protein, using a polyclonal anti-murine 
Muc2 antiserum (Panels M-P). All micrographs were recorded at the identical magnification of 200x. 
Please also see page 219.
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Muc2 levels in BALB/c and IL10-/- mice
Muc2 precursor synthesis was determined as the metabolic incorporation 
of [35S]methionine/cysteine into this protein in tissue explants. The level of Muc2 
precursor synthesis was approximately ten-fold lower in each of the large intestinal 
regions of GF IL10-/- mice than in the respective regions of the large intestines of GF 
BALB/c mice (Fig.4). Following colonization with bacteria, the BALB/c mice exhibited 
no significant differences in precursor biosynthesis. In contrast, IL10-/- mice exposed 
to SPF bacteria for 7 days showed a 5- to 20-fold increase in Muc2 precursor 
synthesis, which returned to levels similar to those of GF IL10-/- mice after 14 days of 
exposure to bacteria (Fig. 4). Thus, early colonization (7 days) with bacteria induced 
a strong, but transient, increase in Muc2 precursor biosynthesis in IL10-/- mice, which 
at other time points showed defective Muc2 synthesis.
The total levels of Muc2 were determined by Western-type spot-blotting that 
measures the levels of mature Muc2 plus Muc2 precursor (Fig. 5). GF IL10-/- mice 
showed statistically significant 3- to 10-fold lower levels of total Muc2, compared to 
GF BALB/c mice. Bacterial colonization induced a statistically significant decrease 
of total Muc2 levels in BALB/c mice by 7 days after inoculation, and total Muc2 levels 
remained significantly reduced until at least 28 days after exposure to bacteria. Muc2 
levels in the IL10-/- mice hardly changed after the introduction of bacteria and total 
levels of Muc2 remained much lower in the IL10-/- mice at each time point compared 
to BALB/c mice (Fig. 5).
The degree of sulfation of the mature Muc2 molecules was measured by 
labeling large intestinal tissue segments metabolically by [35S]sulfate for 30 min, 
chase-incubating in fresh medium for 4 h, and homogenizing the tissue. The 
Figure 4. Muc2 precursor synthesis in BALB/c and IL10-/- mice. Muc2 precursor synthesis was 
measured in tissue explants from the cecum and proximal and distal colon of BALB/c and IL10-/- mice. 
Days after inoculation with normal enteric bacteria are indicated, day 0 indicates the GF status. The 
Muc2 precursor synthesis, in each colonic region, was significantly lower in the GF IL10-/- mice, relative 
to the GF BALB/c mice (*P<.005). The Muc2 precursor biosynthesis increased significantly on day 
7, relative to day 0, in the explants of the IL10-/- mice in each of the respective regions of the large 
intestine (aP<.01, bP<.05). SEMs are indicated.
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incorporation of [35S]sulfate into Muc2 was quantified after SDS-PAGE, and was 
related to the total amount of Muc2 in the homogenate and medium, respectively, 
as determined by Western-type spot-blot analysis (Fig. 6). GF IL10-/- mice showed 
a slightly higher colonic Muc2 sulfation compared to GF BALB/c mice, yet this 
difference was not statistically significant in any region of the large intestine (Fig. 
6 and results not shown). Introduction of bacteria led to progressively increased 
sulfate incorporation in Muc2 in the colon of BALB/c mice after 7 and 28 days after 
inoculation with bacteria (Fig. 6). In contrast, IL10-/- mice revealed a progressive 
decrease in sulfate incorporation into Muc2 upon introduction of bacteria, reaching 
statistical significance after 42 days of exposure to bacteria (Fig. 6).
Muc2 mRNA levels
The Muc2 mRNA levels were measured in the GF BALB/c mice in the cecum 
(980 a.u. [SEM, 80]), proximal colon (2890 a.u. [SEM, 700]), and in the distal colon 
(2630 a.u. [SEM, 760]). When these Muc2 mRNA levels were compared with the 
respective large intestinal regions of bacteria-exposed BALB/c animals, after 7 and 
28 days after the introduction of bacteria, no statistically significant differences in 
Muc2 mRNA levels were identified. Also the Muc2 mRNA levels of the GF IL10-/- 
mice were measured in the cecum (1180 a.u. [SEM, 600]), proximal colon (2540 
a.u. [SEM, 1330]), and in the distal colon (1990 a.u. [SEM, 1000]). After exposure of 
IL10-/- mice to bacteria, for 7, 14 or 42 days, no statistically significant changes were 
found in any of the large intestinal segments. Moreover, the Muc2 mRNA levels in 
the IL10-/- mice did not differ statistically from the levels in the BALB/c mice at any 
time during the experiment in any given large intestinal segment.
Figure 5. Total Muc2 levels in BALB/c and IL10-/- mice. Total Muc2 levels were measured in 
tissue explants from the cecum and proximal and distal colon of BALB/c and IL10-/- mice. Days after 
inoculation with normal enteric bacteria are indicated, day 0 indicates the GF status. The Muc2 level 
was significantly lower in each of the large intestinal regions of the GF IL10-/- mice, relative to the GF 
BALB/c mice (**P<.005). Also on day 7, the Muc2 levels were significantly lower in each of the large 
intestinal regions of the IL10-/- mice, relative to BALB/c mice on day 7 (*P<.05). The Muc2 levels in the 
large intestinal regions of the BALB/c mice decreased significantly on day 7 and 28 after exposure 
to bacteria, relative to the Muc2 levels in the respective regions of GF BALB/c mice (aP<.01, bP<.05). 
SEMs are indicated.
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Figure 6. Muc2 sulfation in BALB/c and IL10-/- mice. The levels of Muc2 sulfation were measured, 
in explants of the proximal colon of BALB/c and IL10-/- mice, of the Muc2 present in the tissue and 
medium and of the total Muc2. Days after inoculation with normal enteric bacteria are indicated, day 
0 indicates the GF status. The sulfation of Muc2 increased gradually and significantly after 7 and 28 
days of exposure to bacteria in the proximal colon of the BALB/c mice, relative to GF BALB/c (aP<.01). 
In IL10-/- mice, the level of sulfation of Muc2 decreased to significantly lower levels at day 42, relative 
to GF IL10-/- (bP<.05). SEMs are indicated.
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Table III. Secretion of total Muc2 in BALB/c and IL10
-/-
 mice.
Region Strain* Day 0 Day 7 Day 14 Day 28 Day 42
BALB/c 40.9 [4.2]
 §
45.9 [5.2] n.d.
 ‡
48.7 [1.9] n.d.
Cecum
IL10
-/-
45.8 [5.7] 27.5 [4.4]
 †
65.5 [6.1] n.d. 29.5 [5.3]
BALB/c 19.7 [3.7] 18.9 [2.0] n.d. 17.0 [1.5] n.d.
Proximal
colon
IL10
-/-
24.1 [7.5] 25.6 [10.9] 31.8 [2.5] n.d. 34.5 [5.5]
BALB/c 24.0 [5.0] 23.6 [3.3] n.d. 25.7 [8.2] n.d.Distal
colon
IL10
-/-
21.9 [4.2] 22.1 [3.6] 31.8 [2.5] n.d. 34.0 [3.1]
NOTE. * On day 0, GF mice from either strain were exposed to normal enteric bacteria under SPF conditions. Days
after inoculation with bacteria are indicated, day 0 indicates the GF status. Secretion of total Muc2 was measured as
explained in the Methods section, and is expressed as percentage of secreted Muc2 during 4 h of tissue culture.
†
 The secretion of Muc2 from the cecum of IL10
-/-
 mice at day 7 decreased specifically relative to both GF IL10
-/-
mice
and IL10
-/-
 mice at day 14 (P<.05).
‡
n.d., not determined.
§
 SEMs are indicated between brackets.
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Secretion of Muc2 and 35SO3-labeled Muc2
Secretion of total Muc2 was quantified by Western-type spot-blotting in tissue 
explants and cognate media of large intestinal segments that were incubated for 4 
h in tissue culture medium (Table III). Upon introduction of bacteria, there were no 
statistically significant differences between the percentages of secreted Muc2 from 
colonic tissues of the BALB/c mice in any of the large intestinal regions. As shown 
in table III, only the cecum of IL10-/- mice showed remarkable changes in Muc2 
secretion. Cecal Muc2 secretion decreased in 7 days after exposure to bacteria, 
then increased after 14 days of exposure, and then returned to basal levels after 
42 days. In the proximal and distal colon of IL10-/- mice, secretion of total Muc2 was 
not significantly altered during the course of the experiment. No statistical significant 
differences were found between the percentage of secretion of Muc2 from IL10-/- 
tissue and BALB/c tissue at any time or any large intestinal region.
We also measured the secretion of 35SO3-labeled Muc2 from the large 
intestinal explants within 4 h of incubation in tissue culture medium (Table IV). With 
one exception there were no significant changes in the secretion of 35SO3-labeled 
Muc2 in the tissues of either the BALB/c mice or the IL10-/- mice. Only the percentage 
of secretion of 35SO3-labeled Muc2 from the distal colon in the IL10-/- mice, 14 days 
after exposure to bacteria, was significantly decreased relative to GF IL10-/- tissue.IL10 deficient mice_t#7F89E.doc
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Table IV. Secretion of 
35
S03-labeled Muc2 in BALB/c and IL10
-/-
 mice.
Region Strain* Day 0 Day 7 Day 14 Day 28 Day 42
BALB/c 39.3 [8.0]
 §
38.0 [9.6] n.d.
 ‡
45.3 [3.3] n.d.
Cecum
IL10
-/-
49.2 [8.0] 36.3 [1.6] 50.4 [1.7] n.d. 42.5 [7.8]
BALB/c 36.0 [11.6] 36.8 [9.3] n.d. 21.3 [9.0] n.d.
Proximal
colon
IL10
-/-
18.4 [3.6] 23.7 [5.8] 18.6 [2.5] n.d. 25.6 [7.7]
BALB/c 37.1 [15.5] 31.7 [5.9] n.d. 25.2 [5.8] n.d.Distal
colon
IL10
-/-
26.4 [5.2] 25.0 [4.4] 11.9 [3.0]
 †
n.d. 10.2 [4.3]
NOTE. * On day 0, GF mice from either strain were exposed to normal enteric bacteria under SPF conditions. Days
after inoculation with bacteria are indicated, day 0 indicates the GF status. Secretion of 
35
S03-labeled Muc2 was
measured, and is expressed as percentage of secreted 
35
S03-labeled Muc2 during 4 h of tissue culture.
†
 The secretion of 
35
S03-labeled Muc2 from the distal colon of IL10
-/-
 mice at day 14 decreased, relative to GF IL10
-/-
mice (P<.05).
‡
 n.d., not determined.
§
  SEMs are indicated between brackets.
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Discussion
Muc2 is the most prominent secretory large intestinal mucin in mammals 
studied so far27-29, 33, 34. It is produced in bulk by the specialized goblet cells, and it 
is seen as the most important compound of the colonic mucus layer. As this mucus 
is strategically positioned between the lumen and the epithelium, it has long been 
hypothesized that this mucus layer, and thus Muc2, may protect the animal against 
the development of colitis. In particular, MUC2 synthesis in humans with IBD was 
found to be decreased 12, 13, particularly in the epithelium adjacent to ileal ulcers of 
Crohn’s disease14. However, it is impossible to determine in these clinical studies 
whether these observed abnormalities in MUC2 synthesis are primary defects or 
whether they are induced by the inflammatory response. One of the most important 
prerequisites for the development of colitis is the presence of bacteria in the colon. 
It has been convincingly shown that normal enteric bacteria can induce immune-
mediated colitis in rodents with genetically-engineered abnormalities in immune 
regulation3, 21-25. Muc2 forms a natural barrier to the contact of bacteria with the 
underlying colonic epithelium. Thus, any change in quantity or structure of Muc2 could 
influence the effects of bacteria on the large intestinal mucosa, and be instrumental 
in the development of colitis.
In this study, we set out to quantify the Muc2 synthesis in IL10-/- and WT mice 
before and after the introduction of bacteria in the lumen of the intestine. In the GF 
state IL10-/- mice have no evidence of biochemical or histological inflammation and 
no activation of innate or acquired immune responses21. This provided us with the 
opportunity to evaluate the possible roles of Muc2 in both the induction as well as the 
perpetuation of the inflammation, and the ensuing epithelial damage, in experimental 
colitis. The first question that we addressed was, is there a primary defect in the Muc2 
synthesis in GF IL10-/- mice? The second question was, is there a difference in the 
Muc2 synthesis following the introduction of normal enteric bacteria into IL10-/- mice, 
and during the early, mid and late phases of colitis and tissue damage? And third 
and finally, does colonization with commensal enteric bacteria alter Muc2 synthesis 
in normal mice? The answer to each question is yes. Both the total Muc2 levels 
and the Muc2 precursor synthesis are dramatically lower in the IL10-/- mice than in 
the WT controls, even before bacterial colonization and the onset of inflammation. 
Interestingly, the IL10-/- mice show a sharply increased Muc2 biosynthesis 7 days 
after introduction of bacteria, which is a transient process that returns to low baseline 
values by 2 weeks of bacterial colonization. This indicates that there is an induction 
of Muc2 synthesis in response to the first exposure to enteric bacteria or to the initial 
development of inflammation in this model. However, this induction is rapidly reversed 
as the inflammatory process progresses. These results are compatible with the 
observations of Madsen et al35, who demonstrated a defect in mucosal permeability 
in young SPF IL10-/- mice prior to the onset of histologic evidence of inflammation. 
This permeability defect corresponded to the presence of luminal bacteria36, and 
could be attenuated by treatment with Lactobacilli35, but the mechanisms regulating 
this permeability defect were not delineated.
The consistency of our findings was indicated by the fact that each change 
in Muc2 synthesis was corroborated by similar results in each of the three large 
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intestinal regions that were studied. Each tissue fragment of the respective colonic 
regions was treated and processed independently. Nevertheless, the cecum, and 
proximal and distal colon showed the same patterns of changes in Muc2 synthesis. 
Moreover, this was true for all parameters of the Muc2 synthesis that were measured. 
This indicates that our results are technically sound, as each finding in a particular 
region of a particular mouse is reproduced by similar findings in another region of the 
same animal. Furthermore, the changes in the Muc2 synthesis occur throughout the 
entire large intestine, and were not restricted to a particular region. This implies that 
the mechanisms that induce the changes in the Muc2 synthesis, either induced by 
the absence of IL-10 in GF -/- mice or by the introduction of bacteria or inflammation 
in the IL10-/- SPF mice, operate in the entire large intestine.
There are various direct and indirect indications that synthesis and secretion 
of secretory mucins are regulated by immune-mediators37-42. Likewise the present 
study suggests that the absence of IL-10 leads to decreased Muc2 synthesis. This 
could be a direct effect of IL-10, suggesting that IL-10 could induce Muc2 synthesis43. 
Alternatively, IL-10 in the healthy mouse could be responsible for the induction of the 
stimulatory factors that normally enhance Muc2 production in the colon. For example, 
IL-10 down-regulates the Th1 response and facilitates TGF-beta production44. In turn, 
TGF-beta can induce MUC2 transcription39. Likewise, enteric bacteria, particularly 
probiotic species, can stimulate mucin gene expression in colonic epithelial cells. 
Lactobacillus species induce MUC2 and MUC3 expression and secretion in cultured 
epithelial cell lines45, 46.
Irrespective of the exact mechanisms of the regulation of Muc2 levels in the 
murine colon, it appears that the large differences in Muc2 protein synthesis were 
not a result of decreased colonic Muc2 mRNA levels in IL10-/- mice. This discrepancy 
between Muc2 mRNA and protein expression was found not only in the differences 
in Muc2 synthesis between the IL10-/- and the BALB/c mice, but also in the transient 
upsurge of Muc2 synthesis in the IL10-/- mice 7 days after introduction of enteric 
bacteria. Technically, we are able to measure Muc2 mRNA quantities in a very large 
range. Therefore, the similar levels of Muc2 mRNA in both mice strains and during 
the development of colitis seem genuine and suggest posttranscriptional regulation 
of colonic Muc2. This lack of correlation between Muc2 mRNA levels and Muc2 
precursor synthesis was previously found in the human and mouse colon12, 26. This 
indicates that the efficiency by which the Muc2 mRNA is translated into Muc2 protein 
may be an important mechanism of the regulation of Muc2 synthesis in the colon.
As colitis progressed from mild to severe in the IL10-/- mice over the 42 days of 
observation, the colonic Muc2 sulfation decreased progressively. Decreased sulfation 
was also observed in human ulcerative colitis13, 47-50, and in the distal colon during 
experimental colitis29, suggesting that changes in Muc2 sulfation are associated with 
colonic inflammation. Sulfation of secretory mucins has two possible roles in their 
biological function. First, the degree of sulfation affects the gel forming properties of the 
secretory mucins. Increasing sulfation of mucins yields a gel with a higher viscosity51, 
which is predicted to be more resistant to physical erosion. The progressively lowered 
levels of sulfate on Muc2 may result in a mucus gel with decreasing viscosity and 
increasing susceptibility to erosion. This may increase the contact of the enteric 
bacteria with the epithelium or increase the penetration of these bacteria into the 
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mucosa, thereby promoting and/or perpetuating mucosal inflammation. Mucosally 
adherent bacteria, especially Bacteroides and Enterobacteriaceae, are dramatically 
increased in IBD patients17. In vitro studies have demonstrated that adherence of 
pathogenic bacteria to epithelial cells can be inhibited by induction of MUC3 by 
Lactobacillus species45, 52, and by serum amyloid A353. In addition, decreased sulfate 
residues on colonic mucins could enhance its degradation by bacterial enzymes48, 
which may further deteriorate the protective mucus gel barrier. Bacteroides vulgatus 
isolated from IBD patients secrete mucin-degrading enzymes31. However, lower 
levels of sulfate on Muc2 could also be beneficial, since fewer sulfates available 
for metabolism by sulfate-reducing bacteria could result in less production of toxic 
sulfides. Increased numbers of sulfate-reducing bacteria have been demonstrated in 
ulcerative colitis patients54. These bacteria are able to use sulfate as energy source 
and reduce the sulfate to highly toxic sulfides32, 55, 56.
While this work was in progress, a Muc2 deficient (Muc2-/-) mouse strain was 
developed by genetic engineering that not only developed intestinal carcinoma57, but 
also developed colonic inflammation under SPF conditions58. Moreover, if challenged 
under SPF conditions by the cytotoxic agent dextran sulfate sodium, Muc2-/- mice 
developed more active and earlier onset colitis than WT mice or heterozygous 
Muc2+/- mice58, 59. These results strongly indicate that Muc2 plays an important role 
in protecting the colonic mucosa against colitis and also against the development of 
adenocarcinoma of the colonic epithelium. It remains to be demonstrated if bacteria 
are instrumental in the induction of colitis in Muc2-/- mice.
In conclusion, IL10-/- mice exhibit a primary defect in the level of large intestinal 
Muc2 synthesis, which may make these mice more susceptible to developing colitis in 
the presence of normal enteric bacteria. Introduction of enteric bacteria induced colitis 
in the IL10-/- mice and led to a reduction in Muc2 sulfation. This decreased sulfation 
may influence the gel-forming properties of Muc2 and contribute to the perpetuation 
of colitis. These quantitative and structural aberrations in Muc2 in IL10-/- mice likely 
reduce the ability of the epithelium to cope with non-pathogenic commensal bacteria 
and may contribute to the sensitivity of these mice to develop colitis.
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Chapter 3
Mucin 2 is Critical for Colonic 
Protection
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Abstract
Expression of mucin MUC2, the structural component of the colonic mucus layer, is lowered 
in inflammatory bowel disease. Our aim was to obtain insight in the role of Muc2 in epithelial 
protection. Thereto Muc2 knockout (Muc2-/-) and Muc2 heterozygous (Muc2+/-) mice were 
characterized and challenged by a colitis-inducing agent, dextran sulfate sodium (DSS). We 
monitored clinical symptoms, intestinal morphology and differences in intestine-specific protein 
and mRNA levels. The Muc2-/- mice showed clinical signs of colitis (as of 5 weeks), aggravating 
as the mice aged. Microscopic analysis of the colon of Muc2-/- showed mucosal thickening, 
increased proliferation and superficial erosions. Colonic goblet cells in the Muc2-/- mice were 
negative for Muc2, but trefoil factor 3 was still detectable. In Muc2-/- mice, transient de novo 
expression of Muc6 mRNA was observed in the distal colon. On day 2 of DSS treatment, the 
histological damage was more severe in Muc2+/- versus wild type (WT) mice, but the disease 
activity index (DAI) was not yet different. By day 7, the DAI and histological score were significantly 
elevated in Muc2+/- versus WT mice. The DAI of the Muc2-/- mice was higher (versus both WT 
and Muc2+/- mice) throughout DSS treatment. The histological damage in the DSS-treated 
Muc2-/- mice was different compared to WT and Muc2+/- mice with many crypt abscesses, 
instead of mucosal ulcerations. Conclusions: This study shows that Muc2 deficiency leads 
to inflammation of the colon, and contributes to the onset and perpetuation of experimental 
colitis.
Abbreviations used in this paper
BrdU, bromodeoxyuridine; DAI, disease activity index; DSS, dextran sulfate sodium; IL, 
interleukin; IBD, inflammatory bowel disease; Muc, Mucin; Muc2-/-, Muc2 deficient; Tff3, trefoil 
factor 3; TNF, tumor necrosis factor.
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Introduction
 Ulcerative colitis and Crohn’s disease are two of the most important 
inflammatory bowel diseases (IBD) characterized by chronic inflammation and 
mucosal tissue damage of parts of the gastrointestinal tract. The etiology of these 
inflammatory disorders remains unknown, but research so far has shown that these 
diseases are caused by a combination of genetic, environmental, immunoregulatory, 
and epithelial factors1-6. 
 The epithelium and mucus layer in the intestinal tract form a physical barrier 
between the potential toxic and noxious agents present in the gut lumen and the 
underlying tissues. Goblet cells exert a vital role since they secrete molecules, which 
serve protective roles in the gut, like mucins and trefoil factors. Mucins are the building 
blocks of the mucus layer and previous studies have shown that human, rat and 
mouse colonic epithelium expresses mainly one secretory mucin in high amounts, 
MUC27-11. The secretory mucin MUC2 is stored in bulky apical granules of the goblet 
cells and is the most important factor determining the goblet cell morphology12, 13. 
Trefoil factor 3 (Tff3) is a protein also expressed by goblet cells in the intestine and 
has shown to play an essential role in the maintenance and repair of the intestinal 
mucosa3. Damage to the epithelium, in particular those events affecting the protective 
properties as offered by the secretory products of the goblet cells, is a likely cause of 
the inflammation.
 Histology of ulcerative colitis patients often shows depletion of recognizable 
goblet cells in the colonic epithelium14. Defects in the intestine, such as loss of 
e-cadherin expression, multi-drug resistant protein or Tff3 deficiency, have been 
shown to lead to higher susceptibility to chronic inflammation that can progressively 
deteriorate the epithelial barrier function3, 4, 6. Furthermore, it has been shown that 
in patients with ulcerative colitis the activity of the mucosal inflammation correlates 
significantly with a decrease in MUC2 synthesis15, and secretion16, again implying 
that the mucosal barrier plays a key role in the course of the disease. 
 To more specifically address the importance of MUC2 in epithelial protection, 
Muc2 deficient (Muc2-/-) mice were generated, through genetic inactivation of 
the murine Muc2 gene12. In these Muc2-/- mice, the intestinal goblet cells were 
seemingly absent. Interestingly, mice lacking Muc2 developed adenomas as of six 
months of age, which progressed to invasive adenocarcinoma in the small intestine 
as well as rectal tumors at an older age. Therefore, Muc2 seems to play a role 
in the suppression of intestinal cancer12, but the exact mechanism whereby Muc2 
suppresses tumorigenesis remains unclear.
 To obtain insight in the role of Muc2 in epithelial barrier function, and thus its 
possible role in IBD, we characterized the Muc2 knockout (Muc2-/-) and heterozygous 
(Muc2+/-) mouse from birth until 16 weeks of age, prior to the development of 
adenomas and challenged these mice with the colitis-inducing agent, dextran sulfate 
sodium (DSS). This animal model is the first to provide the possibility to investigate 
the physiological function of Muc2 in the intestine of the mouse under unchallenged 
and luminally challenged conditions.
C
h
ap
te
r 
3
54
Materials and Methods
Animals 
 The previously described Muc2-/- mice on mixed genetic background12 
were backcrossed onto a 129SV (Charles River, Maastricht, the Netherlands) 
genetic background for nine generations followed by intercrosses to generate mice 
homozygous for the Muc2 disruption. To obtain experimental groups with a minimal 
age difference between the different litters, all mice were generated from Muc2+/- 
breedings. Throughout the backcrossing procedure, the targeted Muc2 gene was 
monitored via PCR assays performed on genomic DNA isolated from tail clips as 
described by Velcich et al12. All the mice were housed in the same specific pathogen-
free environment with free access to standard rodent pellets (Special Diets Services, 
Witham, Essex, England) and acidified tap water in a 12-h light-dark cycle. All animal 
care and procedures were conducted according to institutional guidelines (Erasmus 
MC- Animal Ethics Committee, Rotterdam, the Netherlands). 
Experimental set-up
 Wild type (WT), Muc2+/- and Muc2-/- littermates were scored weekly until the 
age of 16 weeks to obtain a Disease Activity Index (DAI) as described by Cooper 
et al17 (Table I). Briefly, they were scored for the following: weight, softness of the 
stool, occult faecal blood18 and general appearance of the mice. One hour prior to 
sacrifice, bromodeoxyuridine (BrdU), 30 mg/kg body weight (Sigma, St. Louis, USA), 
was injected intraperitoneally to be able to study epithelial proliferation19. The time 
Muc2 is Critical for Colonic Protection 55
curve was started with 16 mice of each genotype, WT, Muc2+/- and Muc2-/-. At the 
ages 5, 8, 12 and 16 weeks, groups of 4 male mice per genotype were sacrificed. 
Small intestine and colon were excised immediately and either fixed in 4% (w/v) 
paraformaldehyde in PBS, stored in RNA later (Qiagen, Venlo, the Netherlands) at 
minus 20oC, or frozen in liquid nitrogen and stored at minus 80°C.
Histology and histological grading
 Tissue fixed in 4% (w/v) paraformaldehyde in PBS was prepared for light 
microscopy and 5 µm thick sections were stained by haematoxylin and eosin 
(HE) to study histological changes as described previously20. Grading of intestinal 
inflammation was determined as described by Rath and co-workers21 with slight 
modifications (Table II). In particular, the scoring of both the percentage of the total 
ulcer area per section and the number of crypt abscesses for each section were 
modified. To detect differences in mucosal and epithelial thickness in the colon, 
10 well-oriented crypts or epithelial cells were chosen per intestinal segment and 
measured using calibrated Leica Image Manager 500 software (Leica Microsystems 
B.V, Rijswijk, the Netherlands). All scores were obtained in a blinded fashion by two 
independent investigators.
Immunohistochemistry
 Five-micrometer-thick sections were cut and prepared for immunohisto-
chemistry, as described previously22 using the Vectastain Elite ABC kit (Vector Labs, 
Burlingame CA, USA) and 3,3’-diaminobenzidine as staining reagent. Expression of 
Muc2 was detected using an anti-Muc2 antibody H-300, (1:1000 in PBS; SC-15334, 
Santa Cruz, SanverTech, Heerhugowaard, the Netherlands). To detect goblet cells, 
anti-trefoil factor 3 (Tff3; 1:3000 in PBS; a generous gift from Prof. Dr. D. K. Podolsky3) 
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was used. As a marker for enterocyte differentiation in the colon villin was used 
which was detected with an anti-villin antibody (1:2000 in PBS, generously given by 
Dr. S. Robine23). To visualize BrdU incorporation, the sections were incubated with 
anti-BrdU (Boehringer Mannheim, Mannheim, Germany) as described previously19, 
20. CD3+ cells were detected using an anti-human CD3 (DAKO, Heverlee, Belgium; 
1:800 in 1% BSA, 0.1% Triton X100 in PBS). Additionally, non-specific binding was 
reduced by blocking with TENG-T (10 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 
0.25% (w/v) gelatin, 0.05% (w/v) Tween-20).
mRNA expression of secretory mucins in the distal colon
 Total RNAs from mouse tissues were prepared using the QIAamp 
RNA midi-kit (Qiagen, Venlo, the Netherlands), following the manufacturer’s 
protocol and treated with DNase (Qiagen). Total RNA (1.5 µg) was used to 
prepare first-strand cDNA (AdvantageTM RT-for-PCR kit; BD Biosciences, Clontech, 
Alphen aan den Rijn, the Netherlands). PCR was performed on 5 µl of cDNA using 
primer pairs specific for Muc5ac 5’-GAGGCCAACAAGGTAGAGCACA-3’ and 5’-
TGGGACAGCAGCAGTATTCAGT-3’24, Muc5b 5’-GAGGTCAACATCACCTTCTGC-3’ and 
5’- TCTCATGGTCAGTTGTGCAGG-3’, Muc6 5’-TGGTCGAAGTACTCATTCTGG-3’ and 
5’-GTGGCTTGTGTGGCAACGCC-3’ and β-actin 5’-TCACGCCATCCTGCGTCTGGACT-
3’ and 5’- CCGGACTCATCGTACTCCT-3’ as an internal standard25. PCR products were 
295 bp, 319 bp, 569 bp and 582 bp respectively. PCR reactions were carried out 
in 50 µl final solutions as described previously26 using Invitrogen TAQ polymerase 
(Invitrogen, Breda, the Netherlands). A positive control for each mucin PCR 
(stomach for Muc5ac and Muc6, larynx for Muc5b) and a negative control without 
cDNA were amplified with each PCR experiment. Annealing temperature was 58oC. 
PCR products were analyzed on 1.5% ethidium bromide stained agarose gels run 
in 1×Tris/borate/EDTA buffer. As a marker, a 100 base pair DNA ladder (Invitrogen) 
was used.
Probe preparation and in situ hybridization
 RNA isolation, cDNA preparation and PCR for Muc6 was performed 
as described above. The resulting 569 bp PCR product was isolated using the 
Qiagen gel extraction kit (Qiagen), ligated into the pGEM-Teasy vector (Promega, 
Madison, WI, USA) and verified for sequence integrity using T7; SP6 primers and 
ABI Prism 310 and software (Applied Biosystems, Nieuwerkerk aan den IJssel, the 
Netherlands). Subsequently, the Muc6 fragment was subcloned into the pBluescript 
KS vector (Stratagene, La Jolla, CA, United States of America) using the EcoRI 
restriction enzyme. The pBluescript KS vector contains T3 and T7 RNA polymerase 
sites. The digoxigenin-11-UTP-labelled sense (T3) and anti sense Muc-6 (T7) RNA 
probes were prepared according to the manufacturer’s protocol (Roche, Almere, the 
Netherlands). Non-radioactive in situ hybridization was performed according to the 
method already described27, with slight modifications28, 29.
Quantitative real-time PCR (Taqman technology) 
 The mRNA expression levels of tumor necrosis factor alpha (TNF-α), interleukin-
1beta (IL1-β) and interleukin-6 (IL-6), as well as the endogenous housekeeping gene 
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β-actin were quantified using real-time PCR analysis (Taqman chemistry) based upon 
the intercalation of SYBR® Green on an ABI Prism 7700 sequence detection system (PE 
Applied Biosystems, Nieuwerkerk aan den IJssel, the Netherlands). Primers combinations 
for β-actin (5´-GGGACCTGACGGACTAC-3´ and 5´-TGCCACAGGATTCCATAC-3´), 
IL-1β (5´-CCCCAACTGGTACATCA-3´ and 5´-AGAATGTGCCATGGTTTC-3´), 
IL-6 (5´CCCAACAGACCTGTCTAT-3´ and 5´-GGCAAATTTCCTGATTAT-3´) and 
TNF-α (5´-TGGCCTCCCTCTCATC-3´ and 5´-GCTGGCACCACTAGTT-3´) were 
designed using the OLIGO 6.22 software (Molecular Biology Insights, Cascade, CO, 
USA) and purchased from Invitrogen. All primers had a melting temperature (Tm; 
nearest neighbor method) between 65-66.5°C. All PCRs performed with comparable 
efficiencies of 95 percent or higher. The PCR was performed using 1x SYBR® Green 
Master mix (Bioké, Leiden, the Netherlands), 1x ROX reference dye, 15 pmol forward 
and reverse primers, and 5 µl 5x diluted cDNA (“RNA isolation and cDNA synthesis”, 
as described above) from each mouse as a template in a total reaction volume of 
50 µl in a MicroAmp optical 96-well plate and covered with MicroAmp optical caps 
(Applied Biosystems). Samples were heated for 10 minutes at 95°C and amplified for 
40 cycles of 15 seconds at 95°C and 60 seconds at 60°C. To verify the amplification 
efficiency within each experiment, a serial dilution of cDNA derived from an RNA-
pool of control colon samples in dH2O was amplified in duplicate on each plate. 
Since all PCRs performed with equal efficiencies, relative mRNA expression levels 
of TNF-α and IL-1β for each mouse can directly be normalized for input RNA against 
the β-actin expression of the mice. For this, the relative mRNA expression levels of 
these target genes were calculated according to the comparative cycle time (Ct) 
method30, following the equation:
relative mRNA expression = 2 -(Ct target-Ct β-actin) × 100%.
DSS treatment
 One week prior to DSS administration, eight-week-old, specified pathogen 
free, male WT, Muc2+/- and Muc2-/- littermates were divided into groups of 6 mice, 
given free access to autoclaved tap water and were weighed daily in order to adjust 
to the experimental conditions. During the experiment, daily prepared autoclaved 
tap water supplemented with 2.5% (w/v) DSS (37-40kD, TdB Consultancy, Uppsala, 
Sweden) was administered for 5 days, followed by a recovery period during which 
the DSS was omitted from the drinking water. Scoring of the mice was performed 
daily, using the DAI as adapted from Cooper et al17 as described above. A group of 
animals were sacrificed on day 2 (onset of disease), day 8 (severe disease) and a 
control group at the end of the experiment (no DSS). Tissue segments were obtained, 
processed, and scored as described above.
Statistical analysis
 All data are expressed as mean ± SEM. Statistical significance of the 3 
different groups of mice during time was assessed by one-way analysis of variance 
test and Tukey t test. The Mann–Whitney U test was used to analyze changes in mRNA 
expression assessed by real-time PCR (Prism, version 4.00; GraphPad software, 
San Diego, CA, USA). The data were considered statistically significant at P<.05.
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Results
Clinical symptoms
 The Muc2 deficient mouse model12 was used in this study to explore the in 
vivo function of Muc2 in the colon. There were no significant differences between 
the WT and Muc2+/- mice regarding body weight at any time (Fig. 1). Moreover, 
occult blood loss, gross bleeding and rectal prolapses did not occur in WT and Muc2+/- 
mice. In contrast, Muc2-/- mice were clearly distinguishable from their Muc2+/- and WT 
littermates at 5 weeks of age due to significant growth retardation [P<.001 Muc2-/- vs. 
Figure 1. Appearance and clinical symptoms of WT, Muc2+/- and Muc2-/- mice in time. (A) Body 
weight of the different mice in time. WT and Muc2+/- were indistinguishable, whereas Muc2-/- mice were 
significantly growth retarded (*WT vs. Muc2-/-; P<.001, Muc2+/- vs. Muc2-/-; P<.001). The arrow in the 
graph depicts spontaneous death of one Muc2-/- mouse. (B) Clinical symptoms of the Muc2-/- mice, 
The arrow indicates that all Muc2-/- animals showed the described symptoms. These symptoms were 
not observed in WT and Muc2+/- mice. (C) Photograph of a WT and Muc2-/- mouse at 16 weeks of age. 
(D) DAI is an accumulative score as adapted from Cooper et al17. To be able to calculate percentage 
weight loss, Muc2+/- and Muc2-/- animals were compared to the average weight of WT littermates of 
the same age. (#WT and Muc2+/- vs. Muc2-/-, P<0.001 at each time point. *WT vs. Muc2+/-; P<.05 at 5 
weeks of age). DAI of the Muc2-/- mice progressively increased with time (†P<.001 week 5 vs. week 
8 and week 8 vs. week 12). The DAI of WT remained zero at each time point investigated. Error bars 
indicate the SEM.
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both WT and Muc2+/-, at each time point] (Fig. 1A and C). Over time, the weight 
difference between the mice increased further as the Muc2-/- mice failed to gain 
weight. In addition to diarrhea at 7 weeks of age, all Muc2-/-   mice showed occult 
blood loss by week 8. Most Muc2-/- mice developed gross bleeding (9 out of 12) or 
some mice showed reversible rectal prolapses (3 out of 8, as of 9 weeks of age). 
Scoring these clinical parameters in conjunction resulted in a DAI as given in Figure 
1D. The Muc2-/- mice had a significantly higher DAI score compared to both WT and 
Muc2+/- mice at each time point investigated [P<.001]. Moreover, the DAI of the Muc2-
/- mice progressively increased with time. One of the Muc2-/- mice died at 12.5 weeks 
of age; therefore, this mouse was excluded from the DAI score. In contrast, none of 
the WT or Muc2+/- mice died during the time frame studied. With respect to clinical 
symptoms there was a statistically significant difference between WT and Muc2+/- 
mice only at 5 weeks of age. Yet, the Muc2+/- mice had a DAI above zero at each time 
point investigated, whereas the DAI of WT remained zero. The increased disease 
score in the Muc2+/- mice was 
attributed to the small, but 
statistically non-significant, 
weight difference between 
WT and Muc2+/- mice, which 
was seen throughout the 
experiment (Fig. 1A).
Morphological analysis
 In agreement with 
the clinical observations, 
there were no morphological 
differences in the proximal 
or distal colon between WT 
and Muc2+/- mice at any of 
the time points investigated 
(data not shown). The main 
characteristic change between 
Muc2-/- and WT mice was the 
lack of recognizable goblet 
cells along the crypt-villus 
axis of the small intestine as 
previously reported12. Despite 
this, the small intestine of 
Figure 2. Colonic morphology and proliferation in WT and Muc2-/- mice. Representative sections 
of WT colon are depicted at 8 weeks of age (A; proximal colon, D; distal colon). (B and C) Proximal 
colon of the Muc2-/- mice at 5 and 16 weeks of age, respectively. (E and F) Distal colon of the Muc2-/- 
mice at 5 and 16 weeks of age, respectively. BrdU staining of the distal colon of (G) WT and (H) Muc2-
/- both 8 weeks old. Higher magnification of the epithelial cells in Muc2-/- mice at (I) 8 weeks and (J) 16 
weeks of age. Arrows indicating loss of epithelial cells. The micrographs show representative results 
of the four mice from each experimental group.
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Muc2-/- mice showed no changes from WT littermates up to 12 weeks of age. At 16 
weeks old, the Muc2-/- mice showed an increase in crypt length compared to the wild 
type mice (data not shown). However, the colonic morphology of Muc2-/- animals 
differed considerably from their WT littermates (Fig. 2A-F). In addition to the absence 
of the characteristic bell shape morphology of the goblet cells in the proximal and 
distal colon of the Muc2-/- mice, we observed a loss of crypt architecture and of overall 
structure of the lamina propria in the proximal colon of Muc2-/- animals, 16 weeks 
of age (Fig. 2C). This was accompanied by a statistically non-significant alteration 
in crypt length in proximal colon observed from 5- up to 8-week-old Muc2-/- mice. A 
significant increase in crypt length of the proximal colon in Muc2-/- mice compared 
to their WT littermates (36%, P<.001) was first detected in 12-week-old mice and 
remained until 16 weeks of age (data not shown).
 Alterations in the distal colon of Muc2-/- mice (Fig 2D-F) were much more 
severe compared to the proximal colon (Fig. 2A-C). Already at 5 weeks of age, crypt 
hyperplasia, mild infiltration, flattening of epithelial cells and distortion of the lamina 
propria were observed. In the distal colon of the Muc2-/- mice, goblet-like cells (Alcian 
blue positive, data not shown) could be seen deep in the crypts of the distal colon 
of 5-week-old animals. These Alcian blue-stained cells disappeared as the overall 
damage of the distal colon increased and were undetectable in tissue sections of 
12- to 16-week-old mice. The structure of the epithelial cells in the Muc2-/- mice was 
distorted and flattened, as depicted in Figure 2F, 2I and 2J. Furthermore, there was 
severe loss of the architecture of the lamina propria, which was most pronounced 
in older mice (16 weeks). This coincided with an increase in infiltrating inflammatory 
cells and the presence of superficial erosions. Figure 3A shows that there was a 
significant increase of crypt length in the distal colon of the Muc2-/- mice throughout 
the experiment. As early as 5 weeks of age, the mucosa of Muc2-/- mice showed a 
thickening of more than 200% [P<.001, Muc2-/- vs. WT, all ages], reaching about 
250% increase by 16 weeks [P<.001].
Figure 3. Quantification of the histological 
changes in the distal colon of Muc2-/- mice. To 
detect differences in (A) crypt length and (B) height of 
the epithelial cells in the Muc2-/- mice, 10 well-oriented 
crypts and epithelial cells in the distal colon were 
chosen from each individual animal in the experimental 
groups and measured using calibrated Leica software. 
At all time points crypt length and cell height were 
expressed as a percentage of the corresponding 
values of WT littermates (#P<.001, aP<.05). Crypt 
length and of the Muc2-/- mice progressively increased 
and epithelial height decreased as the mice aged.
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 Epithelial proliferation was studied by immunohistochemical staining of 
incorporated BrdU. No differences were detected between the WT and Muc2-/- mice in 
distribution or localization of BrdU-positive cells in the proximal colon at all ages (data 
not shown). In WT mice BrdU-positive cells were localized at the base of the crypts in 
the distal colon (Fig. 2G, 8 weeks old). In the distal colon of all Muc2-/- mice, however, 
there was a significant increase in the number of BrdU-positive cells as early as of 5 
weeks of age, which remained constant with time, and these cells extended halfway 
up the crypt (Fig. 2H). There were no differences in number of apoptotic bodies 
along the crypts, between the Muc2-/- and WT mice (data not shown).
 There was significant flattening (P<.001) of colonic epithelial cells of the 
Muc2-/- animals at 5 weeks of age, resulting in cells of only 40% (P<.001) of the 
height of the epithelial cells in WT mice at 16 weeks of age (Fig. 3B). Locally, in 
each of the Muc2-/- mice, there was even complete loss of epithelial cells (Fig. 2I, 2J) 
resulting into superficial erosions.
 Overall, the histology along the proximal-distal axis of the colon in 
Muc2-/- mice showed an increase in damage mainly characterized by thickening of the 
intestinal mucosa, flattening and degeneration of the epithelium, superficial erosions 
and infiltration of inflammatory cells, which aggravated as the mice aged. Moreover, 
untreated Muc2-/- mice from continuing experiments (our unpublished data; n=34, 
8-weeks of age), all show clinical and histological symptoms corresponding to 
animals of the same age as described above.
Expression of goblet cell and enterocyte markers
 Maturation of the intestinal epithelial cells in the Muc2-/- mice was characterized 
using molecular markers for tissue and cell-type specific differentiation. Two markers 
for goblet cells, Muc2 and Tff3, were both expressed throughout the whole crypts in 
the proximal and distal colon of WT and Muc2+/- mice (Fig. 4A and C; showing distal 
Figure 4. Protein expression 
in the distal colon. Goblet 
cells were stained for (A and B) 
Muc2 and (C and D) Tff3. As 
an enterocyte marker villin was 
used (E and F). A, C, and E, are 
sections representing tissue from 
the distal colon of WT animals and 
B, D, and F, represent tissue from 
the distal colon of Muc2-/- animals, 
respectively. Inserts in C and D 
show a close-up of a goblet cell in 
WT and Muc2-/- mice, respectively. 
Insert in E shows a close-up of 
normal villin expression by WT 
enterocytes. F shows loss and 
redistribution (arrow heads) of 
villin expression by the epithelial 
cells of Muc2-/- mice. Please also 
see page 219.
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colon, WT mouse) Goblet cells in the entire colon of the Muc2-/- mice were negative 
for Muc2 (Fig. 4B), but Tff3 was clearly detectable (Fig. 4D). The goblet cells in the 
proximal colon as well as distal colon of the Muc2-/- mice showed a distinct change 
in morphology. Whereas the goblet cells of the WT mice were round and bell shaped 
(insert of panel 4C; distal colon) the goblet cells of the Muc2-/- mice appeared smaller 
and more condensed (insert of panel 4D; distal colon). 
 Villin, a cytoskeletal protein, present in the brush border of enterocytes was 
used as a marker for this cell type23. Villin was uniformly present in the brush border 
of enterocytes in the proximal and distal colon of both WT mice and Muc2+/- mice 
(Fig. 4E; showing distal colon, WT mouse). In the distal colon of the Muc2-/- mice, 
however, a redistribution of villin to the cytoplasm in seemingly unaffected epithelial 
cells was seen (insert of panel 4F).
Figure 5. Increased lymphocyte infiltration and expression of inflammatory cytokines.
Representative sections presenting lymphocyte infiltration into the colon of (A) WT and (B and C) 
Muc2-/- animals, detected using an anti-CD3 antibody. In the Muc2-/- mice there was an increase of 
lymphocyte infiltration, in parts of the colon were there was loss of epithelial cells (B). Parts of the 
colon that were unaffected (C) were comparable to sections of the WT mice. (D) Real time PCR data 
of the inflammatory cytokine TNF-α in the colon of Muc2-/- mice was significantly up regulated (P=.03) 
compared to WT mice. Furthermore, the Muc2-/- mice showed a trend towards up regulation of IL-1β 
mRNA in the colon.
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Increased lymphocyte infiltration and expression of inflammatory cytokines
 Lymphocyte infiltration into the colon was evaluated using an anti-CD3 
antibody. Representative stained tissue samples are shown in Figure 5A-C. In the 
Muc2-/- mice there was an increase of lymphocyte infiltration, e.g. CD3 positive cells, 
in parts of the colon were there was loss of epithelial cells. Parts of the colon that 
were unaffected were comparable to sections of the WT mice.
 In accordance with the histological data, there was a significant increase 
(5-fold) in expression of mRNA of the inflammatory cytokine TNF-α in the colon of 
Muc2-/- mice compared to WT mice (P=.03). Furthermore, the Muc2-/- mice showed a 
trend towards up regulation (4-fold) of IL-1β in the colon (Fig. 5D, showing 8 weeks 
of age), which was at the brink of significance at 16 weeks of age ((P=.05, n=3), 
data not shown). However, IL-6 was below detection levels in both types of mice 
throughout the experiment (data not shown). 
mRNA expression and localization of secretory mucins in the distal colon
 Apart from Muc2, three other secretory mucins are known to be expressed 
by the gastrointestinal tract, that structurally resemble Muc2: Muc5ac, Muc5b and 
Muc631. To evaluate expression of these secretory mucins, we determined the 
mRNA expression of Muc5ac, Muc5b and Muc6 by RT-PCR. WT, Muc2+/- and Muc2-
/- animals showed no expression of Muc5ac and Muc5b mRNA in either the proximal 
or distal colon (data not shown). In the proximal colon of WT, Muc2+/- and Muc2-/- 
mice, Muc6 mRNA was detectable throughout the experiment in very low amounts 
with no differences between the WT and the Muc2-/- mice (data not shown). In the 
distal colon of the Muc2-/- mice, de novo expression of Muc6 mRNA was observed at 
5 weeks of age and the expression declined as the mice aged (Fig. 6A), in contrast 
to WT mice, which showed no expression of Muc6 at 5 to 12 weeks, but only a low 
level of expression at 16 weeks.
Figure 6. mRNA expression and 
localization of Muc6 in the distal 
colon. (A) Endogenous expression of 
Muc6 mRNA and β-actin in the distal 
colon of both WT and Muc2-/- animals. 
The week number above the picture of 
the PCR product stands for the age of 
the animals during the experiment. In situ 
hybridization was used to localize Muc6 
mRNA expression in the distal colon of the 
Muc2-/- mice. (B) Staining of mouse gastric 
glands with Muc6 digoxigenin-labeled 
antisense RNA probe as a positive control. 
(C) Staining of colon mucosa of Muc2-
/- mice with Muc6 digoxigenin-labeled 
sense probe as a negative control. (D) 
Staining of colon mucosa of Muc2-/- mice 
with Muc6 digoxigenin-labeled anti-sense 
probe. Asterisk indicates the lumen of the 
different segments. The tissue samples 
are representative of 4 mice.
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 To localize the cells expressing Muc6 mRNA, in situ hybridization was 
performed. As a positive control, and corresponding to previous studies performed 
in humans32, 33, Muc6 mRNA was detected only in the mucous neck cells of the 
stomach, whereas all surface mucous cells were negative (Fig. 6B). The sense probe 
showed no staining in the stomach (data not shown) and colon, demonstrating that 
the in situ hybridization is specific for Muc6 (Fig. 6C). As shown in Figure 6D, Muc6 
was expressed in the lower parts of the crypts of the distal colon in the Muc2-/- mice 
at 5 weeks. This correlated in time and location with the presence of Alcian blue-
positive cells, seen deep in the crypts of the distal colon of Muc2-/- animals, 5 weeks 
of age (Fig. 2E). These cells disappeared as the overall damage of the distal colon 
increased and were undetectable in sections as from 12 to 16 weeks of age (Fig. 2F, 
16 weeks).
Effects of DSS treatment
 In order to determine the role of Muc2 in epithelial protection, 8-week-old 
Muc2-deficient and heterozygous mice were challenged with DSS. The susceptibility 
to DSS-treatment was determined by analyzing the DAI and the histology of the 
distal colon. During the first days of the DSS-treatment, the WT and Muc2+/- mice 
showed no striking differences in their response to the DSS (Fig. 7A). The Muc2+/- 
mice showed a higher DAI in reaction to DSS on day 7 (P<.04) and day 8 (P=.05), 
when compared to their WT littermates (Fig. 7A). The Muc2-/- mice had a significantly 
higher (P<.001) DAI from the start of the DSS administration, as described above 
(Fig. 1D). The rise in DAI score of the Muc2-/- mice during and after DSS-treatment 
was caused by severe weight loss and the occurrence of severe gross bleeding 
towards the end of the experiment (DAI of Muc2-/- vs. WT P<.001 all time points; DAI 
of Muc2-/- vs. Muc2+/- P<.001 up to day 6, P<.01 day 7 and P<.05 day 8).
 HE-stained sections from paraffin-embedded segments were used to score 
colonic inflammation (Table 2). The Muc2-/- mice showed a different pathology in 
reaction to the DSS-treatment compared to the pathology seen in WT and Muc2+/- 
mice. Before DSS-treatment, the Muc2-/- mice already showed thickening of the 
intestinal mucosa, change in goblet cell morphology, degeneration of the epithelium 
and lamina propria, superficial erosions and infiltration of inflammatory cells. On day 
2, the reaction of the Muc2-/- was comparable to WT and Muc2+/- mice, with a mild 
influx of inflammatory cells and overall loss in architecture. However, during severe 
disease (day 8 after start of DSS-treatment) the Muc2-/- mice displayed substantial 
crypt abscesses vs. extended ulcerations in the WT and Muc2+/- mice (Fig. 7C). 
 To further delineate any difference between the WT and Muc2+/- mice, 
histological damage was scored for mice of both genotypes. No striking differences 
were seen between WT and Muc2+/- mice (Fig. 7C). Fewer goblet cells were present in 
the crypts of the Muc2+/- mice, but this did not result in a significantly higher histology 
score at the start of the DSS-treatment (Fig. 7B). On day 2 (onset of disease) the 
first changes due to DSS-treatment were detectable. This was characterized by an 
overall loss in architecture, loss of goblet cells and a mild influx of inflammatory cells 
(Fig. 7C). During the most severe stage of the disease (day 8), there was a notable 
difference between the WT and Muc2+/- mice in the percentage epithelial ulcers 
present in the sections, general loss of architecture, loss of goblet cells and influx of 
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inflammatory cells (Fig. 7C). When combining the items of the histology score, the 
Muc2+/- mice had a significantly higher score than the WT mice during DSS treatment 
(Fig. 7B, day 2 P<.001; day 8 P<.05).
 Taking these results together, the DSS-experiment showed that predictably, 
Muc2-/- mice are more susceptible to colonic damage compared with their WT 
littermates. Interestingly, the Muc2+/- mice displayed an intermediate sensitivity 
towards DSS-treatment.
Figure 7. Effects of DSS treatment on disease activity score (DAI) and histology. (A) Relative 
changes in the DAI of WT (black bars), Muc2+/- (stippled bars) and Muc2-/- (white bars) DSS-treated 
mice. To be able to calculate percentage weight loss, WT, Muc2+/- and Muc2-/- animals were compared 
to their individual body weight prior to the DSS-administration. Error bars reflect the SEM of the 
changes of the DAI score on each day. Days of DSS/water treatment are indicated as arrows under the 
x-axis. (DAI Muc2-/- vs. WT  #P<.001 all time points; DAI Muc2-/- vs. Muc2+/- P<.001 up to day 6, aP<.01 
day 7 and bP<.05 day 8; DAI WT vs. Muc 2+/- day 7 and 8 P<.05) (B) Histology scores as determined 
according to Rath el al 21 determined for WT vs. Muc2+/- mice (aP<.001,  *P<.05). Error bars reflect the 
SEM. (C) Representative sections of the distal colon on day 2 and day 8 after the start of the DSS-
administration of WT, Muc2+/- and Muc2-/- mice. Please also see page 220.
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Discussion
 Muc2 is generally assumed to be essential for epithelial protection. However, 
this assumption had never been put to the test experimentally. In this study we have 
addressed this question by characterizing mice deficient in Muc2 from birth until 16 
weeks of age and by challenging these mice with an orally administered, noxious 
agent to determine the protective capacity of the Muc2-deficient, epithelial barrier.
 The Muc2-/- animals showed growth retardation and significantly lower 
body weight at 5 weeks of age, compared to WT and Muc2+/- littermates and these 
differences in body weight progressed as the mice aged. Growth failure is associated 
with IBD and is most probably caused by malnutrition34, a multi-factorial problem. As 
the mice aged, the Muc2-/- animals showed occult blood loss to gross bleeding and 
diarrhea. Furthermore, the Muc2-/- mice showed microscopic evidence of colitis as 
early as 5 weeks of age, which aggravated as the mice aged. Moreover, the rectal 
prolapses which occasionally developed in Muc2-/- mice, are a characteristic often 
seen in animal models of IBD such as the IL10-deficient mice35 Together with weight 
loss these symptoms are similar to those experienced by patients that suffer from 
IBD36, indicating that the Muc2-/- mice constitute a model to study aspects of IBD.
 In the proximal colon, there were no distinct changes in epithelial proliferation 
between WT and Muc2-/- mice in contrast to the distal colon where the proliferation 
was very much increased and the proliferative zone was much broader in the crypts 
of the Muc2-/- mice, coinciding with an increase (up to about 250%) in thickness of 
the colonic mucosa. In germ-free mice, colonic crypts were shown to have a lower 
mitotic index and labeling index compared to conventional mice37. An increase in 
proliferation in the distal colon of the Muc2-/- mice could thus be explained by an 
altered bacterial stimulation of the epithelium due to a diminished mucus layer. 
 A histological hallmark of the Muc2-/- mice was the lack of recognizable 
goblet cells throughout the entire intestine. These findings correspond with previous 
studies showing that Muc2, which is stored in apical granules of goblet cells, is the 
most important factor determining the goblet cell morphology11-13, 38, 39. That indeed 
goblet cells were present in the mucosa of the Muc2-/- was determined by using an 
antibody against Tff3. Tff3-positive goblet cells were present throughout the entire 
large intestine. Apparently, goblet cells in absence of Muc2 lose their characteristic 
goblet-like shape, corroborating the notion that Muc2 is the major phenotypic 
determinant of goblet cells. This result also supports the hypothesis that Muc2 and 
Tff3, two markers of the goblet cell phenotype, are not co-coordinately regulated40.
The inflammation of the distal colon in Muc2 deficient mice, also affects the 
differentiation of other epithelial colonic cells like the enterocytes as indicated by loss 
of villin, and the redistribution of villin, from the apical membrane to the cytoplasm. 
Also other enterocyte-specific protein expression were shown to be down-regulated 
during intestinal damage41.
 It is well known that pro-inflammatory cytokines play an important role in 
inflammation of the intestinal mucosa. For instance, TNF-α, IL-1β and IL-6 have 
shown to play a pivotal role in the pathogenesis of IBD1, 42, 43. Analysis of colon tissue 
samples of the Muc2-/- mice by real time PCR, showed an up-regulation of TNF-α and 
IL-1β, but not of IL-6. In conjunction these data further support the Muc2-/- mouse as 
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a unique and new type of colitis model different from previously published models.
 By including all regions of the intestine in our study, we have revealed 
the effect of absence of Muc2 on colonic epithelium throughout the intestine. We 
determined the expression of other secretory mucin genes, structurally related 
to Muc2, by RT-PCR. Results of the proximal colon of both WT and Muc2-/- were 
negative for Muc5ac, Muc5b, and positive for Muc6 mRNA. In the distal colon we 
were not able to detect Muc5ac or Muc5b in both WT and Muc2-/-. These findings are 
consistent with previous studies in both human and mouse colon25, 44 and consistent 
with the previous study on Muc5ac mRNA performed in Muc2-/- mice by Velcich et 
al12. Transient de novo expression of Muc6 mRNA however, was observed in the 
distal colon of Muc2-/- mice at 5 weeks of age and declined as the Muc2-/- mice aged. 
Interestingly, morphological analysis of the distal colon of Muc2-/- mice at 5 weeks of 
age revealed the presence of goblet-like cells in the lower part of the crypts. Moreover, 
these goblet-like cells appeared to be Alcian blue-positive and were depleted at 16 
weeks, indicating that these goblet-like cells might be expressing Muc6. Indeed, in 
situ hybridization studies demonstrated Muc6 mRNA in the goblet cells deep in the 
crypts of the Muc2-/- at 5 weeks of age. The induced Muc6 expression in the Muc2-/- 
mice possibly results from a compensatory protective mechanism within the colonic 
epithelium. Muc6 was previously shown to be aberrantly expressed in the intestine 
in pathological situations when mucosal repair is needed and was then associated 
with trans-differentiation and the development of a gastric cell-like phenotype45. The 
de novo expression of Muc6 mRNA in Muc2-/- mice may reflect such a need as a 
compensatory mechanism. 
 Our results are partly in contrast to data published from previous studies 
using the Muc2-/- mouse12, 13, as we have shown distinct clinical symptoms from an 
early age, no distinct histology in the small intestine and a pathology in the distal 
colon. The studies described by Velcich et al12 were performed using a mixed 
genotypic background (C57/BL6-129SV), while in the current study, the knockout 
mice had a 129SV background only. It is possible that the differences of phenotype 
in the Muc2-/- mice can be attributed to differences in strain background as described 
previously for the IL10 deficient mouse46.
 To investigate the question further, as to whether Muc2 is involved in epithelial 
protection against luminal factors we induced colitis by giving WT, Muc2+/- and Muc2-/- 
mice DSS, a cytotoxic agent. DSS induces several clinical symptoms (i.e. diarrhea, 
bloody stools and weight loss) and histopathological changes (i.e. erosions and crypt 
loss) in normal rats and mice17, 20. Muc2-/- mice showed severe clinical symptoms 
after receiving DSS in their drinking water, as the disease aggravated, marked by 
weight loss and gross bleeding. These findings were consistent with a previous pilot 
conducted in our laboratory38, and were not surprising as Muc2-/- mice had already 
had bloody stools and diarrhea before receiving the DSS. Most interestingly however, 
Muc2+/- mice showed an intermediate clinical response to the DSS-treatment. When 
investigating the histopathology, Muc2+/- mice showed a significantly more severe 
reaction to the DSS compared to WT mice, characterized by crypt loss, infiltration 
and ulcerations. This indicates that (partial) deficiency of Muc2 predisposes 
the development of colonic inflammation. This is further supported by our earlier 
studies performed in IL10-/- mice showing that quantitative and structural aberrations 
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in Muc2, likely reduce the ability of the mucosa to cope with non-pathogenic 
commensal bacteria and that this may contribute to the susceptibility to develop 
colitis39. The Muc2-/- mice showed a different histopathology compared to both WT 
and Muc2+/- mice marked by crypt abscesses. DSS has shown to initially cause 
damage in the intestine by inhibition of proliferation and induction of apoptosis20. The 
different histology displayed by the Muc2-/- mice may be explained by the fact that the 
Muc2-/- initially had an increased proliferation rate before receiving DSS. This 
however, needs to be investigated further.
 To summarize, loss of Muc2 in the intestine, and therefore breaches in 
the epithelial barrier, leads to an abnormal morphology marked by an increase in 
thickness of the gut mucosa, flattening and ulceration of epithelial cells, general loss 
of architecture, mild increase of inflammatory cells, an increase in proliferation, and 
decrease of cell differentiation in the colon. Furthermore, we have shown that changes 
in the mucus composition, caused by Muc2 deficiency, leads to inflammation of the 
colon and that deficiency of Muc2 contributes to the onset and/or perpetuation of 
IBD. Moreover, we believe that the Muc2-/- and the Muc2+/- mice are powerful animal-
models, enabling us to study the physiological role of the epithelial barrier in many 
aspects.
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Chapter 4
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Abstract
Expression of the mucin MUC2, the structural component of the colonic mucus layer, is 
lowered in ulcerative colitis. Furthermore, IL10 knockout (IL10-/-) mice develop colitis and 
have reduced Muc2 levels. Our aim was to obtain insight in the role of Muc2 and IL10 in 
epithelial protection. Muc2-IL10 double knockout (Muc2/IL10DKO) mice were characterized and 
compared to Muc2 knockout (Muc2-/-), IL10-/- and wild type (WT) mice. Clinical symptoms were 
monitored and intestinal morphology and differences in epithelial-specific protein levels were 
analyzed. Additionally, levels of the pro-inflammatory cytokines in colonic tissue and serum 
were determined. IL10-/- mice were indistinguishable from WT mice throughout this experiment 
and showed no clinical or microscopical signs of colitis. Muc2/IL10DKO mice and Muc2 knockout 
(Muc2-/-) mice showed significant growth retardation and clinical signs of colitis as of 4 and 
5 weeks of age, respectively. Muc2/IL10DKO mice had a high mortality rate [50% survival/ 5 
weeks] compared to the other types of mice [100% survival]. Microscopic analysis of the colon 
of Muc2-/- showed mucosal thickening, increased proliferation and superficial erosions, which 
were even more pronounced in Muc2/IL10DKO mice. Furthermore, pro-inflammatory cytokines 
were significantly up-regulated, both in tissue (mRNA) and systemically in Muc2/IL10DKO mice. 
Muc2/IL10DKO mice develop colitis, which is more severe in every aspect compared to Muc2-
/- mice. These data indicate that i) in case of Muc2 deficiency, the anti-inflammatory cytokine 
IL10 can control epithelial damage, though to a limited extent and ii) the mucus layer is most 
likely a key factor determining colitis.  
Abbreviations used in this paper
CD, Crohn’s disease; DAI, disease activity index; IBD, inflammatory bowel disease; IL, 
interleukin; IL10-/-, Interleukin-10 knockout mice; Muc, Mucin; Muc2-/-, Mucin 2 knockout 
mouse; WT, wild type mouse; Muc2/IL10DKO, Mucin2/IL10 double knockout mouse; Tff3, trefoil 
factor 3; TNF-α, tumor necrosis factor alpha; UC, Ulcerative colitis
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Introduction
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and 
Crohn’s disease (CD), are characterized by chronic inflammation and mucosal 
tissue damage of parts of the gastrointestinal tract. A widely accepted hypothesis 
suggests that these diseases are caused by a combination of genetic, environmental, 
immunoregulatory, and epithelial factors1, 2.
Interleukin(IL)-10 plays a major role in maintenance of intestinal homeostasis by 
suppressing proinflammatory cytokine production1, 3, 4. A well described model 
mimicking a immunoregulatory defect, is the IL10 deficient (IL10-/-) mouse4-6. 
IL10-/- mice spontaneously develop chronic colitis, of which the severity is dependent 
on both strain background and environmental factors. Relocation of IL10-/- mice from 
conventional specific pathogen free environments into germ-free isolators eliminates 
immune system activation and colitis development7, 8.
The epithelium and mucus layer in the intestinal tract form a physical barrier between 
the potential noxious agents present in the gut lumen and the underlying tissues. 
Mucins are the building blocks of the mucus layer and previous studies have shown 
that human, rat and mouse colonic epithelium expresses mainly one secretory mucin 
in high amounts, Muc29-13. As we described recently, loss of Muc2 in the intestine, 
and therefore changes in the protective capacities of the mucus layer, leads to 
inflammation of the colon and therefore contributes to the onset and/or perpetuation 
of IBD14. In agreement, it has been shown that in patients with UC, the activity of the 
mucosal inflammation correlates significantly with a decrease in MUC2 synthesis 
and secretion15, 16. 
 Thus, considering that the severity of chronic intestinal inflammation can 
depend on environmental, immunoregulatory, and epithelial factors, we investigated 
the protective capacities of Muc2 and IL10 in the intestine, by generating Muc2/IL10 
double knockout (Muc2/IL10DKO) mice and determining whether the combination 
of defects in the immunoregulatory and epithelial factors could exacerbate the 
pathogenesis of inflammation. We therefore characterized Muc2/IL10DKO mice and 
compared their clinical symptoms and intestinal pathology to Muc2-/- and IL10-/- mice 
of the same age. This animal model is the first to provide insight into the role that 
both immunological and epithelial abnormalities, i.e. IL10 and Muc2 deficiency, play 
in the severity of colonic inflammation.
Materials and Methods
Animals 
 The previously described heterozygous Muc2129SV mice and mice carrying 
a homozygous null-mutation of the IL10 gene (IL10-/-), formally designated IL10tm1Cgn 
were bred to generate heterozygous double KO mice6, 14, 17. These heterozygous 
double knockout mice were bred with each other to generate homozygous Muc2/
IL10DKO mice.
Throughout the crossing procedure, the targeted Muc2 and IL10 gene were 
monitored via PCR assays performed on genomic DNA isolated from tail clips as 
previously described6, 18. The mice were housed in the same specific pathogen-
C
h
ap
te
r 
4
76
free environment, and all animal care and procedures were conducted according 
to institutional guidelines (Erasmus MC- Animal Ethics Committee, Rotterdam, the 
Netherlands). 
Experimental set-up
 The initial set-up of this experiment was to characterize wild type (WT) (n=24), 
IL10-/- (n=20) and Muc2/IL10DKO (n=23) littermates from 5 weeks until the age of 16 
weeks, consistent with our study on the Muc2-/- mouse14. We had to adapt this set-up 
as the Muc2/IL10DKO had a high mortality rate and Disease Activity Index (DAI) and 
it was not considered humane to continue this protocol. Therefore Muc2/IL10DKOand 
corresponding wild type (WT) littermates were sacrificed after 4 (Muc2/IL10DKO n=5, 
WT n=4), 5 (Muc2/IL10DKO n=7, WT n=4) and 7 (Muc2/IL10DKO n=1) weeks. As a 
control, IL10-/- and corresponding WT mice were sacrificed at 5, 8, 12, 16 and 34 
weeks of age (n=4, each time point) as these mice are known to develop colitis at 
a later age7, 19. Furthermore, all results from Muc2/IL10DKO mice were compared to 
previously published results on the Muc2-/- mouse14.
 All mice were scored to obtain a DAI as described by Cooper et al 
(Table I)20.  Briefly, they were scored for the following: weight, softness of the stool, 
occult faecal blood and general appearance of the mice. Epithelial cell proliferation 
was determined by in vivo DNA labelling with bromodeoxyuridine (BrdU), injected 
intraperitoneally 30 mg/kg body weight (Sigma, St. Louis, USA) one hour prior to 
sacrifice21, 22. Small intestine and colon were rapidly excised and either fixed in 4% 
(w/v) paraformaldehyde in PBS, stored in RNA later (Qiagen, Venlo, the Netherlands) 
at –20oC, or frozen in liquid nitrogen and stored at -80°C.
Histology and histological grading
 Tissue fixed in 4% (w/v) paraformaldehyde in PBS was prepared for light 
microscopy and 5 µm thick sections were stained either by 1) haematoxylin and 
eosin (H&E) or 2) Alcian blue (AB) at pH 2.5 followed by periodic acid/ Schiff’s reagent 
(PAS) as described previously to study histological changes23. Intestinal inflammation 
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was determined by monitoring number of goblet cells, mucosal thickening, presence 
of inflammatory cells, general destruction of architecture, presence of ulcers and/ or 
crypt abscesses. 
Immunohistochemistry
 Five-micrometer-thick sections were cut and prepared for 
immunohistochemistry, as described previously using the Vectastain Elite ABC kit 
(Vector Labs, Burlingame CA, USA) and 3,3’-diaminobenzidine as staining reagent22. 
Expression of Muc2 was detected using an anti-Muc2 antibody H-300, (1:1000 in 
PBS; SC-15334, Santa Cruz, SanverTech, Heerhugowaard, the Netherlands). To 
detect goblet cells, anti-trefoil factor 3 (Tff3; 1:3000 in PBS; a generous gift from Prof. 
Dr. D. K. Podolsky) was used 24. Muc4 was stained using anti-hMUC4 polyclonal 
antibody (hHA-1) that recognizes a C-terminal peptidic region of MUC4α subunit 
(1:6000 in 1% BSA, 0.1% Triton X100 in PBS)25.To visualize BrdU incorporation, 
the sections were incubated with anti-BrdU (Boehringer Mannheim, Mannheim, 
Germany) as described previously26. CD3+ cells were detected using an anti-human 
CD3 (DAKO, Heverlee, Belgium; 1:800 in 1% BSA, 0.1% Triton X100 in PBS). 
Additionally, non-specific binding was reduced by blocking with TENG-T (10 mM 
Tris-HCl, 5 mM EDTA, 150 mM NaCl, 0.25% (w/v) gelatin, 0.05% (w/v) Tween-20). 
Quantitative real-time PCR (Sybergreen) 
 The mRNA expression levels of the membrane bound mucins Muc1 
and -4 as well as the endogenous housekeeping gene β-actin were quantified 
using real-time PCR analysis (Taqman chemistry) based upon the intercalation 
of SYBR® Green on an ABI Prism 7700 sequence detection system (PE Applied 
Biosystems) as previously described14. The primers combinations for Muc1 
(5´- CTTTCAGAAGACTCCGCCAG -3´, and 5´- GGCCAAGACTGATTCAGAGC -3´) 
and Muc4 (5’´- CCCGCTCATCCACTATC -3´, and 5´- TGGCCTCCATTGTGAC -3´) 
were designed using the OLIGO 6.22 software (Molecular Biology Insights, Cascade, 
CO, USA) and purchased from Invitrogen (Breda, the Netherlands). All primers had a 
melting temperature (Tm; nearest neighbor method) between 65-66.5°C. In addition 
the mRNA expression levels of tumor necrosis factor alpha (TNF-α), interleukin (IL)-
1beta (IL1β) and IL6 as well as the endogenous housekeeping gene β-actin were 
quantified as previously described14. To verify the amplification efficiency within each 
experiment, a serial dilution of cDNA derived from an RNA-pool of control colon 
samples in dH2O was amplified in duplicate on each plate. Since all PCRs were 
performed with equal efficiencies, relative mRNA expression levels of Muc1, Muc4, 
TNF-α, IL1β and IL6 for each mouse can directly be normalized for input RNA against 
the β-actin expression of the mice. For this, the relative mRNA expression levels of 
these target genes were calculated according to the comparative cycle time (Ct) 
method27, following the equation: 
relative mRNA expression = 2 -(Ct target-Ct β-actin) × 100%.
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Serum cytokine levels
 Serum was obtained from coagulated blood collected by heart puncture 
(15 min at 37°C, then 30 min a 4°C) and stored at –20°C until further analysis. 
The concentrations of several cytokines (IL12, TNF-α, Interferon gamma (IFN-γ), 
Monocyte chemoattractant protein-1 (MCP-1), IL10 and IL6) in serum of the mice 
were determined with a BD Cytometric Bead Array mouse inflammation kit according 
to manufacturers instructions (BD-Pharmingen, San Diego, USA).
Statistical analysis
 All data are expressed as mean ± SEM. Statistical significance of the three 
different groups of mice during time, was assessed by The One way ANOVA test 
followed by a Tukey T-test. The Mann-Whitney U-test was used to analyze changes 
between 2 groups and changes in mRNA expression as assessed by real time PCR 
(PRISM, version 4.00, Graphpad software, San Diego, CA, USA). The data were 
considered statistically significant at P<.05.
Results
Clinical symptoms
 The number of the Muc2/IL10DKO mice was in line with the predicted value 
from Mendelian genetics, indicating that there was no prenatal selection or death 
before 4 weeks of age. However, Muc2/IL10DKO mice showed high mortality rates 
as of 4 weeks of age (Fig.1A). Seven of the 23 mice died between 3 to 4 weeks 
of age, and 3 additional mice died at the age of 4 to 5 weeks, as shown in Figure 
1A. Therefore, we sacrificed two groups of 5 and 7 Muc2/IL10DKO mice at 4 and 5 
weeks of age, respectively. These mice did not contribute to the establishment of the 
survival curve. The only surviving mouse was euthanized at the age of 7 weeks but 
not considered for further analysis.  In contrast, none of the wild type (WT), IL10-/- 
and Muc2-/- mice died during the time frame studied. 
 A significant difference (P=.008) in body weight was detected at 4 weeks of 
age between WT and Muc2/IL10DKO mice. Interestingly WT mice significantly gained 
weight between the age of 4 and 5 weeks [17.2±1.1 g vs. 22.3±1.4 g, respectively, 
P=.016], whereas the weight of Muc2/IL10DKO mice remained stable [6.4±0.4 g vs. 
6.7±0.3 g, respectively, P=.53]. Similarly, although less severely than Muc2/IL10DKO 
mice, 5-week-old Muc2-/- mice showed significant growth retardation (Fig.1B). In 
contrast, there were no significant differences between WT and IL10-/- mice regarding 
body weight (Fig.1B) at five weeks of age. However, at 8 weeks of age the WT mice 
were significantly heavier than IL10-/- mice, [25.6±0.2 g vs. 24.2±0.34 g, respectively, 
P=.005] and this difference was maintained until 34 weeks of age [37.4±1.1 g vs. 
32.1±1.0 g, respectively, P=.024].
 Furthermore, at 4 weeks of age, all the Muc2/IL10DKO mice showed diarrhea 
and gross bleeding which persisted until 5 weeks of age whereas none of the other 
types of mice displayed these clinical symptoms at this age. This resulted in a 
significantly higher DAI score compared to all the other types of mice (Fig.1C). The 
DAI score as shown by the WT and the IL10-/- mice is due to weight differences within 
the groups, and was non significant. 
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Morphological analysis
 In line with the clinical observations, there were no morphological differences 
in the proximal or distal colon between WT and IL10-/- mice at 5 up to 16 weeks of 
age. At 34 weeks of age the distal colon of the IL10-/- mice showed mild inflammation 
characterized by mucosal thickening, influx of inflammatory cells and an overall mild 
distortion of the architecture (data not shown). The colonic morphology of Muc2/IL10DKO 
animals differed considerably from their WT littermates (Fig.2A,B proximal colon and 
Fig.2A,F distal colon). In addition to the absence of the characteristic bell shape 
morphology of the goblet cells, the Muc2/IL10DKO mice showed crypt hyperplasia, 
mild infiltration, flattening of epithelial cells and distortion of the lamina propria as of 4 
weeks of age in the proximal colon. The overall damage of the colon increased along 
the proximal-distal axis and in addition to the histopathology described above, severe 
ulceration and crypt abscesses were observed in the distal colon of the Muc2/Il10DKO 
mice. These histological characteristics were most pronounced in the older mice (5 
weeks). 
 The presence of goblet cells in the colonic mucosa was determined by an AB/
PAS staining, which stains glycoproteins. Goblet cells of the proximal and distal colon 
were mainly positive for AB at the base of the crypts whereas the PAS positive cells 
were concentrated higher in the crypts in WT and IL10-/- mice (Fig.2C and G showing 
WT proximal and distal colon respectively, at 5 weeks of age). This was in contrast to 
the proximal colon of Muc2/IL10DKO mice in which there were hardly any PAS positive 
cells (Fig.2D, showing 5 weeks of age). In the distal colon of the Muc2/IL10DKO mice 
however, there were few small, condensed, PAS positive cells along the crypts and 
AB positive cells at the base of the crypts (Fig.2H, showing 5 weeks of age).    
Figure 1. Appearance and clinical symptoms of WT, IL10-/-, Muc2-/- and Muc2/IL10DKO mice. (A) 
Survival of the Muc2/IL10DKO mice during time. Arrows in the graph indicate time points where groups 
of mice were manually euthanized. N equals the number of mice which survived each time point. None 
of the WT, IL10-/- and Muc2-/- mice died during the time frame studied. (B) Body weight of the different 
mice 5 weeks of age. (*P<.0001; #P=.0002) (C) Disease activity index (DAI) is an accumulative score 
as adapted from Cooper et al.20 (*P<.0001; #P=.0002). Error bars indicate the SEM.
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Figure 3. Increased proliferation in the 
colonic crypts of Muc2/IL10DKO mice. 
BrdU staining of the proximal (A-B) and 
distal colon (C-D). In WT mice BrdU-positive 
cells were localized at the base of the crypts 
in both proximal and distal colon (A and 
B, respectively). The Muc2/IL10DKO mice, 
however, showed a significant increase in 
the number of BrdU-positive cells in both 
the proximal and distal colon and these 
cells extended halfway up the crypt. (C and 
D, respectively). The asterisks represents a 
higher magnification of the crypts in the distal 
colon
Figure 2. Colonic morphology the WT and Muc2/IL10DKO mice. Representative sections of the 
colon are depicted at 5 weeks of age (A-C; proximal colon, D-H; distal colon). A-B; E-F represent H&E 
stainings whereas C-D; G-H represent AB-PAS stainings. A and C, and E and G represent proximal 
colon and distal colon, respectively of the WT mice. B and D, and F and H represent proximal colon 
and distal colon, respectively of the WT  mice.  The insert in H shows a close-up of goblet cells in the 
crypts of Muc2/IL10DKO mice. The asterisks represents a lower magnification of the distal colon. Please 
also see page 221. 
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 Epithelial proliferation was studied by immunohistochemical staining of 
incorporated BrdU. No differences were detected between the WT and IL10-/- mice 
in distribution or localization of BrdU-positive cells in the proximal and distal colon at 
all ages (data not shown). In WT mice BrdU-positive cells were localized at the base, 
and up to 1/3 of the crypts in the proximal and distal colon (Fig.2A-C, respectively, 5 
weeks old). In both the proximal and distal colon of all Muc2/IL10DKO mice, however, 
there was a significant increase in the number of BrdU-positive cells as early as of 4 
weeks of age, which remained constant with time, and these cells extended up, into 
the crypt (Fig. 3B-D respectively, 5 weeks of age). 
Expression of goblet cell markers
 The intestinal epithelium of Muc2/IL10DKO mice, as previously shown for 
the intestine of Muc2ko mice, lack recognizable goblet cells, as determined by AB/
PAS staining, however we ascertained the presence and maturation of the goblet 
cells in the different mouse models by determining the expression of markers 
for goblet cells, more specifically i) Muc2 and ii) Tff3 a bioactive peptide which 
is involved in epithelial repair24. Muc2 was expressed throughout the crypts of 
proximal and distal colon of WT and the IL10-/- mice, but could not be detected in 
both the Muc2-/- and Muc2/IL10DKO mice at any time point (data not shown). Tff3 
was expressed by goblet cells, concentrated mainly in the upper portion of the 
crypts, in both the proximal and distal colon of WT and IL10-/- mice (Fig.4A and C 
showing WT mice, proximal and distal colon respectively). Goblet cells expressing 
Tff3 were present in the crypts of proximal and distal colon of the Muc2-/- mice as 
described previously14. However, Tff3-positive goblet cells were hardly detectable 
in the proximal colon of the Muc2/IL10DKO mice (Fig.4B, showing 5 weeks of age). 
Figure 4. Tff3 expression in colon. Tff3 was 
expressed by goblet cells in the proximal colon 
of (A) WT mice, but was virtually absent in the 
proximal colon of (B) Muc2/IL10DKO mice. In the 
distal colon, Tff3 was present in the goblet cells 
of (C) WT mice, but in larger numbers compared 
to the goblet cells of the (D) Muc2/IL10DKO mice. 
Please also see page 221. 
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Tff3 was detectable in the goblet cells in the distal colon of the Muc2/IL10DKO mice 
(Fig.4D, showing 5 weeks of age), but in smaller numbers compared to WT mice. 
Furthermore, the goblet cells in the distal colon of the Muc2/IL10DKO mice showed a 
distinct change in morphology. Whereas the goblet cells of the WT mice were round 
and bell shaped (insert of panel 4C; distal colon) the goblet cells of the Muc2/IL10DKO 
mice appeared smaller and more condensed (insert of panel 4D; distal colon). 
Expression of the mucins Muc1 and Muc4
 The expression of the membrane bound mucins Muc1 and -4 in the distal 
colon of each type of mice was quantified by using realtime RT-PCR (Fig.5A). 
Muc1 expression in the knockout mice did not differ for WT mice. In contrast, Muc4 
mRNA was decreased in the distal colon of both Muc2-/- and Muc2/IL10DKO mice. The 
Muc4 mRNA expression in the distal colon of the Muc2-/- and Muc2/IL10DKO mice 
correlated to a decreased protein expression in the distal colon as determined by 
immunohistochemistry (Fig.5B and C showing WT and Muc2/IL10DKO respectively). 
As Muc4 was expressed by goblet cells in the distal colon, it was also used as 
a goblet cell marker in the proximal colon of the Muc2/IL10DKO mice. As shown in 
figure 5D, in WT mice, goblet cells in the surface epithelium of the proximal colon 
express Muc4. These cells were, however, undetectable in the proximal colon of 
Muc2/IL10DKO mice (Fig.5E).      
Increased lymphocyte infiltration and expression of inflammatory cytokines
 Lymphocyte infiltration into the colon was evaluated using an anti-CD3 
antibody. In both the proximal and distal colon of the WT and IL10-/- mice, single cells 
Figure 5. Expression of the mucins Muc1 and Muc4. (A) The mRNA expression of the mucins 
Muc1 and -4 in the distal colon were quantified. Expressed values (± SEM) are given relative to control 
values, which were arbitrarily set on 1. (B-E) Muc4 was expressed by goblet cells in both the (B) distal 
colon of WT and (C) Muc2/IL10DKO mice. (D) Muc4 was expressed by the proximal colon of WT mice, 
but is hardly detectable in the proximal colon of (E) Muc2/IL10DKO mice. 
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situated in the lamina propria were detected up to 16 weeks of age. In accordance 
to previously published data there was an increase of lymphocyte infiltration in the 
Muc2-/- mice in parts of the colon were there was loss of epithelial cells. Parts of the 
colon that were unaffected were comparable to sections of the Muc2+/+ mice14. In 
the Muc2/IL10DKO mice there was an increase of lymphocyte infiltration, e.g. CD3 
positive cells in both the proximal and distal colon compared to WT and Muc2-/- mice 
(Fig. 6A, Muc2/IL10DKO mice, showing distal colon, 5 weeks of age). In addition, there 
was an increase of lymphocytes along the proximal-distal axis, which coincided, with 
the increase in histological damage seen in the colon of the Muc2/IL10DKO mice. 
Furthermore there was a significant increase in expression of mRNA of the 
inflammatory cytokines TNF-α, IL1β and IL6 in the distal colon of Muc2/IL10DKO 
mice compared to WT mice as shown in Figure 6B (5 weeks of age). The mRNA 
expression levels of these cytokines were not significantly up regulated in IL10-/- and 
Muc2-/- mice compared to their WT littermates 5 weeks of age (data not shown). As 
the mRNA expression showed a significant increase of TNF-α, IL1β and IL6 in the 
distal colon of the Muc2/IL10DKOmice we evaluated the pro inflammatory cytokine 
levels in the serum of these mice. In accordance with the TAQman data there was an 
increase in expression of inflammatory cytokines IL-12p70, TNF-α, IFN-γ, MIP-1 and 
IL6 in the serum of Muc2/IL10DKO mice compared to WT mice as early as 4 weeks of 
age, which increased as the mice aged (Fig.6C, 5 weeks of age).   
Figure 6. Increased lymphocyte infiltration 
and expression of inflammatory cytokines in 
Muc2/IL10DKO mice. (A) Representative sections 
presenting lymphocyte infiltration into the distal 
colon of Muc2/IL10DKO mice detected using an anti-
CD3 antibody. The asterisks represent a lower 
magnification of the distal colon. (B) Real time 
PCR data showed a significant up regulation of 
the inflammatory cytokines TNF-α, IL-1β and IL6 
(P=.02) in the distal colon of Muc2/IL10DKO mice 
compared to WT mice. (C) Analysis of the serum 
showed an increase in expression of inflammatory 
cytokines IL-12p70, TNF-α, IFN-γ, MIP-1 and IL6 
in the serum of Muc2/IL10DKO mice compared WT 
mice. Error bars indicate the SEM.
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Discussion
In this study, we addressed the question whether immunological and epithelial 
deficiencies, more specifically IL10 and Muc2, sensitize the intestine to severe 
colonic inflammation.
 The Muc2/IL10DKO mice showed a high mortality rate compared to Muc2-/-, 
IL10-/- and WT littermates of which none died during the current time frame. Several 
factors could contribute to the decreased survival rate of Muc2/IL10DKO mice. In fact, 
these animals showed severe growth retardation, as manifested by lower body weight 
at 4 weeks of age, compared to WT littermates, which increased as the mice aged. 
The stunted growth of Muc2/IL10DKO was more severe than that of Muc2-/- mice at 5 
weeks of age. Although multiple factors can affect growth in the context of colonic 
inflammation, the most prominent is the presence and severity of inflammation and 
inadequate nutritional intake28, including the levels of pro-inflammatory cytokines 
(see below)29, 30. The body weight of the Muc2-/- and Muc2/IL10DKO mice support this 
hypotheses, as their weight can be correlated to the severity of inflammation in both 
types of mice. In addition, Muc2/IL10DKO animals also show occult blood loss to gross 
bleeding and diarrhea as of 4 weeks of age whereas the WT and IL10-/- mice showed 
none of these additional symptoms. Interestingly, the Muc2/IL10DKO mouse model 
seems to recapitulate symptoms that are well established in patients with IBD as 
growth failure is frequently observed in children with IBD31. Further, patients with IBD 
can suffer from diarrhea, rectal bleeding and weight loss31. 
 Histological analysis of the colon of the Muc2/IL10DKO mice additionally 
confirmed severe inflammation. In addition to the absence of the characteristic 
bell shape morphology of the goblet cells in the proximal colon the Muc2/IL10DKO 
mice showed distinct differences displayed as crypt hyperplasia, inflammatory cell 
infiltration, flattening of epithelial cells and distortion of the lamina propria, which 
aggravated as the mice aged. This pathology was even more severe and distinct 
in the distal colon, which in addition to the above characteristics, also showed crypt 
abscesses. All together these clinical and histological symptoms indicate that the 
Muc2/IL10DKO mice constitute a model to study aspects of IBD, which has an earlier 
onset and is more severe compared to both IL10-/- and Muc2-/- mice. 
 A characteristic difference between Muc2/IL10DKO and WT mice was the 
lack of recognizable goblet cells throughout the entire intestine. This is in line with 
previously reported results on the Muc2-/- mice in which goblet cells were seemingly 
absent18. The colonic morphology of Muc2/IL10DKO animals differed considerably 
from their WT littermates. That indeed goblet cells were present in the mucosa 
of the Muc2/IL10-/- was determined by using i) an AB/PAS staining ii) an antibody 
against Tff3 and iii) an antibody against Muc4. Tff3-positive goblet cells were present 
throughout the entire large intestine in WT, IL10-/- and Muc2-/- mice. This was in 
contrast to the Muc2/IL10DKO mice, in which Tff3-positive goblet cells were present 
in the small intestine and distal colon. This coincided with the pattern found for the 
PAS positive staining of cells in the intestine. The goblet cells in both small and distal 
colon of the Muc2/IL10-/- mice however, showed loss of their characteristic goblet-
like shape, corroborating the notion that Muc2 is the major phenotypic determinant 
of goblet cells as we described previously for the Muc2-/- mice14. The inflammation 
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of the colon in Muc2/IL10DKO mice apparently affected the differentiation of goblet 
cells as indicated by a diminished or even loss of AB/PAS, Tff3, and Muc4 staining. 
This mechanism needs to be further investigated, however loss of differentiation of 
colonic cells during damage has been described previously as distinct enterocyte-
specific proteins were shown to be down-regulated during intestinal damage14, 32. 
Furthermore, the AB positive cells at the base of the crypts in the Muc2/IL10DKO 
mice could indicate transient expression of other mucins known to be expressed 
in the intestine or de novo expression of Muc6 mRNA as described for the Muc2-/- 
mice at 5 weeks of age14. We can only speculate on the possible function of these 
mucins in the Muc2/IL10DKO as their functionality in the intestine has not been fully 
investigated, but as evidenced by the distinct pathology of the colon, these mucins 
cannot compensate for the absence of Muc2. In addition, in WT and IL10-/- mice 
BrdU-positive cells were localized at the base of the crypts in the distal colon. Only an 
increase of proliferation was observed in the distal colon of the Muc2-/- mice, 5 weeks 
of age14. The Muc2/IL10DKO mice, however, a significant increase in proliferation, in 
both the proximal and distal colon as early as of 4 weeks of age, was observed.
 Membrane mucins are usually found at the apical membrane, thereby 
protecting epithelial cells. However recent studies have also implicated a role for 
these mucins in signaling, contributing to the modulation of intestinal cell proliferation 
and differentiation as reviewed by Hollingsworth and Swanson33. Proliferation and 
differentiation are affected in the Muc2-/- and Muc2/IL10DKO mice, as determined by 
the increased proliferation of the distal colon as well as alteration of markers of 
the goblet cell lineage. Therefore we investigated the expression of the two best 
characterized membrane mucins, Muc1 and Muc4, in these knockout mice. Muc1 
mRNA was unaffected in all types of knock out mice compared to WT mice. In contrast, 
Muc4 mRNA, although modestly downregulated in Muc2-/- mice, was significantly 
downregulated in Muc2/IL10DKO mice. Loss of Muc4 expression in the colon of 
these mice is in line with a previous study in which Muc4 is associated with highly 
differentiated, nonproliferating epithelial cells34.Membrane mucins can be released 
from cells in soluble form, from which the transmembrane domain has been removed 
by either proteolysis or alternative splicing. Previous studies demonstrated that Muc4 
is associated with epithelial secretion granules of the goblet cells35, 36. Furthermore, 
they showed that in the colon, Muc4 is predominantly expressed by the goblet cells 
in both rats and humans and that the soluble form of Muc4 predominates. Muc4 was 
present in fully differentiated goblet cells (present higher in the crypts) through-out the 
colon of the WT mice. Interestingly loss of differentiation of goblet cells in the colon 
of Muc2-/- and Muc2/IL10DKO mice was confirmed by diminished Muc4 expression. 
There was even an almost complete loss of Muc4 protein expression in the goblet 
cells of the proximal colon in both these types of mice. Furthermore, down regulation 
of Muc4 and unaltered Muc1 (mRNA) expression indicate that these mucins cannot 
compensate for the absence of Muc2 in epithelial protection. 
 An increase in exposure to luminal antigens due to a diminished mucus 
layer (decrease of Muc214 and Muc4, this paper), could initiate inflammation. In the 
Muc2/IL10DKO mice there was an increase of lymphocyte infiltration, e.g. CD3 positive 
cells, throughout the colon which was more severe compared to Muc2 -/- mice. The 
increase of infiltration coincided with an up regulation of mRNA for the inflammatory 
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cytokines TNF-α, IL-1β and IL-6 in the distal colon of Muc2/IL10DKO at 5 weeks of 
age. In addition, several proinflammatory cytokines, more specifically TNF-α, IFN-γ 
and IL-6 were significantly up regulated systemically in the Muc2/IL10DKO at 5 weeks 
of age. It is well known that pro-inflammatory cytokines play an important role in 
inflammation of the intestinal mucosa. For instance, TNF-α, IL-1β and IL-6 have 
shown to play a pivotal role in the pathogenesis of IBD1, 3, 4. In addition, previous 
studies demonstrated that IL10 is necessary for the production of TGF-β and that, 
in agreement, IL10-/- mice lack TGF-β signaling37, 38. Lack of both IL10 and TGF-β 
signaling in the Muc2/IL10DKO further explains the excessive inflammation in these 
mice compared to Muc2-/- mice. Furthermore, there is increasing evidence in the 
literature that systemic increase of TNF-α and IL-6 could partly explain the growth 
retardation in IBD patients and in the current study of the Muc2/IL10DKO mice29, 30. 
To summarize, the Muc2/IL10DKO mouse clearly demonstrates that combined 
abnormalities in immunoregulatory and epithelial factors greatly accelerate and 
exacerbate the phenotype of colonic inflammation. In fact,  IL10-/- mice show no 
distinct clinical nor histological signs of colitis at 5 weeks of age indicating that the 
mucus barrier offers enough protection under unchallenged conditions. Muc2-/- mice 
however show an abnormal morphology marked by an increase in thickness of the 
gut mucosa, flattening and ulceration of epithelial cells, general loss of architecture, 
increase of inflammatory cells, an increase in proliferation, and decrease of cell 
differentiation in the colon as described previously14. This inflammation however 
is most likely, partly suppressed by IL10 as damage in the Muc2/IL10DKO mice is 
much more severe, indicating that absence of Muc2 in combination with changes 
in the immunological regulatory mechanisms e.g. lack of IL10, leads to excessive 
uncontrollable inflammation of the colon, ultimately leading to the animals death. 
Therefore this study provides evidence that the mucus layer in the intestine, more 
specifically the mucin Muc2, plays a key role in mucosal protection suggesting that 
the mucus barrier is one of main factors determining colitis.
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Chapter 5
The Mucin 2 Deficient Mouse 
Challenged by Methotrexate
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Abstract 
The mucin Muc2, which is the main structural component of the protective mucus layer, has 
shown to be up regulated during chemotherapy-induced mucositis. As Muc2 has shown to 
have protective capacities, up regulation of Muc2 may be a counter reaction of the intestine 
protecting against mucositis. Therefore, increasing Muc2 protein levels could be a therapeutic 
target in mucositis prevention or reduction. Our aim was to determine the role of Muc2 in 
chemotherapy-induced mucositis. Mucositis was induced in Muc2 knockout (Muc2-/-) and wild 
type (WT) mice by injecting methotrexate (MTX). Animals were weighed and sacrificed on 
days 2-6 after MTX treatment and jejunal segments were analyzed. Before MTX treatment, the 
small intestine of WT and Muc2-/- mice were similar with respect to epithelial morphology and 
proliferation. Moreover, sucrase-isomaltase and trefoil factor-3 protein expression levels were 
comparable between WT and Muc2-/- mice. Up to day 3 after MTX treatment, percentages 
of weight-loss did not differ. Thereafter, WT mice showed a trend towards regaining weight, 
whereas Muc2-/- mice continued to lose weight. Surprisingly, MTX-induced intestinal damage 
of Muc2-/- and WT mice was comparable. Prior to MTX-injection, tumor necrosis factor-α and 
interleukin-10 mRNAs were upregulated in Muc2-/- mice, probably due to continuous exposure 
of the intestine to luminal antigens. ConClusion: Muc2 deficiency does not lead to an increase 
in chemotherapy-induced mucositis. A possible explanation is the mechanism by which Muc2 
deficiency may trigger the immune system to release interleukin-10, an anti-inflammatory 
cytokine before MTX-treatment. 
Abbreviations used in this paper
IELs, Intraepithelial Lymphocytes; IL-10, Interleukin-10; Muc2, Mucin 2; MTX, methotrexate; 
Muc2-/-, Mucin 2 knockout mice; WT, Mucin 2 wild type mice; Tff3, trefoil factor 3; TNF-α, 
Tumor Necrosis Factor-alpha; SI, Sucrase-Isomaltase.
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Introduction 
 Mucositis is one of the most frequent and severest side effects of anti-
cancer chemotherapy, for which there is still no definitive prophylaxis. Around 
500,000 patients world-wide suffer from mucositis annually1. The disorder causes 
considerable oral and abdominal pain, diarrhea and weight-loss. Moreover, patients 
suffering from mucositis are predisposed to life-threatening infections2-4. All together, 
this could lead to forced reduction of chemotherapy intensity, thereby potentially 
reducing the efficacy of anti-cancer treatment2, 5.
The intestinal mucus layer plays an important role in epithelial defense against 
mechanical stress, luminal pathogens, enzymes and toxins6-8. Goblet cells secrete 
molecules, such as mucins and trefoil factors that serve protective roles in the gut. 
Mucins are the most important structural component of mucus layer covering the 
epithelial cells. The intestine abundantly expresses the secretory mucin, Mucin 2 
(Muc2)9,10. Abnormalities of secreted products of goblet cells could affect the physical 
barrier function of the mucus layer in the intestine.
Recent research, supporting the hypothesis that Muc2 might contribute to 
epithelial defense against chemotherapy-induced damage, showed a halving of 
the number of goblet cells on days 1-2 after treatment with methotrexate (MTX)11,12. 
Remarkably, Muc2 protein expression was significantly increased during all phases 
of MTX-induced damage11, 12.
The role of Muc2 in the protection against mucositis is still unclear, but if its 
protective capacities could be demonstrated, increasing Muc2 protein levels could be 
a therapeutic target in mucositis prevention or reduction. We used an experimental 
Muc2 deficient (Muc2-/-) mouse model13,14 to analyze the role of Muc2 in epithelial 
protection against MTX-induced intestinal damage. 
Materials and Methods
Animals 
The previously described Muc2-/- mice of mixed genetic background, were 
backcrossed onto a 129SV (Charles River, Maastricht, the Netherlands) genetic 
background for nine generations followed by intercrosses to generate mice 
homozygous for the Muc2 disruption. Throughout the backcrossing procedure, the 
targeted Muc2 gene was monitored as previously described13. 
All mice were housed in micro-isolator cages under specific pathogen-free 
conditions with free access to standard rodent pellets (Special Diets Services, 
Witham, Essex, UK) and acidified tap water. Animal experiments were performed 
with permission of the Erasmus MC Animal Ethics Committee (Rotterdam, the 
Netherlands).
Clinical symptoms
Groups of wild type (WT) and Muc2-/- mice were monitored from 5 until 12 
weeks of age. Weekly, weight and clinical signs such as softness of the stool and 
appearance of fecal occult blood15 were assessed. At ages 5, 8, and 12 weeks, four 
mice per group were sacrificed.  
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MTX-induced mucositis
Mice, (n=16, each group) 8 weeks of age, were injected intraperitoneally with 
MTX (Emthrexate (PF); Pharmacie B.V., Haarlem, the Netherlands) using dosages 
of 50 and 25 mg/kg body-weight respectively on day –1 and 0. The concentration 
of MTX required to induce severe mucositis, was based on a dose-response-
curve experiment we previously performed using 129SV WT mice (B.A.E. de 
Koning, unpublished observations). The induced mucositis in pilot experiment was 
characterized by villus atrophy, crypt loss and morphological regeneration within six 
days. Controls (n=4, both groups) were given equivalent volumes of 0.9% NaCl. 
Mice were weighed daily and groups of four were sacrificed on respective days 2, 3, 
4 and 6 after the final MTX injection. 
Tissue collection
One hour before sacrifice, the mice were injected with 120 μl 10 mg/ml 5-
Bromo 2’deoxyUridine (BrdU; Sigma-Aldrich, Zwijndrecht, the Netherlands), to locate 
proliferating cells. Segments of the duodenum, mid-jejunum, ileum, proximal and 
distal colon were collected and processed for histological analyses, stored in RNA 
Later (Qiagen, Venlo, the Netherlands) at –20oC, or snap-frozen in liquid nitrogen for 
storage at -80°C and subsequent protein isolation.
(Immuno)histochemistry 
Segments of mid-jejunum were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS), dehydrated and embedded in Paraplast Plus (Sherwood 
Medical, Den Bosch, The Netherlands). Sections were stained with hematoxylin 
(Vector Laboratories, Burlingame, CA) and eosin (Sigma-Aldrich) (HE) to study 
morphological alterations of the crypts and villi. Immunohistochemistry was performed 
as previously described 14, 16. To detect incorporated BrdU, anti-BrdU (1:250 in PBS; 
Roche Applied Sciences, Indianapolis, IN, USA) was used. Expression of Muc2 was 
detected using a goat polyclonal anti-human Muc2 antibody (H-300; 1:1000 in PBS, 
SC-15334, Santa Cruz, SanverTech, Heerhugowaard, the Netherlands). As a marker 
for goblet cell-specific protein expression, a rabbit polyclonal anti-rat trefoil factor 
family (Tff3; 1:3000 in PBS, kindly provided by Prof. Dr. D.K. Podolsky17) was used, 
and to determine enterocyte-specific protein expression a rabbit polyclonal anti-
rat sucrase-isomaltase (SI; 1:9000 in PBS, kindly provided by Dr. K.Y. Yeh18) was 
used. An anti-human CD3 antibody (DAKO, Heverlee, Belgium; 1:800 in 1% BSA, 
0.1% Triton X100 in PBS) was used to detect CD3+ T-cells. Additionally, non-specific 
binding was reduced by blocking with TENG-T (10 mM Tris-HCl, 5 mM EDTA, 150 
mM NaCl, 0.25% (w/v) gelatin, 0.05% (w/v) Tween-20). Appropriate positive and 
negative controls were included in each immunohistochemical assay. 
Morphological analysis
The following intestinal histological parameters were studied: morphology of 
the epithelium, degree of inflammation, villus atrophy, crypt loss, crypt abscess, and 
mucosal bleedings. All scores were obtained in a blinded fashion by two independent 
investigators.
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Crypt and –villus length
Lengths of ten well-orientated crypts and villi of each individual animal were 
measured with the use of a Nikon Eclipse E800 microscope and Leica Image Manager 
500 software (Leica Microsystems B.V, Rijswijk, the Netherlands). However, in cases 
of severe disease crypts could not be measured in all slides, due to extensive crypt 
loss; then, several slides within the jejunal region were combined in order to measure 
ten whole crypts and villi.
Intraepithelial lymphocytes
Numbers of intraepithelial lymphocytes (IELs) in the villi of the small intestine 
were determined by counting the number of CD3 positive cells per ten villi of each 
individual animal. This was done by two independent investigators in a blinded 
fashion. 
Protein dot blotting
The expression of epithelial markers was detected and quantified as previously 
described11. Blots were incubated with anti-SI (1:1000) or anti-Tff3 (1:1500). Bound 
antibodies were detected using HRP conjugated goat anti-rabbit secondary antibodies 
(1:1000 in PBS) and SuperSignal West Femto Luminol Enhancer kit (Pierce, 
Rockford, IL, USA). The signal was detected and quantified by the ChemiGenius gel 
documentation system (Syngene, Cambridge, UK). 
Western-blot analysis
The same protein homogenate was used as described for protein dot blot 
analysis. Twenty μg of protein was loaded per lane and run on a 12.5% SDS-PAGE. 
The separated proteins were transferred to nitrocellulose membranes (Protran 
BA83, 0.2 μm) which were subsequently blocked11. Blots were incubated overnight 
at 4°C with mouse monoclonal anti-human proliferative cell nuclear antigen (PCNA); 
clone PC10 (1:250 in blocking buffer; Novo Castra Laboratories, Newcastle upon 
Tyne, UK). After washing with PBS-0.2% Tween-20, bound antibodies were revealed 
using HRP conjugated goat anti-mouse secondary antibodies (1:1000 in PBS) and 
detected and quantified as described above.  
Quantitative real-time PCR (Sybergreen technology) 
Total RNAs from mouse small intestine were prepared using the QIAamp 
RNA midi-kit (Qiagen), following the manufacturer’s protocol, and treated with 
DNase (Qiagen). Total RNA (1.5 µg) was used to prepare first-strand cDNA 
(AdvantageTM RT-for-PCR kit; BD Biosciences, Clontech, Alphen aan den Rijn, the 
Netherlands). The mRNA expression levels of tumor necrosis factor alpha (TNF-α) 
and interleukin-10 (IL10) as well as the endogenous housekeeping gene β-actin 
were quantified using real-time PCR analysis (Sybergreen chemistry) based upon 
the intercalation of SYBR® Green on an ABI Prism 7700 sequence detection system 
(PE Applied Biosystems, Nieuwerkerk aan de IJsel, the Netherlands) as described 
previously14. Primer combinations for β-actin (5´-GGGACCTGACGGACTAC-3´ and 
5´-TGCCACAGGATTCCATAC-3´), IL-10 (5´-CAAGCCTTATCGGAAATG-3´ and 
5´-CATGGCCTTGTAGACACC-3´), and TNF-α (5´-TGGCCTCCCTCTCATC-3´ and 
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5´-GGCTGGCACCACTAGTT-3´) were designed using the OLIGO 6.22 software 
(Molecular Biology Insights, Cascade, CO, USA) and purchased from Invitrogen 
(Breda, the Netherlands). 
Statistical analysis
The Mann-Whitney U-test was used to analyze changes in protein and mRNA 
expression levels. Results were considered statistically significant at P<.05. Data 
are presented as the mean +/- standard error of the mean (SEM). 
Results
Clinical symptoms
To characterize the phenotype of Muc2-/- mice we monitored their weight in 
relation to WT littermates (Fig. 1). From the start, at week 5 of age, Muc2-/- mice had 
significantly lower body-weight (P<.0001) and showed growth retardation compared 
to WT littermates. At 6 weeks of age, Muc2-/- mice exhibited diarrhea and occult 
blood loss, which occasionally progressed to gross bleeding as of 8 weeks of age. 
Morphological analyses
In order to study morphological changes in the small intestine, HE stained 
slides of the duodenum, jejunum and ileum of Muc2-/- and WT mice were compared 
(Fig. 2A, B jejunum; duodenum and ileum are not shown). The main characteristic 
difference was the lack of recognizable goblet cells along the crypt-villus axis in 
the Muc2-/- mice throughout the small intestine. There were no further pronounced 
differences in epithelial morphology up to 12 weeks of age. There were no differences 
in number of apoptotic bodies along the crypt-villus axis between the Muc2-/- and 
WT mice. Similarly, there were no significant differences in villus and crypt lengths 
between Muc2-/- and WT mice at any time investigated (Fig. 2G and H, week 8, 
jejunum).
Figure 1. Body-weight of  WT  and Muc2-/- mice between 5 and 12 weeks of age. As from the 
start at week 5, Muc2-/- mice weighed significantly less and showed growth retardation compared to 
their WT littermates. Groups follow similar growth curves, but at a different level. Weight per group is 
expressed as Mean ± SEM.
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Two markers for goblet cells were analyzed: Muc2, which is stored in apical 
granules of the goblet cells determining the goblet cell morphology 10, 13, 14 and Tff3, 
a bioactive peptide which is involved in epithelial protection and repair 17, 19, 20. In 
the small intestine of WT mice, Muc2 was expressed in goblet cells from the crypt 
bottom to the tips of the villi (Fig. 2C). Tff3 was also expressed in goblet cells located 
in the crypts, but was more predominant in goblet cells located on the villi (Fig. 2E). 
Goblet cells in the small intestine of the Muc2-/- mice were negative for Muc2 (Fig. 
2D), but remained positive for Tff3 (Fig. 2F) with an expression pattern similar to that 
seen in the small intestine of WT mice. The goblet cells of the Muc2-/- mice showed 
distinctly altered morphology as previously described13, 14. Specifically, the goblet 
cells of the WT mice were round and bell shaped, whereas those of the Muc2-/- mice 
were smaller, flatter and more condensed.
Figure 2. Absence of Muc2 does not affect small intestinal morphology.  Representative sections 
of a hematoxilin eosin (A-B), Muc2 (C-D), and Tff3 (E-F) staining of the small intestine of WT (A,C,E) 
and Muc2-/- (B,D,F) mice at 8 weeks of age. The most characteristic difference between the Muc2-/- and 
WT mice was the lack of recognizable goblet cells along the crypt-villus axis of the small intestine in the 
Muc2-/- mice (B,D). The goblet cells in the small intestine of Muc2-/- mice showed the same expression 
pattern for Tff3, concentrating on the villi, similar as seen in the small intestine of the WT (E), but 
showed a distinct change in morphology of the goblet cells (F). Villi and crypt length (G,H) of WT and 
Muc2-/- littermates 8 weeks of age. Villi and crypt lengths per group are expressed as Mean ± SEM.
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Methotrexate-induced mucositis model
MTX-treated WT mice showed significant weight-loss compared to the WT 
controls on days 1, 2, 3 and 5 (P=.003, P=.002, P=.004, P=.045 respectively). 
After day 3, the treated WT mice started to regain weight, almost equalizing control 
weights by day 6 (Fig 3A). A significant weight-loss was also seen in MTX-treated 
Muc2-/- compared to Muc2-/- controls, on day 1 and 3 after treatment (Fig 3B) 
(P=.008, P=.021, respectively). In addition, weight-loss on day 2 almost reached 
significance (P=.052). In contrast to WT mice, Muc2-/- mice continued to lose weight 
during MTX-treatment. Between day 5 and day 6, three of four MTX-treated Muc2-/- 
mice died, whereas all treated WT mice survived. The three non-surviving mice had 
suffered severe weight-loss (25%) prior to death. On account of the elapsed time 
after death, morphological evaluation could not be performed. The clinical symptoms 
displayed by Muc2-/- mice before MTX treatment, i.e. diarrhea and occult blood, did 
not aggravate after MTX-treatment. 
The effect of MTX-treatment on intestinal morphology  
MTX-induced changes in small intestinal morphology of WT and Muc2-/- mice 
were examined on days 2, 3, and 4 after treatment (Fig. 4 A-F). On day 2, both MTX-
treated WT and Muc2-/- mice showed affected intestinal morphology (Fig. 4A, B). The 
degree of intestinal damage increased with time, indicated by severe villus atrophy, 
epithelial flattening and extensive crypt loss in both WT and Muc2-/- mice by day 3 
(Fig. 4C, D). Although the mucosa was still severely damaged on day 4, both groups 
showed the presence of newly formed crypts (Fig 4E, F). On day 6, the intestinal 
morphology of the WT mice had started to regenerate as evidenced by higher 
numbers of well-formed crypts and villi (Fig 4G), and regeneration corresponded 
with improvement in body-weight. The one surviving Muc2-/- mice by day 6 was not 
considered representative of the whole group and was therefore excluded from 
further analyses. 
Figure 3. Weight-loss of MTX-treated WT and Muc2-/- mice. Weight of the mice on day –1, before 
start of the experiment, was set at 100%. A significant decrease in weight versus the saline-treated 
(i.e. control) mice was seen on days 1, 2, 3 and 5 for the MTX-treated (A) WT mice and on days 1 and 
3 for the MTX-treated (B) Muc2-/- mice. Weight of the MTX-treated Muc2-/- mice differed at the brink 
of significance versus that of the control mice on day 2.  Weight per group is expressed as Mean ± 
SEM
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To exclude death by intestinal failure we analyzed the proximal and distal 
colon segments of both the MTX-treated WT and Muc2-/- mice. Apart from lack of 
recognizable goblet cells in the crypts of the Muc2-/- mice, the proximal segment 
showed no distinct changes in morphology (data not shown). In contrast, microscopic 
analysis of the distal colon of untreated Muc2-/- mice, showed mucosal thickening, 
increased proliferation and superficial erosions in addition to lack of recognizable 
goblet cells14, compared to WT mice (Fig 5 A-B). MTX-treatment did not affect colonic 
morphology in the WT mice, and the pathology of the Muc2-/- mice did not deteriorate 
(Fig. 5 C and D, respectively).
Figure 4. MTX-induced changes in the small intestine in WT and Muc2-/- mice. Morphology of 
the jejunum of WT (A,C,E,G) and Muc2-/- (B,D,F) mice on days 2 (A-B), 3 (C-D), 4 (E-F) and 6 
(G) after MTX-treatment. On day 2, morphology of WT and Muc2-/- mice was mildly affected and 
characterized by mild crypt loss and epithelial flattening. On days 3 and 4, intestinal damage was 
more severe, showing increased crypt loss on day 3 and epithelial flattening and villus atrophy on 
days 3 and 4. Crypt regeneration was seen on day 4, but was more pronounced in the Muc2-/- mice 
compared to WT mice. On day 6, the intestinal morphology of the WT mice had started to regenerate 
as evidenced by higher numbers of well-formed crypts and villi. (H)Crypt and (I) villus lengths of WT 
and Muc2-/- littermates before and after MTX-treatment. Both groups showed significant villus atrophy 
and crypt elongation after MTX-treatment. Significant differences were seen on day 2; Muc2-/- mice 
showed more villus atrophy, but less elongation of crypt length compared to WT mice. On day 3, villus 
atrophy was comparable in both groups, but still minimal differences were seen in crypt length. In the 
regenerative phase, day 6, WT mice showed an increase in villus and crypt length compared to control 
littermates. Bars are expressed in Mean ± SEM. Please also see page 222.
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Crypt and villus length after MTX-treatment
After MTX-treatment crypt length in both WT and Muc2-/- mice progressively 
increased with time (Fig. 4H). On day 2, WT mice showed a significant increase in 
crypt length compared to control mice (P=.004). Muc2-/- mice responded similarly one 
day later. On days 2 and 3, a significant difference (P=.003 and P=.025 respectively) 
in crypt length was observed between the WT and Muc2-/- mice, with crypts of WT 
mice longer than those of Muc2-/- mice. However, on day 4, the increase in crypt 
length was similar in both groups of mice. 
In addition, after MTX-treatment a significant villus shortening was observed 
both in WT mice and in Muc2-/- mice (Fig. 4I). A significant decrease in villus length was 
seen in Muc2-/- mice on days 2 and 3, and in WT mice on days 3 and 4. Subsequent 
regeneration of villus length was seen in the Muc2-/- mice on day 4, but in the WT 
mice not until day 6. MTX-induced changes in villus length between the two types of 
mice were significantly different on day 2 only (P=.0001).
Effect of MTX-treatment on epithelial proliferation
In WT and Muc2-/- saline-treated (control) mice BrdU-positive cells were seen 
from the bottom of the crypt up to three quarters of the crypt height, showing no 
distinct differences in location or number of BrdU positive cells (Fig. 6A, B). On day 2, 
the proliferative zone in WT mice moved progressively upwards in the crypts towards 
the crypt-villus junction (Fig. 6 C). At the same time, the proliferative zone in the 
Muc2-/- mice was only mildly affected, showing a slight shift upwards within the crypts 
(Fig. 6D). On days 3 and 4, the proliferative zone in both groups had broadened and 
moved upwards along the crypt-villus axis (Fig. 6E, F showing day 3). Subsequently, 
Figure 5. Morphology of the distal 
colon before and after MTX-treatment. 
Morphology of the distal colon of (A-
B) WT mice and (C-D) Muc2-/- mice, 
untreated (A , C) and day 4 after MTX-
treatment (B, D). Untreated Muc2-/- 
mice showed mucosal thickening and 
superficial erosions in addition to lack of 
recognizable goblet cells, compared to 
WTmice. MTX-treatment did not affect 
the colonic morphology in the WT mice, 
and the pathology of the Muc2-/- mice 
did not deteriorate as determined by the 
parameters described above.
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proliferation was quantified by Western blot analysis, using a monoclonal antibody 
specific for PCNA, a marker for proliferation21, 22 (Fig. 6G). PCNA expression in the 
small intestine of the WT mice decreased significantly (P=.01) on day 2 compared 
to their controls, while the Muc2-/- animals only showed a non-significant decrease. 
During severe intestinal damage, on days 3 and 4, PCNA expression in both WT 
and Muc2-/- mice had returned to control levels. On day 6, PCNA expression in the 
intestine of the WT mice was similar to control level. Overall, PCNA expression levels 
did not significantly differ between WT and Muc2-/- mice at any time.
Figure 6. Effect of MTX-treatment on epithelial proliferation . BrdU staining of the jejunum of saline-
treated (i.e. control) (A) WT and (B) Muc2-/- mice on day 2 (C-D) and 3 (E-F) after MTX-treatment (BrdU 
was injected one hour before sacrificing the mice). On day 2, the BrdU positive cells in the Muc2-/- mice 
were located higher in the crypt. The BrdU positive cells in the WT mice were seen along the entire 
length of the crypts. A similar pattern was seen in both groups on day 3; BrdU positive cells were 
not restricted to the crypts and showed a scattered pattern along the entire length of the crypts. (G) 
Western blot analysis, using a monoclonal antibody specific for PCNA. Representative western blots 
for each day are shown. The expression of PCNA protein decreased significantly on day 2 in the WT 
mice. PCNA expression on days 3 and 4 showed mild, non-significant changes in MTX-treated WT and 
Muc2-/- mice vs. control mice. Bars are expressed in Mean ± SEM.
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Figure 7. Effect of MTX-treatment on the SI and TFF3 protein expression in the small intestine
Representative sections of SI staining of the small intestine after MTX treatment (A-D).  saline-treated 
(i.e. control) (A) WT and (B) Muc2-/- mice showed a clear SI staining at the brush border along the 
entire villi. (C) On day 4, SI expression in the WT mice was virtually absent  in contrast to (D) the Muc2-
/- mice, in which SI expression was partly regenerated and expressed at the tips of the villi. Dot-blot 
analysis was performed to quantify (E) SI and (F) Tff3 in the small intestine during MTX-treatment. 
Representative spot blots for each antibody are shown. There was no significant difference in SI and 
Tff3 expression levels between the Muc2-/- mice and WT controls. SI expression in the MTX-treated 
WT mice was significantly decreased on days 2, 3 and 4, and returned to control levels on day 6. In 
contrast, SI expression in Muc2-/- mice was significantly decreased on days 2 and 3 only and showed 
regeneration on day 4. On day 2, Tff3 expression of the WT mice significantly increased compared to 
TFF3 expression of the Muc2-/- mice, which maintained at control level. On days 3 and 4, no significant 
changes were seen in either of the MTX-treated groups. Bars are expressed in Mean + SEM.
The Muc2 Deficient Mouse Challenged by MTX 103
Effects of MTX-treatment on enterocyte- and goblet cell-specific protein expression
To gain insight in the functional capacity of the intestinal epithelium after MTX-
treatment, we analyzed the expression pattern of SI (Fig. 7A-D). SI is considered a 
marker for intestinal epithelial differentiation18,23. Control Muc2-/- and WT mice showed 
a clear SI staining at the brush border along the entire villi (Fig. 7A, B). On day 3, 
during severe mucositis, SI expression was undetectable in the intestine of both WT 
and Muc2-/- mice (data not shown). However, on day 4, SI expression in Muc2-/- mice 
had partly regenerated and was detected at the villus tips, in contrast to WT mice 
(Fig. 7C, D) in which expression of SI was still virtually absent.   
SI dot-blot analysis revealed no significant difference in SI expression levels 
between Muc2-/- and WT control mice (Fig. 7E). SI expression in the MTX-treated 
WT mice was significantly decreased on days 2, 3 and 4, (P=.0001, P=.002 and 
P=.0001 respectively) and returned to control levels by day 6, corresponding to the 
results described for immunohistochemical detection of SI. SI expression in Muc2-/- 
mice had significantly decreased on days 2 and 3 (P=.046, P=.001 respectively) and 
was re-established by day 4, in line with the immunohistochemical data. 
To quantify Tff3 expression levels, protein dot-blot analyses were performed 
using a Tff3-specific antibody (Fig. 7F). Interestingly, even though the goblet cells 
of the Muc2-/- mice showed a distinct change in morphology as detected by the 
immunohistochemical staining of Tff3 (Fig. 2F), there were no significant differences 
in Tff3 expression levels between WT and Muc2-/- control mice. On day 2, Tff3 
expression increased significantly in MTX-treated WT mice only, compared to WT 
control mice (P=.001) and MTX-treated Muc2-/- mice (P=.008) and returned to control 
levels by day 3. In MTX-treated Muc2-/- mice, Tff3 expression levels remained stable 
at control level throughout the entire experiment. 
Release of IL-10 and TNF-α in Muc2-/- intestine prior to MTX-treatment
So far, these data in conjunction suggest Muc2-/- and WT mice have similar 
intestinal sensitivity to MTX, or even that Muc2-/- mice are less sensitive to MTX-
treatment, up to day 4. Absence of Muc2 in Muc2-/- mice may lead to a continuous 
exposure to luminal antigens, which might have resulted in disbalance in cytokine 
production prior to MTX-treatment. IELs are one of the first immune cells to encounter 
antigens that have entered the body via the epithelial surface24. Therefore, IELs 
play an in important in mediating local immune responses in the intestine24-26. In 
order to evaluate two major cytokines involved in anti-inflammatory (IL-10) and pro-
inflammatory (TNF-α) responses, we performed quantative real time PCR. Prior to 
MTX-treatment, Muc2-/- mice showed a non-significant increase in mRNA expression 
of TNF-α (Fig 8A), but a significant increase (P=.003) in mRNA expression of the anti-
inflammatory cytokine IL-10 compared to WT mice (Fig. 8B). The presence of IELs 
was determined by staining with anti-CD3, which detects both CD4+ and CD8+ T cells. 
There was an increase of IELs in the Muc2-/- mice before MTX-treatment compared 
to WT mice (Fig.8C), with a difference at the brink of significance (P=.0571).
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Discussion
We addressed the question whether Muc2 is involved in epithelial protection 
against chemotherapy-induced mucositis in the small intestine by challenging 
Muc2 deficient mice with the cytostatic drug MTX. As chemotherapy increases the 
permeability of the intestinal epithelium, we hypothesized that the deficiency of 
Muc2, and resultant major changes of the mucus layer, would sensitize the intestine 
to chemotherapy-induced damage. 
The Muc2-/- mice weighed significantly less than the WT mice and showed 
growth retardation. In addition, they showed diarrhea, occult blood loss and even 
occasional gross bleeding, caused by a distinct pathology in the distal colon14. We 
cannot explain the significant difference in weight at an early age, especially as 
there was no difference in birth-weight (our unpublished data). There is no indication 
that the small intestine contributes to any of the described symptoms above, as 
histological analysis showed no distinct pathology. The only telling difference between 
the WT and the Muc2-/- mice was the lack of recognizable goblet cells in the Muc2-/- 
mice, in line with findings from previous studies13, 14, 27. Quantification of Tff3 and SI, 
important markers of the functionality of goblet cells and enterocytes, respectively, 
showed no difference in expression levels in the small intestine between WT and 
Muc2-/- mice. Neither did crypt and villus lengths differ between the Muc2-/- and WT 
mice. Taken together, these data suggest that under unchallenged conditions, Muc2 
is not essential for normal epithelial morphology and function in the small intestine. 
However, this hypothesis is undermined by the fact that the Muc2-/- mice showed 
significant growth retardation.
Mucositis was induced in WT and Muc2-/- animals by injecting MTX. Up to day 
3 there were no differences in percentage of weight-loss compared to initial body-
Figure 8. Increased release of IL-10 and TNF-α mRNA in the small intesine of Muc2-/- mice, prior 
to MTX- treatment. Real time PCR data of (A) TNF-α and (B) IL-10 on RNA isolated from the small 
intestine of WT and Muc2-/- control, untreated mice. The results were normalized for the housekeeping 
gene β-actin. The Muc2-/- mice showed a non-significant increase in mRNA expression of TNF-α, but 
a significant increase in mRNA expression of the anti-inflammatory cytokine IL-10 compared to WT. 
(C) Quantification of CD3+ IELs in the villi of both types of mice Control, untreated Muc2-/- mice showed 
an increase in IELs compared to WT mice, which was at the brink of significance (p=0.0571) Bars are 
expressed in Mean + SEM. 
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weights between WT and Muc2-/- mice. Thereafter, however, WT mice showed a 
trend towards regaining their initial body-weights, whereas Muc2-/- mice continued 
to lose weight, which may have led to the death of three of four mice on day 5. 
The intestine of the Muc2-/- mice already had started to regenerate on day 4, as 
indicated by an earlier regeneration of crypts, restoration of villus length (on day 4) 
and restoration of enterocyte-specific SI levels in Muc2-/- mice compared to WT mice. 
Furthermore, the proliferative zone in the Muc2-/- mice seemed to be less affected 
by MTX-treatment compared to that in WT mice. These results are contradictive to 
our hypothesis, and do not explain why the mice died during the experiment. We 
therefore have no indication that death of the Muc2-/- animals could be caused by 
intestinal failure. This is supported by data showing that the pathology of the distal 
colon of the Muc2-/- mice did not deteriorate during MTX-treatment, and by the fact 
that clinical symptoms such as diarrhea and occult blood loss did not aggravate. Since 
the Muc2-/- mice were significantly lighter than the WT mice before MTX treatment, 
the same percentage of weight-loss after MTX could have had a bigger impact on 
the Muc2-/- mice and resulting in the sudden death of these mice. We have now 
learned, from continuing experiments, that lighter WT mice are also predisposed 
to death during MTX treatment compared to heavier littermates (B.A.E. de Koning, 
unpublished observations).
Mucositis is the result of a dynamic cascade of events, in which the release of 
pro-inflammatory cytokines, activated by transcription-factors and invading bacteria, 
plays an important role28. Mucositis toxicity is correlated with the release of the pro-
inflammatory cytokine TNF-α, which is involved in intestinal damage induction28-
31. Furthermore, TNF-α was shown to play a pivotal role in the pathogenesis of 
inflammatory bowel disease32,33. In contrast, the anti-inflammatory cytokine IL-10, has 
protective capacities in the intestine, and studies have shown that IL-10-/- mice are 
predisposed to develop chronic mucosal inflammation34-36. As described previously, 
local expression of (anti-)inflammatory cytokines might to be able to modulate local 
immune responses25. Local immune responses are mediated by e.g. the IELs24. IELs 
are instrumental in mediating tolerance and driving immune regulation and could 
be activated in the Muc2-/- mice by an increased stimulation caused by the absence 
of Muc2, the structural component of the mucus layer. Our data reveal a trend 
towards increased numbers of IELs present in the villi of the Muc2-/- mice before 
MTX-treatment. Apart from IELs, we also investigated IL-10 and TNF-α production in 
the intestine of Muc2-/- mice prior to MTX-treatment. Untreated Muc2-/- mice showed 
a non-significant increase in TNF-α mRNA levels, but a significant increase in IL10 
mRNA levels compared to WT mice. These data suggest an opposite TNF-α release 
in which IL-10 restricts the damage-inducing capacity of TNF-α under unchallenged 
condition (i.e. not treated with MTX) in the small intestine of Muc2-/- mice. Further 
support for this hypothesis is the observation that IL-10-/- mice develop more severe 
mucositis after MTX-treatment than their IL-10+/+ littermates and that IELs from 
IL-10-/- mice were unable to control Th1-induced gut inflammation24, 37. Thus, Muc2 
deficiency may have led to an altered immune-response prior to MTX challenge. 
This might explain why the MTX-induced damage was similar, or even less severe in 
the Muc2-/- mice. This mechanism however, needs further investigation.
In conclusion, our data do not provide evidence that Muc2 deficiency leads 
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to an increase in chemotherapy-induced mucositis. A possible explanation is the 
mechanism by which Muc2 deficiency triggers the immune system to release IL-10, 
an anti-inflammatory cytokine, prior to MTX-treatment.
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Abstract 
Mucin 2 (Muc2) is the major secretory mucin of the mucus layer that lines the intestinal 
epithelium. Muc2 is characterized by tandem repeats rich in threonine-proline-serine. Since, 
previous studies in piglets showed that the intestine utilizes 60-90% of dietary threonine 
intake, we compared threonine utilization in the intestines of Muc2 knockout (Muc2-/-) and 
wild type (WT) mice to investigate whether dietary threonine is mainly used for intestinal 
Muc2 synthesis. Concentrations and isotopic enrichment of threonine were measured by GC-
(IR)MS in the small intestine, colon and colonic content of mice given a [U-13C]threonine bolus 
enterally. In the intestinal tract, 40.1% of dietary [13C]threonine was recovered after 6 hours 
in WT mice – i.e. 32.4% as [13C]threonine and 8.3% as [13C]glycine  vs. 43.6% in Muc2-/- mice 
– i.e. 33.1% [13C] as threonine and 9.5% as [13C]glycine. Most of the dietary [13C]threonine 
recovered from the intestinal tract was derived from the colonic content in both types of 
mice. Interestingly, 27.4% of the recovered [13C]threonine in the colonic content of WT mice 
was incorporated into Muc2. Overall, Muc2-/- mice showed higher amounts of incorporated 
[13C]threonine into mucosal proteins. Furthermore the entire intestine of Muc2-/- mice showed 
a significantly higher oxidation rate compared to WT mice. Conclusions: This is the first study 
demonstrating threonine utilization in mice. In absence of Muc2, dietary threonine is used for 
constitutive protein synthesis or is metabolically oxidized as shown in Muc2-/- mice. However, 
one of the pivotal metabolic fates of dietary threonine utilized by the intestine is incorporation 
into Muc2
Abbreviations used in this paper
h, hour(s); MPE, Mole percent excess; Muc2, Mucin 2; Muc2-/-, Mucin 2 knockout mice; 
WT, wild-type mice; NS, non significant; TDG, threonine dehydrogenase; TDH, threonine 
dehydratase; PCA, perchloric acid
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Introduction 
The gastrointestinal tract is lined by a mucus layer – a protective barrier 
between the epithelium and environment. Mucus production, and thus the mucus 
layer, is alerted by intestinal stress, i.e. inflammatory bowel disease1 and its integrity 
has been associated with nutritional state2-5. Mucins represent the principal protein 
constituent of mucus, and Muc2 is the predominant gastrointestinal mucin6, 7. 
Mucins have a central backbone rich in threonine, proline and serine residues that 
account for 20-55% of total amino acid composition8. A characteristic feature is the 
high density of oligosaccharides O-linked to threonine and/or serine residues in the 
central protein backbone resulting in a high resistance to proteolysis9. 
 Animal studies have indicated substantial amino acid metabolism in 
the intestine10. Amino acids are quantitatively important nutrients for growth 
and development, essential in protein synthesis and obligatory for maintaining 
intestinal mass and integrity. Studies in piglets showed high intestinal utilization of 
essential amino acids in first pass. For example, first pass metabolism of lysine and 
leucine accounts for approximately one-third of total dietary intake11-15. The human 
intestine retains between 20-50% of the dietary intake of specific essential amino 
acids including threonine, one of the indispensable amino acids16-19. Recently we 
demonstrated that in piglets between 80-90% of dietary threonine is utilized by the 
intestine20. Interestingly, additional data demonstrated a 60% reduction in whole-
body threonine requirements in piglets receiving total parenteral nutrition, compared 
to orally fed control animals21. In this context, intestinal demand for dietary threonine 
probably results from its incorporation into secretory mucins rich in threonine residues. 
Further support for this hypothesis is a study showing that specific restriction of 
dietary threonine impaired intestinal mucin synthesis22. We therefore hypothesized 
that the major metabolic fate of dietary threonine is incorporation into intestinal 
mucins, specifically Muc2. To directly investigate whether dietary threonine is utilized 
in Muc2 synthesis, we compared [13C]threonine enrichment in the small intestine, 
colon and faecal proteins of Muc2 deficient mice (Muc2-/-), which do not synthesize 
the Muc2 mucin23, 24  to that of wild type (WT) mice. Threonine enrichment was also 
measured in stomach content and in serum to evaluate the whole gastrointestinal 
tract and systemic availability of dietary threonine.
 Once taken up by the mucosal cells, threonine may have different metabolic 
fates, including oxidation. Threonine is catabolized either by threonine dehydratase 
(TDH) to NH4
+ and 2-ketobutyrate, which is irreversibly converted to CO2, or by 
threonine dehydrogenase (TDG) to form 2-amino-3-ketobutyrate, which is mainly 
converted to glycine and acetyl-CoA25. In piglets and rats, the TDG pathway 
accounts for 80% of threonine oxidation25,26. If absorbed dietary threonine is not used 
for intestinal protein synthesis, its metabolic fate might be oxidation. Second, we 
additionally measured intestinal [13C]glycine amounts in WT and Muc2-/- mice.  
Thus, by studying threonine metabolism in Muc2-/- mice and WT mice, we gained 
insight into intestinal threonine metabolism, and specifically into the role of dietary 
threonine in intestinal Muc2 synthesis.
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Materials and Methods
Animals 
 8-week-old, female, previously described Muc2-/- mice24  and corresponding 
WT littermates were housed in the same specific pathogen-free environment; 
animal care and procedures were in compliance with Erasmus MC - Animal Ethics 
Committee guidelines. 
Experimental setup
 Mice (n=17, for both groups) were weighed and fasted 2 hours (h) prior to 
receiving a threonine gavage, but had free access to drinking water. They received 
2.1 µmol [U-13C]threonine/g body weight (Sigma, St. Louis, USA) orally, based on 
i) average normal daily food intake (3 g/d) for female inbred strains27, ii) threonine 
composition of mouse chow (0.69% (w/w) threonine; 0.50% was used to calculate 
the definitive threonine amount, as not to overload the gastrointestinal tract) provided 
by Special Diets Services (Witham, Essex, UK) and iii) corrected for the total 6h 
time span of the experiment28. Similarly, control mice (n=2, for both Muc2-/- and WT 
mice) received an oral gavage of PBS. After the threonine gavage the mice had free 
access to standard rodent pellets (Special Diets Services). However, the experiment 
was initiated in the early morning to simulate normal feeding routine (normal daily 
intake during the night, and little to no food intake during the day as to minimize 
dilution of the [U-13C]threonine).  The mice were sacrificed by CO2 inhalation 1, 3 
or 6 h (n=5, per genotype, at each time point) after threonine administration. Blood 
was collected via heart puncture. Plasma was separated from whole blood by 
centrifugation (3000g for 5 min) and kept at -80oC until further analysis. Subsequently, 
the stomach, small intestine and colon were rapidly removed. The small intestine was 
halved into duodenum-jejunum and jejunum-ileum segments, referred to as proximal 
small intestine and distal small intestine, respectively. Both segments were opened 
longitudinally, thoroughly washed in PBS, weighed, snap frozen in liquid nitrogen 
and stored at -80oC until protein concentration and tracer enrichment analysis. Both 
the colon and stomach were opened longitudinally, the contents were removed, 
weighed, and snap frozen in liquid nitrogen and stored at -80oC. 
The same procedure as described for the small intestine was applied to the 
colon. 
Mass spectrometry
Tissue sample preparation 
Intestinal tissue samples were homogenized in water (100 mg/ml) and 
the faecal samples were homogenized by adding water, ratio 2:1. Total protein 
concentrations were measured using the Bicinchoninic Acid Protein Assay Reagent 
(Pierce, Rockford, IL, USA). The protein fraction was precipitated by adding 0.5 ml of 
2.0 mol/l perchloric acid (PCA) to an aliquot (500µl) of homogenized tissue sample 
and subsequent centrifugation at 2500g and 4ºC for 20 min. The supernatant was 
collected for each individual sample. Pellets were washed three times by adding 4 
ml of 0.2 mol/l PCA followed by centrifugation. The washing fluids from each sample 
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were collected and combined with the corresponding supernatant. Excess PCA was 
neutralized by adding KOH (4 mol/l), followed by brief centrifugation. To be able to 
determine the concentrations of either free [13C]threonine and [13C]glycine, 20 µl of 
internal standard (1 mg/ml Norvaline) was added to each sample. Also a standard 
sample of Norvaline and a known amount of threonine/ or glycine was used to 
determine the response factor for threonine or glycine, respectively. Subsequently, 
this factor was used for determination of threonine and glycine concentrations in 
the samples. These samples were then dried under a nitrogen stream and stored. 
Twenty microlitre internal standard (1 mg/ml Norvaline) was added to each washed 
pellet to be able to determine the concentrations of incorporated [13C]threonine and 
[13C]glycine. Subsequently the pellets were hydrolyzed by adding 0.5 ml of 6 mol/l HCl 
and incubating at 110°C in sealed tubes for 24h. The protein hydrolyzates were dried 
under nitrogen at 55°C and the residue was dissolved in 0.5 ml water. Amino acids were 
isolated from protein hydrolyzates and supernatant by cation exchange separation as 
described previously20. Amino acids were eluted with 3 ml 6M NH4OH and dried under 
nitrogen at 30°C20. Samples were derivatized with ethyl chloroformiate and threonine 
was converted to its N-ethoxycarbonylethylester derivative by a method described 
in our previous work20.
Analysis of tissue samples, stomach and colonic content
[13C]Threonine and [13C]glycine enrichments in the different organs were 
measured by a Thermo Electron Delta-XP isotope ratio MS (Bremen, Germany) 
coupled online with a trace GC (Thermo Electron, Breda, the Netherlands) and a 
combustion interface type 3 (Thermo Electron) which was used for [13C/12C]ratio 
measurement of both threonine and glycine. Aliquots of 1 µl of the chloroform 
suspension containing the amino acid derivatives were introduced into the GC 
system by a CTC PAL autosampler (CTC Switzerland). Chromatographic conditions 
were as described previously. After separation using capillary GC, amino acids were 
combusted online at 940°C and introduced as CO2 into the isotope ratio MS, where 
the [13C/12C]ratio was measured for both threonine and glycine. The atom percent 
enrichment was converted to mole percent threonine or glycine enrichment, after 
accounting for the 2.75-fold or 3.5-fold dilution of carbon in the derivative, respectively, 
and the measured [13C]abundance (98%) of the threonine tracer. The enrichment 
was expressed as mole percent excess (MPE).
Preparation and analysis of blood samples
Small aliquots of plasma (20 µl) were prepared to determine threonine 
enrichment and concentration by gas chromatography-mass spectrometry (GC-MS). 
Briefly, 20µl of internal standard (1 mg/ml Norvaline) was added to 20 µl plasma 
and deproteinized with sulfocalisylicacid 6%. After centrifugation for 10 min at 4°C 
and 1000g, the amino acids in the supernatant were isolated by cation exchange 
separation as described above. The eluate was dried overnight at 30ºC under 
nitrogen. Residues were resuspended by adding 200 µl dichloromethane, and 
subsequently dried under nitrogen for 1h at 35oC. Finally t-butyldimethylsilyl derivates 
were formed by adding 25 µl of dimethyl-formamide and 25 µl of N-methyl-N-(tert-
butyldimethylsilyl)-trifluoroacetamide to the dried residue and heating at 60°C for 1h. 
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Standard curves were prepared by mixing aqueous solutions of natural and labelled 
threonine for both enrichment and concentration determination. GC-MS analyses 
were performed on a Carlo Erba GC8000 gas chromatograph coupled to a Fisons 
MD-800 mass spectrometer (Interscience BV, Breda, the Netherlands). One microliter 
of the derivative was analyzed in split mode (1:20) on a DB-17, 30m x 0.25mm 
capillary column (Agilent, Amstelveen, the Netherlands). Selective ion monitoring was 
carried out at m/z 404.3, 405.3 and 408.3. The enrichment was MPE.
Calculations
 Basal [13C]threonine and [13C]glycine enrichments were determined in each 
tissue of the control (PBS) mice. These enrichments were subtracted from the 
[13C]enrichments measured in the experimental animals. 
Total [13C]threonine amount in each tissue (µmol) was calculated as follows:
(Threonine enrichment (MPE)/100) * Conc. Threonine tissue (µmol/g) * (weight) tissue
Subsequently, for each individual mouse threonine amount was expressed as 
percentage of total threonine administered enterally. An equivalent calculation was 
used to determine total [13C]glycine in each tissue sample.
Statistics
 Data are presented as mean plus the inter-animal standard error of the mean 
(SEM). Differences in [13C]threonine (free and incorporated into proteins) for each 
animal group over time were assessed using ANOVA. Differences in protein levels 
and [13C]threonine and [13C]glycine (free and incorporated) between the Muc2-/- and 
WT mice at each time point were evaluated using the Mann-Whitney test (two-tailed). 
P<.05 was considered to indicate statistical significance.
Results
Dietary [13C]threonine distribution 
 The total [13C]amount recovered consisting of [13C]threonine and [13C]glycine 
was expressed as percentage of total dietary [13C]threonine intake. The total 
[13C]amount recovered in the gastrointestinal organs and serum increased with time 
after threonine administration in both mice types (Fig. 1A). Figure 1B shows that total 
amounts of free [13C]threonine recovered increased significantly from 4.7% at 1h to 
10.1% at 6h after administration in Muc2-/- mice, but not in WT mice. Total amounts of 
recovered bound [13C]threonine significantly increased in both mice types. Figure 1C 
shows the distribution of dietary [13C]threonine 6h after [13C]threonine administration. 
The free amounts of [13C]threonine in the stomach content could not be included in 
our analysis since they exceeded the maximum measurable amount (41% MPE). 
Stomach content
 Incorporated [13C]threonine levels in the stomach content decreased with time in 
both mice types ((WT: 13.9% at 1h vs. 3.6% at 6h, not significant (NS) and (Muc2-/-: 6.4% 
at 1h vs. 2.3% at 6h, NS)). Threonine incorporation did not differ between mice types.
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Small intestine
 Total protein amounts in the distal small intestine significantly exceeded those in 
the proximal small intestine (P<.001, Muc2-/- and WT mice, Fig. 2A,D), and did not differ 
between mice types. 
Free [13C]threonine in the proximal small intestine decreased significantly between 
1 and 6h after threonine gavage in WT mice, but not in Muc2-/- mice, which showed 
only a transient decrease of free [13C]threonine at 3h post threonine delivery (Fig. 2B). 
Incorporated [13C]threonine in the proximal small intestine significantly increased with time 
in both  mice types, but did not significantly differ between types at any time point analyzed 
(Fig. 2E). 
 At all time points, free [13C]threonine percentage in the distal small intestine was 
significantly lower (P<.03) than that in the proximal small intestine in both mice types. In 
contrast to the proximal part (Fig. 2C), a lower amount of [13C]threonine was incorporated 
into proteins of the distal small intestine (Fig. 2F). However, threonine incorporation into 
intestinal proteins significantly increased after the threonine gavage. One hour after 
enteral threonine, the Muc2-/- mice showed significantly higher threonine incorporation into 
intestinal proteins compared to WT mice. This difference leveled off at later time points. 
Figure 1. Dietary threonine distribution and recovery. (A) Total [13C] (threonine+glycine) recovered 
in the tissues sampled (free and incorporated threonine and glycine in serum, proximal and distal 
small intestine, colon and colonic content and incorporated threonine and glycine in the stomach) 
expressed as percentage of threonine administered during time (hatched bars) [13C]Glycine; (stippled 
bars) [13C]Threonine; (B) The total amount of free and incorporated [13C]threonine in the tissues 
sampled. The amounts of free [13C]threonine recovered, increased significantly at 1 h to 6 h after 
administration in the Muc2-/- mice and was significantly higher at 3 and 6 h compared to the WT mice. 
The total amount of recovered bound [13C]threonine, significantly increased in both types of mice. (C) 
The distribution of dietary threonine at 6 hours expressed as percentage of threonine administered. 
The values represent the sum of free and incorporated threonine in the tissues samples, with exception 
of the stomach (free [13C] dietary threonine not determinable). Error bars indicate the standard error of 
mean. All significancies 1 h vs. 3 or 6 hours (* P<.05; †P=.016; **P<.01; # P=.001).
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Colon
 Total protein concentration in the colon of Muc2-/- mice was modestly but 
consistently higher than in WT mice (Fig. 3A). The pool of free [13C]threonine in 
colonic tissue was significantly higher in Muc2-/- mice throughout the experiment and 
its levels significantly declined over time in both mice types. However, kinetics in WT 
mice were faster compared to Muc2-/- mice. Incorporated [13C]threonine levels in the 
colon increased significantly over time and were significantly lower in WT mice at all 
time points.
Colonic content
 WT mice faeces had a significantly higher protein content than those of Muc2-
/- mice (WT: 59.2 mg/g and Muc2-/-: 50.8 mg/g, P=.022), as shown in Figure 3D.
Free [13C]threonine in colonic content increased with time in both mice types 
without significant differences between types. Furthermore, levels of incorporated 
[13C]threonine into the proteins of the colonic content increased significantly over 
time in both mice types. [13C]threonine incorporation in proteins of colonic content of 
WT mice at 6h was consistently higher, yet these differences were not statistically 
Figure 2. The protein content and threonine metabolism in the small intestine. (A, D) total 
protein amounts in the proximal and distal small intestine in WT and Muc2-/- mice.  (B, E) The free 
[13C]threonine in the proximal small intestine decreased during time in the WT mice and remained 
stable in the Muc2-/- and was significantly higher 3 hours after the threonine gavage. The free 
[13C]threonine in the distal small intestine remained stable during the experimental period and was 
significantly higher in the Muc2-/- mice at 1 hour after threonine administration [P=.016 1h, Muc2-/- mice 
vs WT]. (C, F) The incorporated [13C]threonine in proximal small intestine increased during time. The 
incorporated [13C]threonine in the distal small intestine also increased during time. The Muc2-/- mice 
showed a trend towards higher [13C]threonine incorporation which was significantly higher after 1h of 
threonine administration compared to the WT mice. Error bars indicate the standard error of mean. All 
significancies 1 h vs. 3 or 6 hours *P<.05; **P<.01, #P<.001.
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significant. Interestingly, taking into consideration that Muc2 is the principal constituent 
of the intestinal mucus, we suggest that the difference (27.4%) in [13C]threonine 
incorporated in proteins of the colonic content of WT and Muc2-/- mice is attributable to 
the presence of Muc2 mucin in the faeces of WT mice at 6h after threonine intake.
Serum
 Free [13C]threonine levels in serum significantly decreased over time ((WT: 
0.7% at 1h vs. 0.02% at 6h, P<.001) and (Muc2-/-: 0.4% at 1h. vs. 0.02% at 6h, 
P<.001)). Levels of incorporated [13C]threonine into proteins in serum increased over 
time in both groups (0.3% at 1h vs. 1.3% at 6h, P<.01) .
Intestinal and whole body threonine oxidation
 Total [13C]glycine levels reflected metabolic oxidation of threonine in the 
small intestine of both mice types; Figure 4A shows that the initial peak of total 
glycine accumulation at 3h reverted to basal levels in both mice types by 6h post 
threonine gavage. However, Muc2-/- mice had persistently higher oxidation rate of 
dietary threonine, a difference more pronounced in the colon where total [13C]glycine 
amounts also increased over time in both mice types (Fig. 4B).
 Total [13C]glycine amounts in the colonic content of both mice types 
significantly increased  over time without any appreciable difference between types 
Figure 3. The protein content and threonine metabolism in the colon. (A, D) total protein amounts 
in the colon and colonic content in WT and Muc2-/- mice.  (B, E) The free [13C]threonine in the colon 
declined during the experimental period in contrast to the colonic content in which the free [13C]threonine 
increased during the experiment (1 h vs. 3 and 6 h, *P<.05; **P<.01; #P<.001 Muc2-/- mice, WT mice, 
NS all time points). (C, F) The incorporated [13C]threonine in the colon increased during time. The 
incorporated [13C]threonine in the colonic content also increased during time. The WT mice showed 
a trend towards higher [13C]threonine incorporation at 6 h. Error bars indicate the standard error of 
mean. All significancies 1 h vs. 3 or 6 hours *P<.05; **P<.01, #P<.001.
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(Fig. 4C). In serum total [13C]glycine amounts in both mice types also significantly 
increased over time, without significant differences between types (Fig. 4D).
 In summary, WT mice showed 40.1% dietary [13C]threonine recovered in the 
intestinal tract after 6h vs. 43.6% in Muc2-/- mice. In the whole intestine, 26.2% of 
administered [13C]threonine in WT mice and 24.1% in Muc2-/- mice, respectively, was 
incorporated into proteins. Most dietary [13C]threonine recovered from the intestinal 
tract was detected in the colonic content in both mice types. In all other tissues and 
blood, except gastric content, [13C]threonine recovered was two to tenfold lower than 
in colonic content. Interestingly, 27.4% of recovered [13C]threonine in the colonic 
content of WT mice was incorporated into Muc2.  Finally, the entire intestine of the 
Muc2-/- mice showed a significantly higher oxidation rate compared to WT mice.
Discussion
 Previous studies showed that there is substantial amino acid metabolism 
in the intestine10. Specifically, the essential amino acid threonine is thought to be of 
utmost importance for intestinal Muc2 synthesis12, 20, 21. In the current study we aimed 
to gain more insight into intestinal threonine metabolism, and more specifically the 
role of dietary threonine in intestinal Muc2 synthesis, by studying threonine utilization 
in Muc2-/- and WT mice. 
 In line with previous studies, we found that the murine gastrointestinal tract 
takes up dietary threonine11, 20, 21. We retrieved 40.1% and 43.7% of dietary threonine 
in WT and Muc2-/- mice, respectively, either as free or incorporated threonine (Fig. 
1B). Interestingly, we detected threonine incorporated into proteins of the stomach 
content after 1h. To our knowledge these results are the first to indicate absorption of 
dietary nutrients from the lumen of the stomach. As previous studies demonstrated 
that the stomach wall secretes Muc5ac and Muc629, threonine might be incorporated 
into these proteins in the stomach. However, this remains to be investigated. In the 
Figure 4. Intestinal and whole body 
threonine oxidation. (A) The total 
[13C]glycine amounts inthe small 
intestine and colon (B) of WT and Muc2-/- 
mice increased during time. Overall, the 
Muc2-/- mice showed a higher oxidation 
of dietary threonine compared to WT 
mice, which was significantly higher in 
the small intestine and colon at each time 
point. (C) The total [13C]glycine amounts 
in the colonic content and serum (D) 
of WT and Muc2-/- mice significantly 
increased during time. There were no 
significant differences in [13C]glycine 
levels in the serum between the Muc2-/- 
and WT mice throughout the experiment. 
Error bars indicate the standard error of 
mean. All significancies 1 h vs. 3 or 6 
hours *P<.05; **P<.01, #P<.001
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present study, threonine distribution in the gastrointestinal tract and in serum was 
similar for both mice types studied. Muc2 deficiency therefore seems to have no initial 
impact on the intestinal threonine absorption capacity and the systemic availability of 
dietary threonine. However, [13C]threonine was given as dietary free threonine. The 
molecular form of ingested threonine (free, peptide bound or protein bound) offered 
to the epithelium of the gastrointestinal tract might affect whole-body threonine 
kinetics. This phenomenon was earlier described by Daenzer et al., demonstrating 
that protein-bound leucine was used more efficiently for liver protein synthesis than 
dietary free leucine30. More specifically, in the gastrointestinal tract we recovered 
41.5% of dietary [13C]threonine after 6h in WT mice vs. 44.8% in Muc2-/- mice, either 
as free or incorporated threonine or glycine. Thus, while dietary threonine utilization 
seems similar between Muc2-/- and WT mice, the primary metabolic fate, such as 
protein synthesis or oxidation, may differ. For this reason we investigated threonine 
metabolism in different intestinal segments. 
Overall, the pool of free threonine in the total small intestine remained constant in 
concentration and amount during the 6h experiment with no significant differences 
between mice types. In contrast, free threonine in colonic tissue decreased over 
time in both groups. Remarkably, Muc2-/- mice showed significantly higher amounts 
of free threonine in colonic tissue, suggesting a dietary threonine excess due to 
Muc2 deficiency. In contrast to the tissue samples, the colonic content showed a 
similar increase of free threonine over time in both mice types. This might be due 
to breakdown of de novo synthesized proteins other than Muc2. Our results are 
supported by findings from previous studies showing that the Muc2 central peptide 
backbone is highly resistant to proteolytic breakdown by bacteria and enzymes9. 
Additionally, the increase of free [13C]threonine in the colonic content might be 
caused by saturation of the small intestinal absorption capacity due to excess of 
[13C]threonine given by gavage. 
 Incorporation of dietary threonine into intestinal proteins was found to be 
higher in the proximal small intestine compared to other further distal intestinal 
segments. The proximal small intestine therefore seems to play a major role in the 
utilization of dietary threonine, in line with other studies suggesting that most of dietary 
proteins and amino acids are absorbed by the proximal jejunum31. Incorporation of 
dietary threonine increased in each intestinal segment sampled for both mice types. 
The higher amounts of [13C]threonine incorporated into proteins of the proximal small 
intestine – as compared to the distal small intestine and colon – can be explained by i) 
higher availability of [13C]threonine in the proximal small intestine or ii) higher turnover 
of secreted proteins along the intestinal proximal-distal axis. The latter hypothesis 
is supported by a previous study showing that total protein synthesis, and more 
specifically Muc2 secretion, is higher in the distal colon compared to the proximal 
colon32 and is hardly detectable in the small intestine (our unpublished data). In 
agreement, Atuma et al. showed that mucus thickness increases over the intestinal 
proximal-distal axis33. Moreover, in our study total protein amount in colonic content 
was higher in WT mice, demonstrating that Muc2 is mainly secreted by the colon. 
Furthermore, most dietary [13C]threonine recovered from the intestinal tract was 
derived from the colonic content, 27.4% of which was incorporated into the protein 
Muc2 in WT mice. In addition, a previous study in Muc2-/- mice showed no evidence 
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of up-regulation of other known secretory mucins of the intestinal tract to compensate 
for the lack of Muc224. Assuming that this does occur however, 27.4% incorporation 
of threonine into Muc2 in the WT mice would be an underestimation. Altogether, 
these data strengthen our hypothesis that dietary threonine is incorporated into the 
secretory mucin Muc2, with increased secretion rate along the intestinal proximal-
distal axis. Furthermore, our data in Muc2-/- mice demonstrate that dietary threonine 
is also used for intestinal constitutive protein synthesis and secretion. 
 Regarding the issue of intestinal and whole body threonine oxidation, our 
data suggest that a large proportion of absorbed threonine is incorporated into 
Muc2, although not in Muc2 deficient mice. This is why a larger proportion of dietary 
threonine may have been oxidized. However, there are no data on the presence of 
catabolic enzymes in murine intestinal mucosa. Previous studies reported absence 
or only negligible activity of threonine catabolic enzymes in piglet intestinal mucosa34. 
However, in the present study [13C]glycine was detectable in the intestine of both 
mice types, strongly suggesting that the catabolic enzyme TDG is  present and active 
in murine intestinal mucosa. Overall, Muc2-/- mice oxidized more dietary threonine 
than WT mice, indicating that Muc2 deficiency results in more inefficient utilization of 
dietary threonine. 
In summary, to our knowledge this is the first study demonstrating threonine 
utilization in mice. One of the pivotal metabolic fates of dietary threonine utilized by 
the intestine is its incorporation into Muc2. In the absence of Muc2, dietary threonine 
is mainly used for constitutive protein synthesis or becomes a substrate for metabolic 
oxidation. 
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Part II
Regulation of Mucin Gene Expression

Chapter 7
Regulation of Mouse Mucin 2 
by GATA Factors
Partly published as: 
Maria van der Sluis, Monique H.M. Melis, Nicolas Jonckheere, Marie-Paule 
Ducourouble, Hans A. Büller, Ingrid B. Renes, Alexandra W.C. Einerhand, and 
Isabelle Van Seuningen. The murine Muc2 mucin gene is transcriptionally regulated 
by the zinc-finger GATA-4 transcription factor in intestinal cells. 
Biochemical & Biophysical Research Communications, Vol 325(3);952-960, 2004
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Abstract
Mucin 2 (MUC2), the major mucin in the intestine, is expressed early during development and 
shows an altered expression pattern in intestinal bowel diseases. However the mechanisms 
responsible for MUC2 expression in the intestine during these events are largely unknown. 
Having found putative GATA binding sites in the murine Muc2 promoter and that GATA-4 
is expressed in Muc2-expressing goblet cells of the mouse small intestine, we undertook 
to study its regulation by GATA factors. A panel of deletion mutants made in pGL3 vector 
and covering 2.2 kb of the promoter were used to transfect the murine CMT-93 colorectal 
cancer cell line. The role of the GATA factors on the Muc2 gene regulation was investigated 
by RT-PCR and co-transfections in the presence of expression vectors encoding either wild 
type or mutated GATA factors or by mutating the GATA site identified within Muc2 promoter. 
Four GATA-4 cis-elements were identified in the promoter by EMSA and Muc2 promoter was 
efficiently activated when GATA-4 was overexpressed in the cells with a loss of transactivation 
when those sites were either mutated or a mutated form of GATA-4 was used. Overexpression 
of GATA-5 and GATA-6 also induced activity of Muc2 promoter. Conclusions: Altogether these 
results point out an important role for GATA factors as potent activators of Muc2 expression 
in the intestine.
Abbreviations used in this paper
EMSA , Electrophoretic Mobility Shift Assay; LPH, Lactase Phlorizin Hydrolase; Muc, Mucin; 
SI , Sucrase Isomaltase, WT, wild type
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Introduction
 The mucus layer in the lumen of the gut forms a physical barrier against 
micro-organisms and insoluble material1. Goblet cells are a hallmark of the 
intestinal epithelium, and are known to secrete mucins that participate in mucus 
formation to protect the underlying mucosa. The secretory mucin Muc2, a very large 
O-glycoprotein, is particularly relevant for the study of goblet cell biology as it is 
exclusively and abundantly expressed by intestinal goblet cells2, 3. It is produced 
throughout the gastro-intestinal tract increasing from small intestine to colon. 
 Muc2 is expressed early during embryonic development of the intestine4, 
which suggests that Muc2 transcription is under the influence of transcription factors 
responsible for intestinal development and cell differentiation. The early expression 
of mucin before mucus cell differentiation or during the process of differentiation 
indicates that they may be the targets of transcription factors responsible for those 
programs 5. This hypothesis has been recently confirmed in a previous study where 
we showed that the human MUC2 mucin gene is regulated by Cdx1 and Cdx2 
transcription factors6, which are both involved in intestinal cell differentiation7.
 GATA transcription factors belong to another family of transcription factors 
involved in development and cell differentiation. GATA factors can be grouped into 
two subfamilies based on structural features and expression patterns. GATA-1, 
GATA-2 and GATA-3 are involved in haematopoiesis and neurogenesis whereas 
GATA-4, GATA-5 and GATA-6 possess overlapping patterns in the developing 
cardiovascular system and in endoderm-derived tissues including the liver, lungs, 
pancreas, stomach and intestine8.
 During embryonic development GATA-4, GATA-5 and GATA-6 mRNA are 
expressed in the primitive intestine9, 10 in which Muc2 is also found4. Their expression 
in the intestine is sustained during adulthood with a distinct expression pattern along 
the crypt-villus axis, which strongly correlates with the status of differentiation of the 
cells. GATA-6 is highly expressed in the proliferating and less differentiated area in the 
crypts fading in the differentiated cells in the villi whereas GATA-4 and GATA-5 show 
an opposite pattern with highest expression on the tips of the villi fading towards the 
crypt11. Moreover, GATA factors are known to regulate other intestine-specific genes, 
which are considered as markers of enterocytes, such as fatty acid binding binding 
protein11, intestinal lactase-phlorizin hydrolase (LPH)11, 12 and sucrase isomaltase (SI)13.
 Characterization of the 5’-regulatory regions of numerous genes has 
demonstrated that GATA-4, GATA-5 and GATA-6 factors interact with a DNA sequence 
element containing the core GATA motif (A/T)GATA(A/G)8. Computer analysis of the 
murine Muc2 promoter sequence14 revealed the presence of several putative GATA 
binding sites throughout the promoter region.
 Altogether these data are in favour of a role for GATA factors in regulating 
Muc2 gene expression. Having found binding sites for these factors in the promoter 
of Muc2, and because of the spatio-temporal restricted pattern of expression of 
MUC2 and GATA factors along the crypt-villus axis in the intestine, we undertook 
to study the regulation of the promoter of mouse Muc2 by GATA-4/-5/-6 factors in a 
murine colorectal cancer cell line. Implications for MUC2 expression during intestine 
development and cell differentiation are discussed. 
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Materials and Methods
Animals
Adult specified pathogen-free Balb/c mice, obtained from Harlan (Zoetermeer, 
the Netherlands), were killed by cervical dislocation. The intestine was removed 
and fixed in 4% paraformaldehyde in PBS and subsequently processed for light 
microscopy as described previously15. The animal experiments were performed with 
the approval of the Animal Studies Ethics Committee of the Erasmus MC (Rotterdam, 
the Netherlands).
Immunohistochemistry
Five µm thick paraffin sections were cut and deparaffinized through a graded 
series of xylol-ethanol. Endogenous peroxidase activity was inactivated by 1.5% 
(v/v) hydrogen peroxide in PBS for 30 min, followed by antigen retrieval in 0.01 M 
citrate buffer for 10 min at 100°C. Thereafter, sections were incubated with TENG-
T (10 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 0.25% (w/v) gelatin, 0.05% (w/v) 
Tween-20) for 30 min to reduce non-specific binding. This was followed by overnight 
incubation with a 1:2500 dilution of goat anti-GATA-4 antibody (sc-1237X, Santa 
Cruz Biotechnology, USA) in PBS containing 1% (w/v) bovine serum albumin and 
0.1% (v/v) Triton X-100. Then, the sections were incubated for 1h with biotinylated 
horse anti-goat IgG (diluted 1:2000, Vector Laboratories, England) followed by a 1h 
incubation with ABC/PO complex (Vectastain Elite Kit, Vector Laboratories) diluted 
1:400. Binding was visualized after incubation in 0.5 mg/ml 3,3’-diaminobenzidine 
(DAB), 0.02% (v/v) H2O2 in 30 mM imidazole, 1 mM EDTA (pH 7.0). To visualize 
goblet cells, sections were stained with Alcian Blue 8GX (BDH, Brunschwig Chemie, 
Amsterdam, the Netherlands). Finally, sections were dehydrated and mounted.
Muc2-pGL3 deletion mutant constructs
The Muc2-pGL3 deletion mutants that cover 2.2 kb of the promoter (Genbank 
accession number AF221746) were constructed into promoterless pGL3 Basic 
vector (Promega, Madison, WI, USA) using a PCR-based method as described 
previously16, 17. Briefly, PCR reactions were carried out on mouse genomic DNA using 
the primers depicted in Table I. PCR products were then subcloned into pCR2.1 
vector (Invitrogen, Breda, the Netherlands) before subcloning into BglII–MluI sites of 
the pGL3 Basic vector previously linearized with the same restriction enzymes. All 
clones were sequenced on both strands on an automatic LICOR sequencer using 
infrared-labeled RV3 and GL2 primers (Promega). Plasmids used for transfection 
studies were prepared using the Endofree plasmid Mega kit (Qiagen, Venlo, the 
Netherlands).
Cell culture
Murine rectal cancer cell line CMT-93 was a kind gift of Dr D. Podolsky 
(Massachusetts General Hospital, Boston, MA, U.S.A.). The CMT-93 cells were 
cultured in Dulbecco’s modified essential medium containing 10% fetal bovine serum 
(Roche, Molecular Biochemicals, Meylan, France), 4 mM L-glutamine, penicillin 
(100 units/ml) and streptomycin (100 µg/ml) as previously discribed18. IEC-6 cells 
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were purchased from the ECACC (European Collection of Animal Cell Cultures). 
This cell line was established from rat small intestine crypt cells and was cultured in 
Dulbecco’s modified essential medium containing 5% fetal bovine serum, 2 mM L-
glutamine, 10 µg/ml insulin, 50 units/ml penicillin and 50 µg/ ml streptomycin. All cells 
were cultured at 37°C in a humidified 5% CO2 water-jacketed incubator. All reagents 
were from Invitrogen unless otherwise indicated.
Transfections
Transfections and co-transfections experiments were performed using 
Effectene® reagent (Qiagen) as described previously17 using 1 µg of Muc2-pGL3 
deletion mutants. Total cell extracts were prepared after a 48 h incubation at 37oC 
using 1×Reagent Lysis Buffer (Promega) as described in the manufacturer’s 
instruction manual. Luciferase activity (20 µl) was measured on a TD 20/20 
luminometer (Turner Design, Promega). Total protein content in the extract (4 µl) 
was measured using the bicinchoninic acid method in 96-well plates as described in 
the manufacturer’s instruction manual (Pierce, Bezons, France). In co-transfection 
experiments, 1 µg of the deletion mutant of interest was transfected with 0.25 µg of 
the expression plasmid encoding the transcription factor of interest (pMT2-GATA-4 
C
h
ap
te
r 
7
132
(Dr. S. Cereghini, INSERM, Hôpital Necker, Paris, France), pSG5-GATA-5, pSG5-
GATA-6 (Dr. J. K. Divine, Washington University, St-Louis, USA), wild type (WT) 
pcDNA GATA-4 and mutated forms pcDNA-(-Act) GATA-4, and pcDNA-(C290S) 
GATA-4, Dr. S. D. Krasinski (Harvard Medical School, Boston, MA, USA). Results 
were expressed as fold activation of luciferase activity in samples co-transfected with 
the transcription factor of interest compared with the control co-transfected with the 
corresponding empty vector. To study the effect on endogenous Muc2 expression, 
cells (0.5 x 106) were transfected with 4 µg of the expression vector of interest, and 
cultured for 48h before being lysed and processed for total RNA preparation.
RT-PCR
Total RNA from CMT-93 cells was prepared using the RNeasy mini-kit from 
Qiagen. 1.5 µg of total RNA was used to prepare cDNA (AdvantageTM RT-for-PCR 
kit, Clontech, Ozym, Saint Quentin Fallavier, France). PCR was performed on 
5 µl of cDNA using a specific pair of primers (MWG-Biotech, Ebersberg, Germany) 
for mouse Muc2 mucin gene: forward primer: 5’-TGTGGCCTGTGTGGGAACTTT-
3’, reverse primer: 5’-CATAGAGGGCCTGTCCTCAGG-3’. Mouse β-actin 
(forward primer: 5’-TCACGCCATCCTGCGTCTGGACT-3’; reverse primer: 
5’-CCGGACTCATCGTACTCCT-3’) was used as the internal control. PCR reactions 
were carried out in 50 µl final solutions as previously described6. Annealing 
temperature was 62°C and 59°C, respectively. PCR products were analyzed on a 
1.5% agarose gel run in 1X Tris-borate-EDTA buffer. A 100 basepair DNA ladder was 
purchased from Amersham Biosciences (GE Healthcare Bio-Sciences, Orsay, 
France). Expected size for Muc2 and β-actin PCR products are 558 and 582 
basepairs, respectively. RT-PCRs were carried out on cDNAs from three different 
sets of experiments. 
Nuclear extract preparation
Nuclear extracts from CMT-93 cells were prepared as described by Van 
Seuningen et al.19, and kept at –80°C until use. Protein content (2 µl of cell extracts) 
was measured using the bicinchoninic acid method as described above.
Oligonucleotides and DNA probes
Oligonucleotides used as probes and competitors in EMSAs are shown in 
Table II. They were synthesized by MWG-Biotech (Ebersberg, Germany). Equimolar 
amounts of single-stranded oligonucleotides were annealed and radiolabelled using 
T4 polynucleotide kinase (Promega) and [γ-32P] dATP. Radiolabelled probes were 
purified by chromatography on a Bio-Gel P-6 column (Bio-Rad, Ivry-sur-Seine, 
France).
EMSA (electrophoretic mobility shift assay)
The sequence of Muc2 promoter was analyzed with MatInspector V2.2 
and Alibaba2 softwares based on the genomatix and gene-regulation databases, 
respectively, to determine the location of putative transcription factor binding sites20. 
EMSAs were performed as described previously by Mesquita et al.6. Supershift 
analyses were carried out using 1 µl of the anti-GATA-4 antibody (sc-1237X, 
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SantaCruz). Reactions were stopped by adding 2 µl of loading buffer. Samples were 
loaded on to a 4% non-denaturing polyacrylamide gel and electrophoresis conditions 
were as described previously17. Gels were vacuum-dried and autoradiographed 
overnight at –80°C.
Site-directed mutagenesis
QuickChange site-directed mutagenesis kit (Stratagene, Amsterdam, the 
Netherlands) was used to generate site specific mutations in the two proximal 
GATA sites found in the Muc2 promoter at -168/-165 and -158/-155, respectively. 
The oligonucleotide containing the double mutation was designed according to the 
manufacturer’s instructions and its sequence is depicted in Table II.
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Results and Discussion
The GATA-4, GATA-5 and GATA-6 transcriptions factors are expressed 
simultaneously in mouse embryonic intestinal tissue as early as ED 9.58. Their 
importance in regulating several promoters of enterocyte-specific genes, has been 
previously described11-13. The MUC2 mucin is a marker of another intestinal cell type, 
the goblet cell, and possesses a spatio-temporal pattern of expression in embryonic, 
fetal and adult intestine4, 21. However, regulation of MUC2 mucin expression during 
development is largely unknown and is mandatory to better understand intestine 
differentiation and cell lineage establishment22. In this work we studied the 
transcriptional regulation of murine Muc2 by GATA factors and mapped the cognate 
cis-elements within the promoter. We focused on the role of GATA-4 factor since it 
is known to play an important role in directing cell lineage-specific gene expression 
during development of the vertebrate gut. 
GATA-4 is expressed in goblet cells of the mouse small intestine
Muc2 is the main mucin expressed by intestinal goblet cells2. Alcian blue 
staining of the mouse small intestine indicates the presence and location of these 
goblet cells (Fig. 1). Alcian blue-positive goblet cells are present both along the villi 
and in the crypts. Immunohistochemical staining of the same section with a GATA-4 
specific antibody showed staining of nuclei of all the cells along the crypt-villus 
axis, including goblet cells (Fig. 1). We can thus conclude that GATA-4 transcription 
factor is expressed in Muc2-expressing goblet cells in the small intestine. The fact 
that GATA-4 has been shown to play an important role in the regulation of genes 
Figure 1. Expression of GATA-4 transcription 
factor in mouse small intestine by immuno-
histochemistry. Alcian blue staining was 
performed as described in the material and 
methods section. GATA-4 immunostaining was 
carried out on the same section of mid jejunum 
of an adult mice using a specific antibody for 
GATA-4. Sections were counterstained with 
haematoxylin. Inset : close-up of one GATA-4 
expressing goblet cell. Please also see page 
223.
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expressed in the intestine11-13 and its co-localization with Muc2 in the goblet cells 
suggests an important role for GATA-4 in the regulation of Muc2 gene. In order to 
confirm this hypothesis we first identified GATA-4 responsive regions within Muc2 
promoter by co-transfection experiments in the presence of WT or mutated forms of 
either Muc2 promoter or GATA-4 factor and then identified GATA-4 cis-elements by 
gel-shift assays.
Muc2 promoter activity in murine and rat intestinal cells
To define essential regions that drive Muc2 transcription, six deletion mutants 
covering 2.2 kb of the promoter were constructed in the promoterless pGL3 Basic 
vector (Fig. 2A). Numbering refers to the transcription start site designated as +1 
that was previously described23. These constructs were then transfected into two 
different cell lines, a goblet-like cell line CMT-9324 and a crypt-like cell line IEC-
625, that both express Muc2 mRNA. The luciferase diagram shown in Figure 2B, 
indicates that Muc2 promoter activity is the strongest in the CMT-93 cell line (black 
bars). In both cell lines, the highest luciferase activity was obtained with fragment 
-729/+29. Since the activity increased from the fragment -563/+29 to -729/+29, it 
indicates that the -729/-564 region possesses essential positive regulatory elements 
that confer maximal activity to the promoter. In both cell lines, a decreased activity 
was seen with fragment -1568/+29 when compared with fragments -1001/+29 and 
-2213/+29. This indicates that there are inhibitory elements present within the 
-1568/-1002 region of the promoter. In conclusion, despite being active in both cell 
lines, Muc2 promoter appears more active in goblet-like CMT-93 cells than in crypt-
like IEC-6 cells.
Figure 2. Muc2 promoter constructs 
and promoter activity in CMT-93 and 
IEC-6 intestinal cells. (A) Schematic 
representation of the different 
deletion mutants used to study Muc2 
promoter activity. Numbering refers to 
transcription initiation site designated 
+1. (B) Luciferase activity diagrams 
showing Muc2 promoter activity in 
murine rectal CMT-93 (black bars) 
and rat colon IEC-6 cells (white bars). 
Results are expressed as fold activity 
of the deletion mutant of interest 
compared with the activity of empty 
pGL3 Basic vector. Results represent 
means ± S.D. obtained in triplicate in 
three separate experiments.
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GATA-4 regulates Muc2 expression at the transcriptional level 
Effect of GATA-4 overexpression on Muc2 endogenous expression in CMT-93 
cells was studied by RT-PCR (Fig. 3A). The result indicates that Muc2 mRNA level 
is substantially increased when GATA-4 is overexpressed in the cells (lane 2) when 
compared with cells transfected with the empty vector (lane 1). In order to identify 
GATA-4 responsive regions within Muc2 promoter, co-transfection experiments 
were then carried out in the presence of pGL3-Muc2 deletion mutant -221/+29 and 
GATA-4 expression vector (Fig. 3B, black bars). The luciferase diagram indicates 
that overexpression of GATA-4 resulted in a 10-fold increase of luciferase activity of 
the -221/+29 construct. When a mutated form of the -221/+29 construct was used, 
in which the GATA sites at -168/-165 and -158/-155 were mutated (GATA to CTTA, 
Table II), 30% of the transactivating activity was lost (white bars). The fact that the 
luciferase activity did not return to basal levels suggests that either other GATA 
sites are present with the –221/+29 region and contribute to the GATA-4-mediated 
transactivating activity or that GATA-4 acts indirectly on the promoter via interactions 
with co-factors. In order to investigate the latter hypothesis, we co-transfected cells 
in the presence of the -221/+29 deletion construct with either WT GATA-4 vector 
or mutated forms (-Act and C290S) (Fig. 3C). The –Act GATA-4 vector encodes 
a mutated form of GATA-4 in which the activation domains were deleted whereas 
C290S mutant encodes a GATA-4 form bearing a point mutation at amino acid position 
290 (cysteine to serine) in the COOH-terminal zinc finger26. Both forms are not able 
Figure 3. Activation of Muc2 mRNA level 
and promoter activity by GATA-4 in CMT-93 
cells by RT-PCR and transfection assays, 
respectively. (A) Endogenous expression of 
Muc2 mRNA after co-transfection with GATA-
4 expression vector (lane 2) or corresponding 
empty vector (lane 1). 10 µl (Muc2) and 2 µl 
(β-actin) of the PCR products were loaded on 
a 1.5 % agarose gel and electrophoresed in a 
1X Tris-borate buffer in the presence of ethidium 
bromide. (B) Luciferase diagram showing the 
effects of overexpression of GATA-4 on WT 
deletion construct –221/+29 (black bars) or 
deletion construct –221/+29 with two mutated 
GATA-4 sites at -168/-165;-158/-155 (white 
bars). (C) Luciferase diagram showing the 
effects of co-transfection of WT –221/+29 or -
563/+29 pGL3-Muc2 deletion mutants with WT 
GATA-4 or mutated GATA-4 expression vectors 
(-Act GATA-4 and C290S GATA-4). Results are 
expressed as fold activation of luciferase activity 
in samples co-transfected with the transcription 
factor of interest compared with the control co-
transfected with the corresponding empty vector 
(REF.). Results represent means ± S.D. obtained 
in triplicate in three separate experiments.
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to bind DNA cognate element. Co-transfections with the WT vector (WT GATA-4) led 
to a two-fold activation of both fragments tested (-221/+29 and –563/+29). When the 
same experiment was performed with the mutated GATA-4 vectors (-Act and C290S), 
the luciferase activity decreased and returned to basal levels. This implicates that 
the transcription activation of the Muc2 promoter by GATA-4 is mediated by a direct 
interaction of GATA-4 with the DNA sequence.
In conclusion, these experiments demonstrate that (i) GATA-4 induces Muc2 
transcription, (ii) responsive elements are present within the –221/+29 region of 
the promoter and (iii) GATA-4 binds directly to the promoter to transactivate Muc2 
promoter.
Figure 4. Sequence of the proximal part 
of Muc2 promoter and identification of 
GATA-4 cis-elements by EMSA. (A) The 
transcription site +1 (bold and underlined) 
is located 29 nucleotides downstream of 
the TATA box. Gray boxes indicate putative 
binding sites for transcription factors and 
boxed sequences indicate the sequences 
of oligonucleotides used in gel-shift 
assays. Arrows delineate the sequence 
of the deletion mutants used in this study. 
(B) Nuclear extracts were incubated with 
radiolabeled probe T216 (lanes 1-7). Probe 
alone (lane 1), radiolabeled T216 with 
nuclear extract (lane 2), cold competition 
with 50x excess of wt T216 probe (lane 
3). Super shift analysis was performed 
by preincubating the nuclear extract with 
1 µl of anti-GATA-4 (lane 4), anti-HNF-3α 
(lane 5), anti-HNF-3β (lane 6), or antiHNF-
4γ (lane 7) antiβodies, respectively. (C) 
Nuclear extracts were incubated with wild-
type (lanes 1-5) and mutated (lanes 6-8) 
radiolabeled T168 probe, respectively. 
Probe alone (lanes 1 and 6), radiolabeled 
probes with nuclear extract (lanes 2 and 
7), cold competition with 50x excess of 
wt T168 probe (lane 3), cold competition 
with 50x excess of mutated T168 probe 
(lanes 4 and 8). Supershift analysis with 
1 µl of anti-GATA-4 antibody (lane 5). (D) 
Nuclear extracts were incubated with WT 
(lanes 9-13) and mutated (lanes 14 and15) 
radiolabeled T169 probe, respectively. 
Probe alone (lanes 9 and 14), radiolabeled 
probes with nuclear extract (lanes 10 and 
15), cold competition with 50x excess of 
wt T169 probe (lane 11), cold competition 
with 50x excess of mutated T169 probe 
(lane 12). Supershift analysis with 1 µl of 
anti-GATA-4 antibody (lane 13).
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Identification of GATA-4 cis-elements within Muc2 promoter
Analysis of the proximal part of Muc2 promoter sequence with MatInspector 
V2.2 and Alibaba2 softwares indicated the presence of four several putative GATA 
binding sites at -99/-96, -168/-165, -158/-155 and -401/-398, respectively (Fig. 4A). 
They all contain the conserved consensus sequence required for GATA binding. 
To confirm the binding of GATA-4 to these sites, EMSAs were carried out in the 
presence of nuclear extracts prepared from CMT-93 cells. As shown in Figures 4B 
and 4C three GATA-4 binding sites were identified in the T216 (one GATA site at 
–99/-96) and T168 (two GATA sites at -168/-165 and -158/-155) probes, respectively. 
When radiolabeled probes were incubated with nuclear extracts, two specific shifted 
bands were visualized with T216 probe (Fig. 4B, lane 2) whereas only one was seen 
with T168 probe (Fig. 4C, lane 2). Specificity of the protein-DNA complexes were 
confirmed by the loss of the bands when cold competitions were performed with a 50x 
excess of the cold probes (Figs. 4B and 4C, lanes 3). As expected, cold competition 
with a 50x excess of a cold T168 mutated probe (Fig. 4C, lane 4) did not modify 
the pattern of the shift. Moreover, when the mutated T168 probe was radiolabeled 
and incubated with nuclear extracts, no shift corresponding to the GATA binding 
was visualized (Fig. 4C, lane 7). The same result was obtained with radiolabeled 
mutated T216 (not shown). Finally, implication of GATA-4 in the binding to the T216 
and T168 probes was proven by the supershifts (ssGATA-4) obtained when nuclear 
extracts and radiolabeled probes were incubated with an anti-GATA-4 antibody 
(Fig. 4B, lane 4 and Fig. 4C, lane 5, respectively). The identification of another 
GATA-4 cis-element at -99/-96 may thus explain the result shown in Figure 3B in which 
GATA-4 transactivation was not completely lost when GATA sites at -168/-165 and 
-158/-155 were mutated. That third proximal GATA-4 cis-element is therefore most 
likely involved in the regulation of proximal Muc2 promoter by GATA-4. Of interest, 
this element (-99/-96) is conserved in the promoter of human MUC2 23, 27, which 
makes it central in the regulation of MUC2 by GATA-4 between species. When 
EMSA was performed with radiolabeled probe T225 containing the fourth putative 
GATA binding site at -401/-398, no binding was observed, indicating that no GATA 
factor is binding to that site (not shown).
Having found that GATA-4 transactivates the 2.2 kb fragment of Muc2 promoter 
(not shown) and that a putative GATA binding site was present at -1521/-1518, we 
undertook to study whether GATA-4 was binding to that site. The result is shown in 
Figure 4D. As for T168, when radiolabeled T169 was incubated with CMT-93 nuclear 
extracts one specific retarded band was visualized (GATA, lane 10). The binding was 
lost when cold competition was carried out in the presence of a 50x excess of the 
cold T169 probe (lane 11) whereas nothing happened when cold mutated probe was 
used in the competition (lane 12). Involvement of the GATA consensus sequence in 
the binding was confirmed by absence of complex formation when the mutated probe 
was radiolabeled and incubated with nuclear extracts (lane 15). Finally, binding of 
GATA-4 on that element was confirmed when supershift analysis was performed in 
the presence of an anti-GATA-4 antibody in the reaction mixture and resulted in a 
complete supershifting of the protein-DNA complex (ssGATA-4, lane 13).
Of interest, we noticed that when the radioactive probe T216 was incubated 
with nuclear extracts (Fig. 4B, lane 2) two specific shifted bands were visualized. As 
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described above, the low mobility complex corresponds to a GATA-4 cis-element. 
Analysis of the sequence showed that the T216 probe also contained a putative 
HNF-3 binding site (Fig. 4A), that may be responsible for the second shifted band. To 
confirm implication of HNF-3 factors in the binding, we performed supershift analysis 
with specific anti-HNF-3α and anti-HNF-3β antibodies and one irrelevant anti-HNF-
4γ antibody, respectively. As can be seen in Figure 4B, incubation with anti-HNF-3α 
(lane 5) and anti-HNF-3β (lane 6) resulted in the disappearance of the high mobility 
complex (HNF), indicated by an asterisk, whereas nothing happened with anti-HNF-
4γ (lane 7) antibody. This result indicates that HNF-3α and HNF-3β factors bind 
to their cognate element at -108/-104, located next to the GATA-4 cis-element at 
-99/-96 within Muc2 proximal promoter. Previous studies have shown that transcription 
factors from HNF and GATA families are able to act synergistically to transactivate 
target genes28-30. These mechanisms imply either direct binding to DNA or physical 
interactions between HNF and GATA factors. It is of importance as HNF3 factors are 
also involved in the formation of mammalian gut endoderm, early lineage specification 
and intestinal cell differentiation28-30. Preliminary results indicate that HNF-3β is also 
expressed in Muc2-expressing goblet cells in the murine small intestine (I. Renes, 
unpublished data), which makes it an important factor to consider in Muc2 regulation 
as well. Cooperation between factors of the HNF and GATA families has already 
been described and either implied interaction between GATA-5 and HNF-1α12, 13 or 
between GATA-4 and HNF-1α31. Our results suggest that such a cooperation may 
exist between GATA-4 and HNF-3α or HNF-3β to regulate Muc2.
In conclusion the binding studies allowed us to identify three GATA-4 cis-
elements within the proximal part of Muc2 promoter at -99/-96, -168/-165, and 
-158/-155, respectively, and one in its distal part at -1521/-1518. Moreover, a HNF-
3α/3β cis-element was identified at-108/-104.
GATA-5 and GATA-6 regulate the activity of the promoter of Muc2
GATA factors bind to the same DNA consensus sequence8. Since GATA-5 and 
GATA-6 are also expressed in the small intestine and have been shown to regulate 
intestine-specific genes11-13, we undertook to study whether they were also capable 
of regulating Muc2 at the transcriptional level. To this aim, CMT-93 cells were co-
transfected with WT (black bars) or the mutated form (white bars) of pGL3 deletion 
mutant -221/+29 and GATA-5 or GATA-6 expression vectors, respectively. As shown 
in Figure 5A, co transfection of the deletion mutant -221/+29 with either GATA-5 or 
GATA-6 resulted in a very strong induction of luciferase activity (250 fold activation 
for both factors, black bars). When mutating the -168/-165 and -158/-155 sites in 
that fragment, the transactivating effect was completely lost (white bars). This shows 
that GATA-5 and GATA-6 are also able to transactivate the proximal part of Muc2 
promoter. When the same experiments were performed using the longer deletion 
mutant -563/+29 similar effects were obtained (Fig. 5B), with a 12 fold activation 
of that region of the promoter by both factors. When using the mutated form of that 
deletion mutant, GATA-5 transactivating effect was only partially lost (30% reduction, 
white bars). On the other hand, co-transfection of that mutant with GATA-6 resulted in 
a total loss of GATA-6 transactivating effect, suggesting that the mutated nucleotides 
are directly involved in the Muc2 transactivation. Since GATA-5 transactivation was 
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not completely abolished when using the mutated form of the longest Muc2 deletion 
mutant (-563/+27), it suggests that Muc2 activation by GATA-5 occurs via indirect 
mechanisms, most likely involving interactions with co-factors, which bind to the 
-563/-222 region of the promoter.
We then studied regulation of Muc2 by GATA-5 and GATA-6 in vivo by 
overexpressing GATA-5 and GATA-6 in the cells followed by the measurement 
of the level of Muc2 mRNA. When GATA-5 and GATA-6 were overexpressed in 
CMT-93 cells, only a slight increase of endogenous Muc2 mRNA level was visualized 
(Fig. 5C, compare lanes 2 and 3 to lane 1). This is in sharp contrast with the strong 
transactivation at the promoter level and suggests that GATA-5 and GATA-6 need 
cell-specific co-factors to substantially increase Muc2 endogenous expression in 
CMT-93 cells. However, it is in agreement with previous data that had established 
that GATA-5 and GATA-6, which are expressed in numerous tissues, cooperate with 
cell-specific transcription factors to activate their target genes and confer them a 
cell-specific pattern of expression8-11. For example, GATA-5 was shown to upregulate 
Muc2 mRNA expression in kidney 293T epithelial cells32, LPH promoter is efficiently 
activated when GATA-5 cooperates with HNF-1α and in this case HNF-1α first binds 
to DNA and then recruits co-factors such as GATA-5, which allows cooperative 
activation of LPH13, 33. Further studies will now be needed to demonstrate whether 
such a mechanism is also used to upregulate Muc2 expression.
In conclusion, we have shown that GATA-4, which co-localizes with Muc2 
in intestinal goblet cells, is a strong transactivator of Muc2 gene expression. 
GATA-4 induces Muc2 transcription by directly binding to its cognate cis-elements 
within the promoter. We also showed that GATA-5 and GATA-6, two other members 
of that family, transactivate Muc2 promoter and that HNF-3α and HNF-3β bind to a 
Figure 5. Regulation of Muc2 mRNA level and 
promoter activity by GATA-5 and GATA-6 in CMT-
93 cells by RT-PCR and transfection assays, 
respectively. (A) Luciferase diagram showing the 
effects of overexpression of GATA-5 and GATA-
6 on WT deletion construct -221/+29 (black bars) 
or deletion construct -221/+29 with two mutated 
GATA-4 sites at -168/-165;-158/-155 (white bars). 
(B) Luciferase diagram showing the effects of 
overexpression of GATA-5 and GATA-6 on WT -
563/+29 deletion mutant (black bars) or deletion 
construct -563/+29 with two mutated GATA-4 sites 
at -168/-165;-158/-155 (white bars). Results are 
expressed as fold activation of luciferase activity in 
samples co-transfected with the transcription factor 
of interest compared with the control co-transfected 
with the corresponding empty vector (REF.). Results 
represent means ± S.D. obtained in triplicate in three 
separate experiments. (C) Endogenous expression 
of Muc2 mRNA after cell transfection with either 
GATA-5 (lane 2) or GATA-6 (lane 3) expression 
vector or the corresponding empty vector (lane 1). 
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cis-element within the proximal promoter. All these data are in favor of an important 
role for GATA-4 factor in Muc2 spatio-temporal expression pattern observed in 
embryonic, fetal and adult small intestine and identifies for the first time Muc2, 
a gene that is a marker of goblet cells, as a direct target of transcription factors 
involved in intestinal development and cell differentiation. The identification of 
GATA-4 as a main regulator of Muc2 is not only important for intestine differentiation 
but also in other tissues where both GATA-4 and MUC2 are co-expressed. The 
gastric epithelium in which GATA-4 is also expressed34 is a good example, especially 
in gastric cancers associated with development of intestinal metaplasia which are 
characterized by the ectopic expression of Muc2 35. Thus GATA-4 appears as an 
important general regulator of Muc2 expression and identifies Muc2 as a target of 
GATA-4 in differentiated intestinal mucosa and metaplastic stomach. Further work 
is now required to confirm the implication of the other factors, GATA-5, GATA-6 
and HNF-3α /3β in the regulation of Muc2 in the intestine and to identify co-factors 
necessary to activate Muc2 expression in vivo.
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Chapter 8
Regulation of Mouse Mucin 2 by 
Hepatocyte Nuclear Factor -3 Factors
Maria van der Sluis*, Audrey Vincent*, Janneke Bouma, Anita Korteland-Van 
Male, Johannes B. van Goudoever, Ingrid B. Renes and Isabelle Van Seuningen. 
Hepatocyte Nuclear Factor 3alpha and -3beta are two important transcriptional 
regulators of the mucin Muc2 gene in intestinal goblet cells.
* Both authors participated equally in this study
Manuscript in preparation
C
h
ap
te
r 
8
146
Abstract 
The secretory mucin Muc2, a goblet cell marker, is the major structural component of intestinal 
mucus and thus plays an important role in maintaining intestinal homeostasis. This mucin 
has a spatio-temporal pattern of expression during intestinal development and goblet cell 
differentiation. However, the molecular mechanisms governing its expression during these 
biological processes are still poorly understood. We previously identified a cis-element for 
the hepatocyte nuclear factor-3alpha (HNF-3α) and -3beta (HNF-3β) transcription factors 
next to an important GATA-4 regulatory element. Since HNF-3α and HNF-3β participate in 
transcriptional programs governing intestinal cell differentiation, we undertook to study their 
role in Muc2 regulation. Immunohistochemical studies in the mouse small intestine showed 
co-localisation of HNF-3α and HNF-3β in Muc2-expressing goblet cells. Those two factors 
were also expressed in the murine CMT-93 colorectal cancer cell line that was used for our 
transcriptional studies. Gene targeting using RNA interference approach demonstrated that 
both transcription factors regulate Muc2 transcription. In vivo binding of HNF-3α and HNF-3β to 
the Muc2 promoter was assessed by chromatin immunoprecipitation assay. Co-transfections 
experiments with wild-type and mutated forms (for the four HNF3 elements) of the proximal 
promoter of Muc2 indicated that these four HNF3 elements are necessary to convey Muc2 
transcriptional activation. We did not find synergistic activity between GATA-4 and HNF-3α/3β 
in the proximal promoter. Altogether these results identify Muc2 as a new target of HNF-3α 
and HNF-3β and point out an important role for these transcription factors in Muc2 expression 
in the intestine during development and goblet cell differentiation.
Abbreviations used in this paper
ChIP, Chromatin Immunoprecipitation; E, embryonic day; EMSA, Electrophoretic Mobility Shift 
Assay; HNF, Hepatocyte nuclear Factor; LPH, Lactase Phlorizin Hydrolase; P, Postnatal days; 
SI, Sucrase Isomaltase
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Introduction
Mucins are complex glycoproteins that represent the major structural proteins 
of the mucus gel covering the digestive tract surface1. The secretory mucin Muc2 
is particularly relevant for the study of goblet cell biology as it is exclusively and 
abundantly expressed by intestinal goblet cells2, 3. 
Muc2 is expressed early during embryonic development of the intestine in 
a specific spatio-temporal pattern of expression4. Moreover, it has been recently 
identified as a marker of goblet cell since its expression has been associated 
with differentiation of this type of intestinal cells5. Altogether, these data suggest 
that Muc2 transcription is under the influence of transcription factors responsible 
for endoderm-derived cell types during intestinal development and goblet cell 
differentiation. The early expression of mucins before mucus cell differentiation or 
during the process of differentiation indicates that their genes may be the targets 
of transcription factors responsible for those programs6. This hypothesis has been 
recently confirmed in previous studies where we showed that the MUC2 gene is 
regulated by Cdx1, Cdx2 and GATA-4 transcription factors, which are all involved 
in intestinal cell differentiation7-9. Hepatocyte nuclear factor-3 (HNF-3) HNF-3α and 
HNF-3β belong to the winged helix/forkhead class of DNA binding proteins also 
known as Foxa1 and Foxa2, respectively (Fox refers to the Forkhead box)10. We 
will refer to HNF genes in the current manuscript. During embryonic development 
HNF-3α and HNF-3β mRNA are expressed in the primitive intestine in which Muc2 is also 
found4, 11-15. Intestine-specific enterocyte markers, such as intestinal lactase-phlorizin 
hydrolase (LPH) and sucrase isomaltase (SI), are controlled at the transcriptional 
level and relies on the activity of multiple tissue-enriched transcription factors such as 
Cdx-1/-2, HNF-1/-3/-4 and GATA-4/-5/-615 16-19. HNF3 factors bind the DNA consensus 
sequence 5’-GATTATTGACTT-3’ as monomers20, 21. The MUC2 gene is also regulated 
at the transcriptional level by Cdx7 and GATA8 factors however nothing is known 
regarding its regulation by HNF factors. In a previous study in which we identified 
GATA-4 as an important regulator of the murine Muc2 gene, we also found a HNF-3α 
and -3β binding site within the proximal region of the promoter8. Moreover, further 
computer analysis of the murine Muc2 promoter sequence22 indicated the presence 
of several putative HNF binding sites throughout the promoter region. Our previous 
work suggested a complex regulation of Muc2 in the intestine and more particularly 
in goblet cells. In order to demonstrate whether HNF3α and HNF3β transcription 
factors could be part of that complex transcriptional machinery, we undertook to 
investigate Muc2 regulation by these two factors. Our data demonstrate that both 
factors bind the promoter in vivo and are essential to the basal promoter activity and 
as such represent important regulators of Muc2 expression in the intestine.
Materials and Methods
Animals
Pregnant female Balb/c mice (Charles River, Maastricht, the Netherlands) were 
housed at constant temperature and humidity on a 12-h light-dark cycle. The mice 
had free access to a standard pelleted diet (Special Diets Services, Witham, Essex, 
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England) and tap water. Pregnant females were sacrificed by cervical dislocation, 
embryos were isolated and the intestine was excised at E15.5, E17.5, E18.5, postnatal 
day (P) 1.5 and adults. The small intestine was fixed in 4% paraformaldehyde in 
PBS and prepared for light microscopy. All the experiments were performed with the 
approval of the Animal Studies Ethics Committee of our institution (Erasmus MC, 
Animal Ethics Committee, Rotterdam, the Netherlands).
Immunohistochemistry
Five µm thick paraffin sections were cut and deparaffinized through a graded 
series of xylol-ethanol. Endogenous peroxidase activity was inactivated by 1.5% 
(vol/vol) hydrogen peroxide in PBS for 30 min, followed by antigen retrieval in 
0.01 M citrate buffer for 10 min at 100°C. Thereafter, sections were incubated with 
TENG-T (10 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 0.25% (w/v) gelatin, 0.05% 
(w/v) Tween-20) for 30 min to reduce non-specific binding. This was followed by 
overnight incubation with a 1:1000 dilution of goat anti- HNF-3α (sc-6553X) and 
HNF-3β (sc-9187X) antibodies (Santa Cruz laboratories, Tebu-Bio, Le Perray en 
Yvelines, France) in PBS containing 1% (w/v) bovine serum albumin and 0.1% (v/v) 
Triton X-100. Then, the sections were incubated for 1h with biotinylated horse anti-
goat IgG (diluted 1:2000, Vector Laboratories, Peterborough, England) followed by a 
1h incubation with ABC/PO complex (Vectastain Elite Kit, Vector Laboratories) diluted 
1:400. Binding was visualized after incubation in 0.5 mg/ml 3,3’-diaminobenzidine 
(DAB), 0.02% (v/v) H2O2 in 30 mM imidazole, 1 mM EDTA (pH 7.0). To visualize 
goblet cells, sections were stained with Alcian Blue 8GX (BDH, Brunschwig Chemie, 
Amsterdam, the Netherlands). Finally, sections were dehydrated and mounted.
Cell culture
The murine rectal cancer cell line CMT-93 was a kind gift of Dr D. Podolsky 
(Massachusetts General Hospital, Boston, MA, U.S.A.). The CMT-93 cells were 
cultured as described in van der Sluis et al. 8.
Nuclear extract preparation
Nuclear extracts from CMT-93 cells were prepared as described by Van 
Seuningen et al.23, and kept at –80°C until use. Protein content (2 µl of cell extracts) 
was measured using the bicinchoninic acid method as described above.
Western Blotting 
The nuclear proteins (20 µg) were separated by electrophoresis using 10% 
SDS-polyacrylamide gels, followed by electotransfer on a 0.45 µm PVDF membrane 
(Millipore). Immunostaining was performed as described previously24. Briefly, the 
membrane was washed with Tris-buffered saline-0.2% Tween20 (TBST) containing 
20 % non-fat dry milk (w/v), incubated for 1 h at room temperature with the antibodies 
specific for HNF-3α and HNF-3β (1:1000 dilution, Santa Cruz Laboratories) and then 
subsequently washed again three times with phosphate-buffered saline containing 
0.1% (v/v) Tween-20 before being probed with alkaline phosphatase-conjugated 
IgGs (Promega). For detection, blots were incubated with Nitro Blue Tetrazolium 
Chloride and 5-bromo-4-chloro-3-indolyl phosphate substrate (Life Technologies, 
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Cergy-Pontoise, France). The enzymatic reaction was stopped by soaking the 
membrane in distilled water.
Cell transfection and luciferase activity assays
The Muc2-pGL3 deletion mutants that cover 2.2 kb of the murine Muc2 
promoter (Genbank accession number AF221746) were described previously8. All 
plasmids used for transfection were prepared using the Endofree plasmid Mega kit 
(Qiagen). 
Transfections and co-transfections experiments were performed using 
Effectene® reagent (Qiagen, Courtaboeuf, France) as described previously25 using 
1 µg of Muc2-pGL3 deletion mutants. Total cell extracts were prepared after 48 h 
incubation at 37oC using 1×Reagent Lysis Buffer (Promega, Charbonnières, France) 
as described in the manufacturer’s instruction manual. Luciferase activity (20 µl) 
was measured on a TD 20/20 luminometer (Turner Design, Promega). Total protein 
content in the extract (4 µl) was measured using the bicinchoninic acid method in 96-
well plates as described in the manufacturer’s instruction manual (Pierce, Bezons, 
France). In co-transfection experiments, 1 µg of the deletion mutant was transfected 
with 0.25 µg of the expression plasmid encoding the transcription factor of interest 
(pMT2-GATA-4 (Dr. S. Cereghini, INSERM, Hôpital Necker, Paris, France), pHD-
HNF-3α and pHD-HNF-3β (Dr. J. K. Divine, Washington University, St-Louis, USA). 
Results were expressed as fold activation of luciferase activity in samples co-
transfected with the transcription factor of interest compared with the control co-
transfected with the corresponding empty vector. 
Site-directed mutagenesis
 QuickChange site-directed mutagenesis kit (Stratagene) was used to 
generate site specific mutations in the four HNF3 binding sites found in the proximal 
part of Muc2 promoter. The oligonucleotides containing the mutation were designed 
according to the manufacturer’s instructions and their sequences are depicted in 
Table I. All mutations were confirmed by DNA sequencing.
RNA interference 
 CMT-93 cells were seeded 24h before transfection in 24-well tissue 
culture plates at a density of 23 x 103 cells/well in antibiotic free medium. Cells 
were transfected with 100 nM of either mouse HNF-3α SMARTpool® or mouse 
HNF-3β SMARTpool® small interfering RNA (siRNA), using 0.5 µl of DharmaFECT2 
transfection reagent according to the manufacturer’s instructions. Cells transfected 
with either siCONTROL GAPD siRNA or siCONTROL Non-Targeting siRNA Pool#2 
and mock-transfected cells were included as controls. DharmaFECT2 transfection 
reagent and siRNAs were diluted in serum free medium and incubated for 5 min 
at room temperature before being mixed and incubated at room temperature for 
another 20 min. Complete medium (400 µl) was then added to the transfection mix 
and transferred to the cells. Total RNA was isolated 96h after transfection using 
the Nucleospin RNA II kit (Macherey-Nagel, Hoerdt, France). Total RNA (1µg) was 
used to prepare cDNA using oligod(T) (1µl) and recombinant reverse transcriptase 
M-MLV (1µl)  from Promega. PCR was performed on 5 µl of cDNA using a specific 
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pair of primers (MWG-Biotech, Berlin, Germany) for mouse Muc2 mucin gene 
(5’-TGTGGCCTGTGTGGGAACTTT-3’, and 5’-CATAGAGGGCCTGTCCTCAGG-
3’. Mouse GAPDH (forward primer: 5’-TGAAGGGCGACAATCTTCCTC-3’; reverse 
primer: 5’-CATGTGGGCCATGAGGTCCACCAC-3’) was used as the internal control. 
PCR reactions were carried out in 50 µl final solutions as previously described7. 
Annealing temperatures were 62°C and 59°C, respectively. PCR products were 
analyzed on a 1.5% agarose gel run in 1X Tris-borate-EDTA buffer. A 100 basepair 
DNA ladder was purchased from Amersham Biosciences. Expected size for Muc2 
and GAPDH PCR products are 558 and 980 basepairs, respectively. All reagents 
were from Dharmacon (Brebières, France), unless otherwise indicated. 
Chromatin Immunoprecipitation Assay
Soluble chromatin was prepared from 1.0 × 108 CMT-93 cells. Cells were 
fixed for 10 min at room temperature in 1% (v/v) formaldehyde diluted in the culture 
medium. Crosslinks were quenched for 5 min with 1x Dulbecco’s-PBS (Gibco, 
Courbevoie, France) supplemented with 0.125 M Glycine. Thereafter cells were 
washed consecutively with D-PBS and D-PBS containing 0.5 mM PMSF, 10 µg/ml 
aprotinin (Sigma, St. Louis, MO, USA), 10 µg/ml leupeptin (Sigma) and 0.2 mM 
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EDTA. Cells were scraped and collected by centrifugation at 685 x g at 4oC for 5 
min. Cells were then lysed for 10 min on ice in 2ml of 10mM HEPES buffer pH 
7.9 containing 10mM KCl, 1.5 mM MgCl2, 0.1% (v/v) NP-40, 0.2 mM EDTA, 0.5 
mM PMSF, 10 µg/ml aprotinin and 10 µg/ml leupeptin. Chromatin was sonicated 
using Bioruptor apparatus (Diagenode, Liège, Belgium) for 10 cycles of 30 sec 
“on” and 30 sec “off” at 200 W. Debris were cleared by centrifugation at 10,000 x 
g for 10 min at 4oC. The supernatant was pre-cleared by incubating with 50% (v/v) 
sonicated salmon sperm DNA/protein G agarose gel slurry (Upstate, Mundolsheim, 
France), to which was added 20 µg/ml BSA and 10 µg/ml sonicated salmon sperm 
DNA, for 1h at 4°C on a rotating platform. After centrifugation at 1500 x g for 1 min 
at 4°C, an aliquot of the total supernatant was removed as a control (input) and 
the rest was divided into fractions to be precipitated with either 4 µg of specific 
antibodies (anti-HNF-3α (sc-6553X), anti-HNF-3β (sc-9187X), anti-GATA4 (sc-
1237X), SantaCruz Biotechnology) or with normal rabbit IgGs (Upstate) as the 
negative control. Immunoprecipitation was performed overnight on a rotating 
platform at 4°C. Protein G-agarose gel slurry was then added and the incubation 
was continued for 2 h. Agarose beads were collected and washed sequentially for 4 
min in Low Salt Immune Complex Wash Buffer, High Salt buffer, LiCl buffer (Upstate) 
and twice with TE buffer (pH 8.0). The complexes were eluted with 2 x 0.25 ml of 
1% SDS-0.1 M NaHCO3 after a 15 min incubation at room temperature. The eluted 
immunoprecipitates and the input fraction were incubated overnight in 0.3M NaCl 
at 65oC followed by a digestion with Qiagen Protease for 1h at 50oC. The DNA was 
recovered using the Wizard® DNA Clean Up System (Promega) and eluted in 30 
µl of 1× TE pH8.0. Three microliters of DNA solution was used as a template for 
PCR. The primers used for PCR were 5’-AAAGGAATGGAGTTAGTTCAC-3’ and 
5’-CTTAGCAGGCATCCGAGG-3’, covering the -209/-31 region of Muc2 promoter. 
PCR was performed in a 30 µl final volume consisting of 1x PCR buffer II, 2.5 mM 
MgCl2, 1.5U AmpliTaq Gold polymerase (Applied Biosystems, Courtaboeuf, France) 
and 5 pmoles of each primer. The temperature-cycling protocol consisted of 12 min 
of preheating at 94°C followed by 35 cycles of 45 sec of denaturation at 94°C, 1 min 
of primer annealing at 50°C, and 1 min of primer extension at 72°C followed by a 10 
min final extension at 72°C. Fifteen microliters of the PCR products (239 bp) were 
loaded and separated on a 2 % agarose gel containing ethidium bromide.
Results 
HNF-3α and HNF-3β are expressed in goblet cells of the mouse small intestine
At E15.5, HNF-3α was uniformly expressed by all cells in the developing 
gut, whereas HNF-3β expression was restricted to the pseudostratified epithelium 
(Fig1A, showing HNF-3β). HNF3α was expressed by all epithelial and goblet cells in 
developing crypts and villi, with a slight decrease in intensity of the staining towards 
the top of the villi (Fig 1C, E, G showing E 18.5, P1.5 and adult respectively). From 
E17.5 until adulthood the expression of HNF-3β showed a spatio-temporal pattern. 
More specifically, HNF-3β was observed in the nuclei of the intervillus region (from 
E 17.5 till P 1.5, Fig. 1D, F and H), in the crypts (adult mice, Fig. 1H) and in goblet 
cells along the villi (Fig. 1F and H). Alcian blue staining of the mouse small intestine 
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indicates the location of the goblet cells. Furthermore, immunohistochemical studies 
performed in developing mouse intestine showed that as from E17.5, the goblet cell 
markers Muc2 and Tff3  markers were detectable (data not shown).
We can thus conclude that both HNF-3α and HNF-3β transcription factors are 
expressed in Muc2-expressing goblet cells in the small intestine. 
Transcriptional regulation of Muc2 by HNF-3α and HNF-3β in murine CMT-93 cells
 To study Muc2 transcriptional regulation by HNF-3α and HNF-3β we used 
the murine colorectal cancer cell line CMT-93. These cells expressed Muc2 mRNA 
as shown by RT-PCR (Fig. 2A). Furthermore, these cells expressed HNF-3α and 
HNF-3β proteins (Fig. 2A) as determined by western blot. In order to identify HNF-3 
responsive regions within Muc2 promoter, co-transfection experiments were then 
carried out in the presence of pGL3-Muc2 deletion mutant -221/+29 and HNF-3α or 
HNF-3β expression vectors (Fig. 2B, black bars and gray bars, respectively). The 
luciferase diagram indicates that overexpression of both the HNF3 factors resulted in 
an increase (4-6 fold) of luciferase activity of the -221/+29 construct. When mutated 
forms of the -221/+29 construct were used, in which the four putative HNF sites were 
mutated as indicated, transactivation by HNF-3α and -3β was completely lost except 
for the construct bearing a mutation in the most distal HNF site at -180/-175 (20-30% 
luciferase activity remaining). This indicates that each of these sites are essential for 
Figure 1.  Spatio-temporal expression of 
HNF-3α and HNF-3β in the mouse small 
intestine. HNF-3β expression was observed 
in (A) the pseudostratified epithelium at 
E15.5, and in the intervillus cells and goblet 
cells along the villi at (B) E17.5. HNF-3α and 
-3β staining, respectively of (C-D) E18.5 (E-F) 
P1.5 and (G-H) adult small intestine. Inserts 
of G and H show a close-up of a goblet cell 
stained with HNF-3α and -3β, respectively and 
counterstained with Alcian Blue. Magnification 
in A-D and E-H are equal, respectively, bar 
representing 75µm. Please also see page 
223.
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efficient transactivation of the proximal promoter of Muc2 both by HNF3α and HNF3β. 
In vivo gene silencing of HNF3α and HNF3β using siRNA approach, confirmed the 
fact that these two transcription factors regulate Muc2 transcription. Transfection of 
CMT-93 cells with siRNA specific for HNF3α or HNF3β respectively resulted in a 
40%-60% decrease of the amount of Muc2 mRNA in the cells as determined by RT-
PCR (Fig. 3).
Figure 2. Regulation of Muc2 by HNF-3α 
and HNF-3β in CMT-93 cells. (A) Endogenous 
Muc2 mRNA and HNF-3α or HNF-3β protein 
expression in confluent CMT-93 cells as 
determined by RT-PCR and western blot, 
respectively. (B) Luciferase diagram showing 
the effects of overexpression of HNF-3α 
(black bars) or HNF-3β (gray bars) on wild-
type Muc2 deletion construct –221/+29 or 
different deletion constructs as schematically 
represented. Results are expressed as fold 
activation of luciferase activity in samples 
co-transfected with the transcription factor 
of interest compared with the control co-
transfected with the corresponding empty 
vector (REF.). Results represent means ± 
S.D. obtained in triplicate in three separate 
experiments. 
Figure 3. Effect of HNF-3α and HNF-3β 
in vivo silencing on Muc2 expression in 
CMT-93 cells and in vivo binding to Muc2 
promoter. (A) CMT-93 cells were transfected 
with siRNA specific for HNF-3α and HNF-3β 
as described in the Material and Methods. 
The graph represents densitometric values of 
the RT-PCR results. A representative example 
of the RT-PCR results is shown. (B) Protein-
DNA complexes from CMT-93 cells were 
formaldehyde-cross-linked in vivo. Chromatin 
fragments from these cells were subjected to 
immunoprecipitation with antibodies against 
HNF-3α (lane 3), HNF-3β (lane 4), GATA-4 
(lane 5) and normal rabbit IgGs (lane 6). After 
cross-link reversal, the co-immunoprecipitated 
DNA was amplified by PCR using the indicated 
primers, and resolved in 2% agarose gel.
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In vivo binding of HNF-3α and HNF-3β to the Muc2 promoter in CMT-93 cells
 To examine whether HNF-3α and HNF-3β bind to the Muc2 promoter in 
vivo, chromatin from confluent CMT-93 cells was fixed and used for ChIP assays. A 
specific PCR primer set was used to produce a 239 bp DNA fragment of the –269/–31 
Muc2 promoter region. This region included the four putative HNF3 binding sites 
determined using MatInspector V2.226 and Alibaba2 softwares as well as the GATA-
4 cis-element previously identified8. The 239 bp PCR product was obtained from 
immunoprecipitates with anti-HNF-3α, anti-HNF-3β and anti-GATA-4 antibodies (Fig. 
4A, lanes 3-5). No amplified PCR product was observed when ChIP was carried out 
with normal rabbit IgGs as the negative control (Fig. 4A, lane 6). These results show 
that the transcription factors HNF-3α, HNF-3β and GATA-4 bind to the -269/-1 region 
of Muc2 promoter in vivo.
GATA-4 and HNF3 transcription factors do not synergize to activate Muc2 promoter
 Transcription factors from the HNF and GATA families have been shown to 
be able to act synergistically in transactivating target genes14, 15, 17. The luciferase 
diagram (Fig. 5A) shows that overexpression of GATA-4 and both the HNF3 factors 
resulted in an increased luciferase activity of the -221/+29 construct corresponding 
with our previous experiments. However there was no synergistic effect when co-
transfecting GATA-4 and HNF-3α or HNF-3β with the -221/+29 deletion construct. 
When mutating the different GATA sites in the -221/+29 deletion construct there 
Figure 4. GATA-4 and HNF3 transcription 
factors do not synergize to activate 
Muc2 promoter. (A) Luciferase diagram 
showing the effects of overexpression of 
GATA-4, HNF-3α or HNF-3β on wild-type 
deletion construct 221/+29 (black bars). (B) 
Luciferase diagram showing the effects of 
co-transfection of wild-type 221/+29 pGL3-
Muc2 deletion construct or different mutated 
221/+29 pGL3-Muc2 deletion constructs as 
represented schematically with the wild-type 
GATA-4 expression vector. (C) Luciferase 
diagram showing the effects of co-transfection 
of wild-type 221/+29 pGL3-Muc2 deletion 
construct or different mutated 221/+29 pGL3-
Muc2 deletion constructs as represented 
schematically with wild-type GATA-4 and 
HNF-3α (black bars) or HNF3β (gray bars) 
expression vectors. Results are expressed 
as fold activation of luciferase activity in 
samples co-transfected with the transcription 
factor of interest compared with the control 
co-transfected with the corresponding empty 
vector(s) (REF; white bars). Results represent 
means ± SD obtained in triplicate in three 
separate experiments.
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was loss of transactivation with different efficiencies. Mutation of the two GATA 
sites within the T168 probe at -168/-165 and -158/-155 resulted into a diminished 
luciferase activity corresponding to previously published results8. This indicates that 
the more proximal GATA-4 site (at -99/-96) was also active. Indeed when mutating 
only this site the transactivating effect of GATA-4 on the -221/+29 deletion construct 
was completely lost, suggesting that this GATA-4 site was the most important to 
convey Muc2 proximal promoter transactivation. Surprisingly, when mutating all 
three the GATA sites within the -221/+29 deletion construct, luciferase activity was 
partly restored.
Co-transfections with GATA-4 and either HNF-3α or -3β and different mutated 
deletion constructs bearing double GATA/HNF mutations were also performed to 
identify which site is playing critical role in regulating Muc2 transcription. As expected, 
co-transfections with wild type (WT) GATA-4 and either HNF-3α or -3β resulted into 
activation of the wild type -221/+29 deletion construct (Fig. 5C). When mutating the 
most proximal HNF site (HNF prox., -164/-161) within the T168 region, no loss of 
transactivation was observed in the presence of HNF-3_ (black bar) whereas 75% was 
lost in the presence of HNF-3β_(grey bar). When mutating the most distal HNF site 
(HNF dist.; -180/-175) within the T168 region, 100% and 60% of the transactivation 
was lost in the presence of HNF-3α or HNF-3β, respectively. However, as the HNF 
ext. site at -150/-144, proximal to the T216 region and the GATA-4 sites within T216 
region were still active (as shown in Figures 2- and 5B), the resulting transactivity 
with HNF-3β might be caused by these sites. When mutating the HNF ext. site at 
-150/-144, in addition to the two GATA-4 sites in the T168 region, transactivation by 
GATA-4/HNF-3α was lost whereas 25% of the activity remained in the presence of 
HNF-3β. When mutating the two GATA-4 sites in the T168 region (at -168/-165 and 
-158/-155) and the HNF-3α/3β site at -108/-104 in the T216 region, transactivation by 
GATA-4 and HNF-3α was completely abolished whereas transactivation by GATA-4 
and HNF-3β was reduced by half. Overall, HNF mutations at -180/-175, -150/-144 
and -108/-104 completely abolished effects mediated by HNF-3α and mutations 
at -150/-144 and -164/-161 were the most efficient in inhibiting HNF-3β-mediated 
effects.
Discussion
Muc2 is expressed early during embryonic development of the intestine4, 
which suggests that Muc2 transcription is under the influence of transcription factors 
responsible for intestinal development and cell differentiation. The early expression 
of mucin before mucus cell differentiation or during the process of differentiation 
indicates that they may be the targets of transcription factors responsible for those 
programs6. This hypothesis has been recently confirmed in previous studies on 
human and mouse Muc2 promoters, in which we showed that the mucin 2 gene is 
regulated by Cdx1, Cdx2 and GATA-4 transcription factors7, 8. Cdx1, Cdx2 and GATA-
4 are transcription factors which are also involved in intestinal cell differentiation9. 
During embryonic development HNF-3α and HNF-3β transcription factors are also 
expressed in the primitive intestine4, 11-15. Computer analysis of the murine Muc2 
promoter sequence22 revealed the presence of several putative HNF binding 
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sites throughout the promoter region. This added to previous results in which we 
identified a HNF-3α and -3β cis-element within the proximal region of the murine 
Muc2 promoter8, suggests that HNF3 transcription factors play an important role in 
the regulation of Muc2 gene. 
 In this report we demonstrate that HNF3α and HNF3β transcription factors 
(i) are co-expressed with Muc2 in colonic goblet cells of the mouse and (ii) that 
these two transcription factors bind to Muc2 promoter and regulate its transcription 
in vivo. Immunohistochemistry showed that HNF3α was expressed by all epithelial 
and goblet cells in the crypt and villi, with a slight decrease in intensity of the staining 
towards the tips of the villi which is in agreement with previous work showing the 
same pattern of HNF-3α expression along the crypt-villus axis27. Localization of 
HNF-3α in the intestine could imply that this transcription factor is involved in 
maintaining the differentiation potential of intestinal cells. Further support for this 
hypothesis are results from previous studies in which they showed that HNF-3α was 
a critical factor for maintaining the differentiation potential in cell line13, 28. 
 Immunohistochemical analysis revealed that HNF-3β was expressed in 
the region were intestinal stem cells and proliferating cells reside, namely in the 
intervillus/crypt region, thus suggesting involvement of HNF-3β in maintaining the 
epithelial cells in an undifferentiated state probably to stimulate epithelial proliferation. 
This hypothesis is supported by results from a previous study, in which the authors 
showed that isoforms of the winged helix transcription factors, more specifically, 
HNF-3/fork head homolog 11A and -11B, induced proliferative signals20. Localization 
of HNF-3β in the crypts our study corresponds to results as previously described by 
Besnard et al.27. However, in the current study HNF-3β expression was also observed 
in differentiated goblet cells along the villi (as of E17.5). This suggests that HNF-3β is 
required for goblet cell differentiation during development and/or goblet cell-specific 
gene expression. 
 Our study shows that HNF-3α and HNF-3β each have the individual capacity 
of activating Muc2 both in vivo and in vitro. HNF-3α has been described as a poor 
activator compared to HNF3β strong as they would interact with the same DNA 
binding sequence29. However, transfection assays and specific siRNA of these factors 
showed no distinct differences in potential activation of Muc2, implying that both these 
factors play a major role in activating Muc2 transcription. Co-transfection assays with 
GATA-4 and HNF-3α or HNF-3β showed no distinct synergistic effects. Interestingly, 
as the transcriptions factors are located close to each other on the -221/+29 deletion 
construct of the Muc2 promoter there may be competition between the transcription 
factors for the binding. This suggests that the amount of each transcription factor in 
the cell will be critical and will determine which will be controlling Muc2 transcription. 
Moreover, preliminary data on a larger fragment of the Muc2 promoter (-1568/+29) 
indicated that synergistic effects between HNF-3 and GATA-4 occur (unpublished 
data). This suggests as it has already been described for other intestine-specific 
genes that synergy between GATA and HNF transcription factors may also control 
Muc2 transcription17, 19, 30. These more remote binding sites within the Muc2 promoter 
will have to be identified in future experiments. There is increasing evidence that 
expression levels of intestinal specific target genes (e.g. Muc2/ SI) may be a result of 
gradients and combination of factors during development and differentiation7, 16, 17, 19, 
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30, 31. Distinct spatio-temporal patterns for several family members of developmental 
transcription factors (GATA-4/-4/-6, Cdx-2 and HNF-1α/-1β) have been determined 
in relation to SI and LPH32, however the expression pattern of these factors in relation 
to Muc2 in addition to the expression pattern of HNF-3α and -3β and remains to be 
investigated.  
 To determine the in vivo role of HNF-3α and -3β on Muc2 expression in the 
intestine of  both HNF-3α and -3β deficient mice would be interesting. However, to 
our knowledge Muc2 expression in these mice has not been determined. HNF-3β 
deficient mice embryos die because of defect in neural tube and HNF-3α deficient 
mice develop hypoglycemia and die parentally13, 29. Our data however, imply that 
both HNF-3α and –β could modulate Muc2 expression during development. 
 In summary, we were able to identify HNF-3α and -3β as major regulators 
Muc2 gene expression, and showed that HNF-3α and -3β i) are both expressed in 
Muc2-expressing goblet cells in the small intestine, ii) are both potent activators of 
the Muc2 promoter activity, iii) mediate Muc2 regulation by directly interacting with 
their cognate elements within Muc2 proximal promoter, and iv) are both required for 
endogenous expression of Muc2. Our results identify Muc2, a goblet cell marker, as 
a new target gene of HNF-3α and HNF-3β and point out an important role for these 
factors in Muc2 expression in the intestine.
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Abstract
Changes in the expression of mucin genes in gastrointestinal cancers is thought to contribute 
to the development of the disease. In our laboratory we have previously shown that MUC5AC is 
aberrantly expressed in rectosigmoid villous adenomas. However, the regulatory mechanisms 
underlying that altered profile of expression is unknown. In order to study its regulation at the 
transcriptional level, we have isolated and characterized 5.5 kb of the 5’-flanking region of the 
mouse Muc5ac mucin gene. Results & Conclusions: The promoter is flanked by a TATA box 
and a transcriptional start site is located 22 bp downstream of the TATA box. Analysis of the 
sequence showed a high density of binding sites for Smad4, an essential factor in the signaling 
cascade activated by TGF-β, and Sp1, an important factor in the regulation of MUC5AC. This 
led us to study Muc5ac regulation by TGF-β. We show that exogenous addition of TGF-β 
to the cells induces Muc5ac endogenous expression, promoter activity and Smad4 binding 
to the promoter. By co-transfection studies we show that Smad4 is essential for Muc5ac 
promoter activation and that it does not synergize with Smad2 or Smad3. By gel-retardation 
and co-transfection assays, we identified Sp1 and Sp3 as important regulators of Muc5ac 
expression and showed that Smad4 and Sp1 act in a cooperative manner to transactivate 
Muc5ac promoter activity. Altogether these results bring new insights into the molecular 
mechanisms of TGF-β-mediated up-regulation of Muc5ac and enhance our understanding as 
to how Muc5ac is regulated in certain pathologies of the gastrointestinal tract.
Abbreviations used in this paper 
aa, amino acid; EMSA, Electrophoretic Mobility Shift Assay; TBST, Tris-Buffered Saline-Tween 
20; TGF-β, Transforming Growth Factor-β; SSC 
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Introduction
 Mucins have been postulated to be important molecules in maintaining 
epithelial homeostasis in inflammatory diseases and cancer. Mucins are large O-
glycoproteins expressed either at the cell surface as transmembrane proteins or as 
secreted oligomeric molecules to form a protective gel1-4. In the gastrointestinal tract, 
they play a cytoprotective role against acid and pepsin in the gastric juice and against 
deleterious effects of exogenous agents (pathogens, drugs) and against mechanical 
damage5, 6. MUC5AC belongs to the family of secreted mucins that participate in 
mucus formation and is encoded by a gene located on the p15 arm of chromosome 
11 within a cluster of four mucin genes along with MUC2, MUC5B and MUC67, 8.
 In normal adult, MUC5AC main territories of expression are the surface 
epithelium of the respiratory tract and stomach9. This expression is restricted to 
mucus-producing lung goblet cells and gastric pit cells. MUC5AC normal pattern 
of expression is altered in several epithelial diseases of the gastrointestinal tract. 
It is aberrantly expressed in Barrett’s esophagus10, 11, in gastric metaplasia in the 
duodenum12, in colon adenoma and cancer6, 13. In rectosigmoid villous adenoma, 
MUC5AC expression was found very early during the carcinogenetic sequence, 
in low grade dysplasia, which makes it a valuable marker for recurrent patients14. 
Despite increasing amounts of data regarding its expression pattern in normal 
human tissues compared with that in disease6, 15, the precise biological role of 
MUC5AC as a key gene during sequential steps of carcinogenesis or in inflammatory 
processes has yet to be proven. Moreover, the molecular mechanisms that govern 
MUC5AC expression in the gastrointestinal tract are still largely unknown, thus their 
identification is necessary if one wants to better understand the role of MUC5AC in 
the pathologies of the gastrointestinal epithelium. 
 Transforming growth factor-beta (TGF-β) is a member of the superfamily of 
cytokines that affect a variety of cell types and elicit a wide array of cell-type-specific 
biological effects such as differentiation, migration, cell cycle arrest, adhesion, 
extracellular matrix production, and apoptosis16. TGF-β is also an agent involved 
in gastritis and development of gastric cancer17, two pathologies in which MUC5AC 
expression is altered. TGF-β-induced signaling occurs when the TGF-β ligand binds 
to the type II receptor (TGF-β RII), which heterodimerizes with the type I receptor 
(RI). RI then phosphorylates receptor-activated Smads (Smad2, Smad3). Once 
activated Smad2 and Smad3 bind to Smad4 and this complex translocates to the 
nucleus whereupon transcription activation of the target gene occurs18.
 Recent isolation of Muc1 and Muc2 murine mucin genes as well as their 
regulatory regions has helped a great deal in defining their biological roles in vivo and 
the molecular mechanisms responsible for their regulation. The studies performed 
on murine Muc1 mucin gene, which encodes a transmembrane mucin, and on Muc1-
/- mice showed that it is overexpressed in most carcinomas, correlates with high 
metastatic potential and poor survival and participates to tumor progression19. More 
recently, the promoter region of murine Muc2, which belongs to the secreted mucins, 
was characterized20. The authors showed, as for its human counterpart and other 
mucin genes, that Sp1 is an important factor in Muc2 regulation20. Interestingly, the 
knock-out mice for Muc2 mucin gene allowed the authors to demonstrate for the first 
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time a direct link between Muc2 expression and tumor formation as Muc2-/- mice 
started to develop intestinal adenomas that progressed to invasive adenocarcinoma 
and colorectal tumors as they were getting older21. From this work, the authors 
concluded that Muc2 is involved in colon cancer and may be considered as a tumor 
suppressor gene21.
 Murine Muc5ac mucin gene is partially characterized and part of its tandem 
repeat region was published by Shekels et al22. Of interest, the authors showed that 
Muc5ac is located on murine chromosome 7 that is the syntenic chromosomal region 
corresponding to human chromosome 11. Thus, it appears from this work and recent 
data released from the human and mouse genome databases (NCBI, MGI) that 
murine Muc2, Muc5ac, Muc5b and Muc6 are clustered on murine chromosome 7, 
which means that this cluster of mucin genes is conserved throughout evolution23.
Our aim is to better understand the transcriptional regulation of human and 
murine mucin genes in order to propose new therapeutic targets in epithelial diseases 
(inflammation and cancer) and better understand their role during embryonic 
development and differentiation of the gastrointestinal epithelium8. In this study, we 
have isolated, characterized and studied the regulation of the 5’-flanking region of 
murine Muc5ac mucin gene in order to obtain a base for future studies in animal 
models6 and better understand MUC5AC biological role in the pathophysiology of the 
epithelium. We show for the first time that Muc5ac is regulated at the transcriptional 
level by TGF-β, an agent involved in gastritis and development of gastric cancer. 
Material and methods
Cloning and characterization of murine Muc5ac 5’-flanking region
The 5’-flanking region of murine Muc5ac mucin gene was isolated and 
characterized after screening a murine OLA 129 genomic DNA library made in 
λGEM12 (kindly provided by Dr. A. Berns, Amsterdam, the Netherlands) with a probe 
spanning 750 basepairs (bp) of the human MUC5AC N-terminus (AF043909)24. Two 
positive plaques were identified and the corresponding DNA was isolated from the 
bacteriophages by using the Lambda DNA isolation kit (Qiagen, Courtaboeuf, France) 
according to the manufacturer’s protocol. Southern blot analysis and restriction 
mapping of both inserts identified a 5.5 kilobases (kb) fragment that hybridized with 
750 bp of the human MUC5AC. The positive 5.5 kb fragment was subsequently cloned 
into the SstI site of pBluescript II SK (+/-) (Stratagene, Amsterdam, the Netherlands), 
which resulted in clone pMS1. That fragment was then digested by ApaI and PstI 
to raise smaller fragments pMS2-pMS7. The clones pMS1-pMS7 were sequenced 
by Eurogentec (Seraing, Belgium) using T3 and T7 primers, and in the laboratory 
using the DYEnamic ET* Terminator Cycle Sequencing Kit, with fluorescent-labeled 
nucleotides (Amersham, GE Healthcare Bio-Sciences, Orsay, France), according to 
the manufacturer’s protocol. Sequence reactions were analyzed on an ABI-PRISM 
310 Genetic analyzer (Perkin Elmer-Applied Biosystems, Courtaboeuf, France). 
The obtained sequences were aligned with the BioEdit sequence alignment editor. 
The derived 5.5 kb nucleotide and amino acid sequences were compared to known 
sequences using NCBI-blast database. In addition, the sequence was analyzed with 
PC/Gene software (Intelligenetics, Inc., Mountain View, CA, USA), INFOBIOGEN 
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database and MatInspector V2.2 and Alibaba2 softwares based on the Genomatix 
database to determine the location of putative transcription factor binding sites25. The 
nucleotide sequence of pMS1 clone was submitted to Genbank under the accession 
number AF288076.
Determination of 5’-end of Muc5ac mRNA by RACE-PCR
The transcription start site was determined by 5’-RACE (rapid amplification of 
cDNA ends) using the 5’/3’ RACE kit (Roche Molecular Biochemicals, Meylan, France) 
according to the manufacturer’s instructions. RACE-PCR was conducted on mouse 
total gastric RNA (2 µg) using oligonucleotides 5’-CAGGGAAGTAGAAGACCTGTCC-3’ 
as first primer and 5’-TGTGCATTGGCTGCAGGCCAG-3’ as nested primer for 
reverse transcription and amplification. Resulting amplified PCR products were 
cloned directly into TA cloning vector (Invitrogen, Cergy Pontoise, France) and 
sequenced on an automatic LI-COR sequencer (ScienceTech, Bordeaux, France) 
with T7 and RM13 primers as described thereafter. 
Animals
Adult specified pathogen free Balb/c mice, obtained from Harlan (Zoetermeer, 
the Netherlands), were sacrificed by cervical dislocation. Stomach was removed 
and fixed in 4% paraformaldehyde in PBS and subsequently processed for light 
microscopy as previously described26. The animal experiments were performed with 
the approval of the Animal Studies Ethics Committee of the Erasmus MC (Rotterdam, 
the Netherlands).
Histology
Five µm-thick sections of mouse stomach tissue were routinely stained with 
hematoxylin and eosin (HE) to study the morphology, or stained with Alcian Blue/
Periodic Acid Schiff (PAS) reagent to stain for acidic and neutral mucins, respectively. 
Immunolocalization of mouse Muc5ac was carried out as previously described11 
using 45M1 monoclonal antibody (Novocastra, Valkenswaard, the Netherlands).
Probe preparation for in situ hybridization
Total RNA was extracted from murine stomach using TRIzol (Life technologies, 
Breda, the Netherlands) following the manufacturer’s protocol. RNA (1 µg) was 
transcribed at 42°C into cDNA using M-MLV Reverse transcriptase (Promega, 
Madison, WI, USA) in a total volume of 20 µl following the manufacturer's protocol. 
This was followed by a PCR reaction using 1 µl cDNA as template in 10 mM Tris-
HCl buffer pH 8.4, containing 50 mM KCl, 2 mM MgCl2, 0.01% gelatin, 1 U Taq 
polymerase (Eurogentec, Seraing, Belgium), 0.2 mM dNTPs, and 10 pmoles 
of each primer. The primers were (5’-CCAATTGGCTAGATGGCAGT-3’) and 
(5’-AGATCAAACCCTCCTCTCG-3’), which corresponds to nucleotides 374-394 and 
552-572 of murine Muc5ac, Genbank L4229222. The PCR sample (20 µl) was first 
denatured at 96°C for 5 min, followed by 30 cycles at 96°C for 1 min, 60°C for 1 min, 
and 72°C for 1 min and a final extension step at 72°C for 2 min. The resulting 199 
bp PCR product was isolated using the Qiagen gel extraction kit and ligated into the 
EcoRI site of pBluescript SK vector and subsequently sequenced. The digoxigenin-
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11-UTP-labeled sense and antisense Muc5ac RNA probes were prepared according 
to the manufacturer’s protocol (Roche, Almere, the Netherlands).
In situ hybridization
Tissue sections were deparafinized with xylene and rehydrated through 
RNase free ethanol/water solutions. The non-radioactive in situ hybridization was 
essentially carried out as described previously27. Briefly, the riboprobes were diluted 
in hybridization solution (50% deionized formamide (v/v), 10% dextran sulfate (w/v), 
2X SSC, 1X Denhardt’s solution, 1 µg/ml tRNA, 250 µg/ml herring sperm DNA) to 
a concentration of 100 ng/ml, hybridized overnight at 55°C in a humid chamber. 
Post-hybridization washes were performed at 45°C using the following steps: 50% 
formamide (v/v) in 2X SSC, 50% formamide (v/v) in 1X SSC and 0.1X SSC. A 15 
min incubation with RNase T1 (2 U/ml in 1 mM EDTA in 2X SSC) at 37 °C was 
followed by washes of 0.1X SSC at 45°C and 2X SSC at room temperature (RT). The 
digoxigenin-labeled hybrids were detected by incubation with anti-digoxigenin (Fab, 
1:2000) conjugated to alkaline phosphatase for 2.5 h at RT. Thereafter, sections 
were washed in 0.025% (v/v) Tween in Tris-buffered saline pH 7.5. For staining, 
sections were layered with detection buffer (0.1M Tris-HCl, pH 9.5 containing 0.1M 
NaCl and 0.05M MgCl2) containing 0.33 mg/ml 4-nitroblue tetrazolium chloride, 
0.16 mg/ml 5-bromo-4-chloro-3-indolyl-phosphate, 8% (v/v) polyvinylalcohol (Mw 
31000-50000 Aldrich Chemical, Milwaukee, WI, USA) and 1 mM levamisol (Sigma, 
St. Louis, MO, USA). Development of the reaction was performed overnight in the 
dark and was stopped when the desired intensity of the resulting blue precipitate 
was reached. Finally, sections were washed in distilled water and mounted with 
Aquamount improved (Gurr, Brunschwig, Amsterdam, the Netherlands).
Muc5ac-pGL3 deletion mutant constructions
The Muc5ac-pGL3 deletion mutants that cover 1.2 kb of the promoter were 
constructed into pGL3 Basic vector (Promega, Charbonnieres-les-Bains, France) 
using a PCR-based method as previously described28, 29. PCR reactions were 
carried out on pMS1 clone in order to subclone the promoter region of Muc5ac. PCR 
products were then subcloned into pCR2.1 vector (Invitrogen) before subcloning 
into SacI-MluI sites of the promoterless pGL3 Basic vector. Internal deletion mutants 
were generated by PCR using pairs of primers bearing specific restriction sites at 
their 5’ and 3’ ends (Table I). PCR products were digested, gel-purified (Qiaquick 
gel extraction kit, Qiagen) and subcloned into the pGL3 Basic vector that had been 
previously cut with the same restriction enzymes. All clones were sequenced on both 
strands on an automatic LI-COR sequencer using infra-red labeled RV3 and GL2 
primers (Promega). Plasmids used for transfection studies were prepared using the 
Endofree plasmid Mega kit (Qiagen).
Cell culture
Murine rectal cancer cell line CMT-93 was a kind gift of Dr. D. Podolsky (Boston, 
USA). CMT-93 were cultured in DMEM medium containing 10% fetal bovine serum, 
4 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 µg/ml). IEC-6 cells 
were purchased from ECACC (European collection of animal cell cultures). This cell 
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line was established from rat small intestine crypt cells and was cultured in DMEM 
medium containing 5% fetal bovine serum, 2 mM L-glutamine, 10 µg/ml insulin, 50 
U/ml penicillin and 50 µg/ml streptomycin. HCT116-Smad4+/+ and HCT116-Smad4-/- 
cells were a kind gift of Dr. A. Atfi (INSERM U482, Paris). Cells were cultured in 
DMEM supplemented with 2 mM glutamine and 10 % fetal calf serum. Human 
gastric cancer cell line KATO-III was cultured as previously described30. All cells 
were cultured at 37°C in a humidified 5% CO2 water-jacketed incubator. To study 
TGF-β effect, cells were incubated for 24h with TGF-β (recombinant human TGF-β, 
10 ng/ml). All reagents were from Sigma unless otherwise indicated.
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Reverse transcriptase PCR
Total RNAs from cultured cells and mouse tissues were prepared 
using the QIAamp RNA blood mini-kit and midi-kit (Qiagen), respectively. 
Total RNA (1.5 µg) was used to prepare first strand cDNA (AdvantageTM RT-
for-PCR kit, Clontech, Ozym, Saint Quentin Fallavier, France). PCR was 
performed on 2 µl of cDNA using specific pairs of primers as follows: Muc5ac 
(5’-GAGGGCCCAGTGAGCATCTCC-3’, and 5’-TGGGACAGCAGCAGTATTCAGT-
3’; accession number AJ010792); β-actin was used as an internal control 
(5’-GTGGGCCGCTCTAGGCACCA-3’ and 5’-TGGCCTTAGGGTGCAGGGGG-3’; 
accession number M12481). Muc5ac and β-actin PCR product sizes are 361 and 
241 bp, respectively. Mouse TGF-βRII (5’-CGTGTGGAGGAAGAACAACA-3’ and 
5’-TCTCAAACTGCTCTGAGGTG-3’; accession number S69114). PCR product 
is 560 bp long. Rat β-actin (5’-ATATCGCTGCGCTCGTCGTCGACAA-3’ and 
5’-AACACAGCCTGGATGGCTACGTACAT-3’; accession number V01217). PCR 
reactions were carried out in 50 µl final solutions as described in Mesquita et al31. 
Annealing temperature was 58°C. PCR products were analyzed on 1.5% ethidium 
bromide-agarose gels run in 1X Tris-borate-EDTA buffer. A 100 bp DNA ladder was 
purchased from Amersham Bioscience.
Transfections
Transfections and co-transfections experiments were performed using 
Effectene® reagent (Qiagen) as previously described using 1 µg of pGL3-Muc5ac 
deletion mutants28. Total cell extracts were prepared after a 48h incubation at 37°C 
using 1X Reagent Lysis Buffer (Promega) as described in the manufacturer’s 
instruction manual. Luciferase activity (20 µl) was measured on a TD 20/20 
luminometer (Turner Design, Promega). Total protein content in the extract (4 µl) 
was measured using the bicinchoninic acid method in 96-well plates as described in 
the manufacturer’s instruction manual (Pierce, Bezons, France). In co-transfection 
experiments, 1 µg of the deletion mutant of interest was transfected with 0.25 µg of 
the expression plasmid encoding the transcription factor of interest. Results were 
expressed as fold activation of luciferase activity in samples co-transfected with 
the transcription factor of interest compared to the control co-transfected with the 
corresponding empty vector.
Nuclear extract preparation
Nuclear extracts from the different cells were prepared as described by Van 
Seuningen et al32 and kept at -80°C until use. Protein content (2 µl of cell extracts) 
was measured using the bicinchoninic acid as described above.
Western-blotting
20 µg of nuclear proteins and 8 µl of prestained molecular weight markers 
(Life technologies, Cergy Pontoise, France) were loaded on a 10% SDS gel and 
electrophoresed for 1h15 min at 35 mA until bromophenol blue reached the bottom 
of the gel. The polyacrylamide gel was then electrotransferred on a 0.45 µm PVDF 
membrane (Millipore, Saint-Quentin-en-Yvelines, France) for 1h at 100V using a 
Bio-Rad transfer apparatus. Immunostaining was performed as follows: the PVDF 
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membrane was incubated with Tris-buffered saline-0.2% Tween20 (TBST) containing 
20 % (w/v) non-fat dry milk for 2h at RT, then washed 3x5 min with TBST. Incubation 
with polyclonal anti-Sp1 PEP2 (sc-59) and anti-Sp3 (sc-644) antibodies (Santa Cruz 
laboratories, Tebu-Bio, Le Perray en Yvelines, France) at 1:1,275 dilution in TBST 
was carried out for 2h at RT under shaking. The membrane was then washed 3x5 
min at RT with TBST before adding alkaline phosphatase conjugated-anti-rabbit 
IgGs (Promega) for 30 min at RT. The membrane was washed 1x5 min with TBST 
and 1x5 min with substrate buffer (0.1M Tris-HCl, pH 9.5 containing 0.1M NaCl and 
0.05M MgCl2). Staining was developed by incubating the membrane with 10 ml of 
substrate buffer containing 0.33 mg/ml 4-nitroblue tetrazolium chloride and 0.16 mg/
ml 5-bromo-4-chloro-3-indolyl-phosphate. The enzymatic reaction was stopped by 
soaking the membrane in distilled water.
Oligonucleotides and DNA probes
The sequences of the oligonucleotides used for gel-shift assays are indicated in 
Table II. They were synthesized by MWG-Biotech (Ebersberg, Germany). Equimolar 
amounts of single-stranded oligonucleotides were annealed and radiolabeled using 
T4 polynucleotide kinase (Promega) and [γ32P]-dATP. Radiolabeled probes were 
purified by chromatography on a Bio-Gel P-6 column (Bio-Rad, Ivry-sur-Seine, 
France).
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Electrophoretic mobility shift assays (EMSA)
Incubation of nuclear proteins (8 µg) with radiolabeld probes, supershift 
analyses, and cold competitions were carried out as in Mesquita et al31. Anti-Sp1, 
anti-Sp3, anti-Smad2, anti-Smad4, and anti-NF-κB p65 antibodies and consensus 
Smad4 oligonucleotide were purchased from Santa-Cruz laboratories. Reactions 
were stopped by adding 2 µl of loading buffer. Samples were loaded onto a 4% non-
denaturing polyacrylamide gel and electrophoresis conditions were as described 
previously29. Gels were vacuum-dried and autoradiographed overnight at -80°C.
Results
Cloning and characterization of murine Muc5ac mucin gene 5’-flanking region
In order to obtain the mouse Muc5ac 5’-flanking region, a mouse genomic 
library in λGEM12 was screened with a 750 bp DNA fragment encoding the N-
terminal region of human MUC5AC24. The two positive plaques contained inserts 
of approximately 18 kb. After restriction mapping and Southern blot analysis, seven 
clones (pMS1-pMS7) were isolated and sequenced (see Materials and Methods 
section). Sequencing of the 5.5 kb pMS1 clone indicated that it contains the promoter 
region, the first three exons and the first three introns of the mouse Muc5ac mucin 
gene (Fig. 1A). Sequence analysis of the pMS1 clone and alignment to human and 
rat MUC5AC 5’-flanking regions revealed a translational start codon at position 3211 
identical to rat Muc5ac first codon and 3 short exons encoding a total of 72 amino acids 
with 52% identity to human MUC5AC and 79% identity to rat Muc5ac (Fig.1B).
Figure 1. Isolation and characterization of a 5.5 kb genomic DNA fragment containing the 5’-
flanking region of murine Muc5ac mucin gene.  (A) Schematic representation of the organization 
of the 5’-flanking region of Muc5ac gene showing the promoter, the first three exons, ATG and 
transcription initiation site locations. (B) Alignment of deduced N-terminal amino acid sequences of 
mouse (mMuc5ac), rat (rMuc5ac) and human (hMuc5ac) MUC5AC peptides. Black boxes indicate 
conserved amino acid residues in the three species and gray boxes amino acid residues identical in 
two different species. The deduced consensus sequence is indicated at the bottom
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Determination of the transcription start site of Muc5ac gene
To determine the transcription start site, 5’-RACE assays were performed on 
mouse gastric RNA using two nested antisense primers selected at about 300 bp and 
70 bp downstream of the presumed start codon, respectively, based on comparison 
with the human MUC5AC gene33. The sequences showed 100% homology when 
aligned with the 5’-flanking sequence of mouse Muc5ac. The 5’-end of the longest 
product (117 bp) corresponded to a thymidine residue located 33 nucleotides 
upstream of the first ATG and 22 nucleotides downstream of the TATA box (Fig. 2). 
In conclusion, Muc5ac transcription start site is a T residue located 22 nucleotides 
downstream of the TATA box.
Characterization of the promoter sequence of Muc5ac
The sequence found upstream of the transcription initiation site is characterized 
by the presence of a TATA box (TACAAAA) at –28/-22 (Fig. 2). The first 150 
nucleotides upstream of the TATA box are rich in GC and CACCC boxes and Sp1 
binding sites. Putative binding sites for Smad factors are present throughout the 
promoter sequence. It is interesting to note that the Smad sites are always found 
in close vicinity or embedded within Sp1 binding sites and/or GC-rich sequences. 
More upstream (-944/-938) is found an AT-rich sequence that is a putative site 
representative of a TATA box. Note that this sequence may also bind the Cdx 
transcription factor. Two putative binding sites for GATA factors were found at -1001/-
998 and -774/-771. Consensus binding sites for retinoid (ATF/RXR-α-837/-832) or 
thyroid hormone (T3R-α -634/-626) receptors were also found. In the 5’-UTR region, 
that is 33 nucleotides long, putative binding sites for AP-1 and Sp1 were found at 
+2/+10 and +14/+23, respectively. In the first exon, a putative binding site for YY1 
transcription factor is found at +47/+56 adjoining an Sp1 binding site at +54/+63.
Figure 2. Sequence of the 5.5 kb genomic 
fragment containing Muc5ac promoter. The 
transcription start site +1 (bold and underlined) 
is located 22 nucleotides downstream of 
the TATA box (double underlined). The first 
ATG (+34) is bold, italicized and underlined. 
Nucleotides representing the first exon are 
italicized and underlined. Gray boxes indicate 
putative binding sites for transcription factors 
and boxed sequences indicate the sequences 
of oligonucleotides used in gel-shift assays. 
Broken arrows delimit the sequence of the 
deletion mutants used in this study.
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Expression of Muc5ac in mouse tissues
Expression of Muc5ac mRNA in mouse tissues was studied by RT-PCR and 
in situ hybridization. By reverse transcriptase PCR, Muc5ac expression is only seen 
in stomach (Fig. 3A). No expression was found in submaxillary glands, parotid 
glands, trachea, thymus, gallbladder, liver, small intestine, colon or kidney. In situ 
hybridization was performed to localize Muc5ac expression in the stomach. Alcian 
blue-PAS staining of acidic mucins was found in mucus granules of surface epithelial 
cells (Fig. 3C). Labeling with Muc5ac anti-sense probe showed that Muc5ac mRNA 
is only expressed in the surface epithelium of the stomach (Fig. 3D). The specificity 
of the labeling was confirmed by the absence of signal when using a sense probe 
(Fig. 3E) and by absence of signal in colon when using the antisense probe (Fig. 3F). 
Immunohistochemical staining of a mouse gastric mucosa with 45M1 monoclonal 
anti-MUC5AC antibody confirmed the expression of Muc5ac mucin in surface 
gastric epithelial cells (Fig. 3G). In conclusion, Muc5ac expression in normal mice is 
restricted to the surface epithelium of the stomach.
Characterization of Muc5ac promoter activity
To study Muc5ac promoter activity we used two Muc5ac-expressing (CMT-93, 
IEC-6) and one Muc5ac non-expressing (KATO-III) cell lines. Expression of Muc5ac 
in the murine rectal cancer cells (CMT-93, lane 3) and in the rat intestinal cell line 
(IEC-6, lane 6) is shown in Figure 4A. Absence of MUC5AC expression in KATO-III 
cells was previously published8. To define essential regions that drive transcription 
Figure 3. Expression of Muc5ac in mouse tissues by RT-PCR, in situ hybridization and 
immunohistochemistry. (A) Muc5ac (10 µl) and β-actin (2 µl) PCR products were separated on a 
1.5% agarose gel. In situ hybridization (B-F) and immunohistochemistry (G) studies. (B) Hematoxylin 
and eosin staining of gastric mucosa, (C) Alcian blue and PAS staining of gastric mucosa, (D) Staining of 
gastric mucosa with Muc5ac digoxigenin-labeled antisense RNA probe, (E) Staining of gastric mucosa 
with Muc5ac digoxigenin-labeled sense probe, (F) Staining of colon mucosa with Muc5ac digoxigenin-
labeled antisense probe, (G) Immunostaining of Muc5ac in gastric mucosa with monoclonal 45M1 
antibody. Magnification x 200.
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of Muc5ac promoter, ten deletion mutants, that cover 1.2 kb of the promoter, were 
constructed in promoterless pGL3 basic vector (Fig. 4B). Numbering refers to the 
transcription start site designated as +1. Deletion mutants –1021/-828 and –1171/-828 
were made in order to check the functional activity of the distal TATA box found at 
-944/-939.
The luciferase diagrams obtained in the three cell lines indicate that Muc5ac promoter 
activity is the strongest in Muc5ac-expressing cell lines (Fig. 4C). In CMT-93 and 
IEC-6 cells, the highest luciferase activity was obtained with fragment –199/+3 (17-
20 fold activation), which indicates that this region possesses essential positive 
regulatory elements that confer maximal activity to the promoter. In CMT-93 cells, the 
luciferase activity gradually decreases as the constructs include longer portion of the 
distal region of the promoter. In IEC-6 cells, a strong decrease in luciferase activity 
is seen with fragment –376/+3 (6 fold activation) and this decrease is maintained in 
fragments –1021/+3 and –1171/+3. This indicates that inhibitory elements, active in 
IEC-6 cells, are present within the –376/-200 region of the promoter. Interestingly, 
one can note that the fragments, in which the +3/+132 region was added, have a 
decreased luciferase activity of about 50% to 100%. The inhibitory activity was found 
in the three cell lines. That region includes the 5’-UTR and first exon in which a 
binding site for YY1 repressor (+47/+56) is clustered between two Sp1 binding sites 
Figure 4. Characterization of Muc5ac promoter activity in CMT-93, IEC-6 and KATO-III cell lines 
by transient transfection. (A) Expression of Muc5ac mucin gene in CMT-93 (lane 3) and IEC-6 (lane 
6) cells by RT-PCR. Mouse (lane 2) and rat (lane 5) β-actins (2 µl) were used as internal controls. A 100 
bp DNA ladder (lanes 1 and 4). (B) Schematic representation of the different deletion mutants used to 
study Muc5ac promoter activity. Numbering refers to transcription initiation site designated as +1, (C) 
Luciferase activity diagrams showing Muc5ac promoter activity in murine rectal CMT-93, rat colon IEC-
6 and human gastric KATO-III cells. Results are expressed as fold activation of luciferase activity of the 
deletion mutant of interest compared with the activity of empty pGL3 basic vector (white bar). Standard 
deviation represents the means of values obtained in triplicate in three separate experiments.
C
h
ap
te
r 
9
174
at +29/+38 and +54/+63, respectively. The –1021/+3 and –1171/+3 mutants that 
contain the distal TATA box located at -944/-939 are not active in the cell lines tested. 
In conclusion, essential regulatory elements for the basal activity of the promoter are 
found within the –199/+3 proximal region of Muc5ac promoter and negative elements 
are present within the 5’-UTR.
Regulation of Muc5ac promoter by TGF-β and Smads transcription factors
The high amount of putative binding sites for Smad transcription factors 
within Muc5ac promoter (Fig. 2) is in favor of a regulatory role for TGF-β on Muc5ac 
promoter activity. Smads are the main factors activated by TGF-β18. For this reason 
and because it was previously shown that MUC5AC mucin gene expression is altered 
in inflammatory pathologies of the epithelium in which TGF-β is implicated34, we 
undertook to study the regulation of Muc5ac promoter by TGF-β and Smad factors. 
TGF-β sends intracellular signals after binding to TGF-βRII on the cell membrane. 
Thus, before studying TGF-β signaling pathway on Muc5ac expression in CMT-93 
cells, we checked whether the cells expressed TGF-βRII. As shown in Figure 5A, 
TGF-βRII mRNAs are highly expressed in CMT-93 cells. Treatment of CMT-93 cells 
with TGF-β substantially induced the amount of Muc5ac mRNA in the cells (Fig. 5B). 
Identification of TGF-β responsive elements within Muc5ac promoter was then tested 
in transfection studies in which transfected cells were treated with TGF-β under the 
same conditions (Fig. 5C). The luciferase diagram indicates that exogenous TGF-β 
induces the activity of the fragments covering the -1021/+3 region (2.0, 2.7 and 1.8 
fold, respectively). Induction was lost when the longest fragment (-1171/+3) was 
used. These results indicate that TGF-β responsive elements are present within the 
–1021/+3 region of the promoter of Muc5ac, which contains seven putative Smad 
binding sites (CAGAC).
Figure 5. Regulation of Muc5ac mRNA 
expression and promoter activity by 
exogenous TGF-β in CMT-93 cells. (A) 
Expression of TGF-βRII in CMT-93 cells by 
RT-PCR. (B) Expression of Muc5ac mRNA 
by RT-PCR in untreated cells (control) 
and TGF-β-treated (TGF-β) cells. (C): 
Luciferase diagram showing effect of TGF-
β on Muc5ac promoter activity. Results are 
expressed as fold activation of luciferase 
activity in samples treated with TGF-β 
(black bars) compared to the control (Ref., 
untreated cells, white bar).
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In order to identify Smad binding sites, EMSA were performed with double-stranded 
oligonucleotides representative of the Smad binding sites found at -538/-534, 
-641/-637, -1131/-1128, -458/-454 and -84/-80, respectively (Table II). Incubation of 
the radiolabeled probes with CMT-93 nuclear extracts resulted in one shifted band 
characteristic of Smad DNA complexes (Fig. 6A, lanes 2, 7, 12) when compared with 
mobility of Smad4 consensus radiolabeled probe (lane 17). The specificity of the 
complexes were confirmed by total disappearance of the shifted bands when cold 
competition was performed (lanes 3, 8, 13, 18). Involvement of Smad4 in the DNA-
protein shifted complex was then proven by inhibition of complex formation upon 
addition of Smad4 antibody (lanes 5, 10 and 14) whereas no effect was observed 
upon addition of Smad2 antibody (lanes 4, 9, and 15). The same result was obtained 
with -552/-529 and -92/-71 probes (not shown). Induction of Smad4 binding by TGF-β 
was then tested on nuclear extracts from TGF-β-treated cells. Increase of Smad4 
binding to the Smad cis-elements was indeed observed with nuclear extracts from 
TGF-β-treated cells (lane 21) when compared with untreated cells (lane 20). These 
studies indicate that Smad4 binds to five cognate cis-elements at -84/-80, -458/-454, 
-538/-534, -641/-635 and -1131/-1128 within the TGF-β inducible region of Muc5ac 
promoter.
Figure 6. Identification of Smad4 binding sites within the promoter of Muc5ac by EMSA and 
regulation of the promoter by the Smads by transient transfection. (A) Nuclear extracts from 
CMT-93 cells were incubated with radiolabeled DNA probes, -645/-622 (lanes 1-5), -1146/-1126 (lanes 
6-10), -467/-444 (lanes 11-15) and consensus Smad4 (lanes 16-19) probes. Radiolabeled probes 
alone (lanes 1, 6, 11, 16), nuclear extract incubated with radiolabeled probe (lanes 2, 7, 12, 17), cold 
competition with x50 excess of cold probe (lanes 3, 8, 13, 18), supershift analysis by preincubating 
nuclear extract with 1 µl of anti-Smad2 (lanes 4, 9, 15) or anti-Smad4 (lanes 5, 10, 14, 19) antibodies 
before adding the radiolabeled probe. The arrow on the left hand side of the gel indicates the position 
of the DNA-protein complex engaging Smad4. Smad4-DNA complex formation with nuclear extracts 
from untreated (lane 20) and TGF-β-treated (lane 21) cells. (B) Regulation of Muc5ac promoter by 
Smad2, Smad3 and Smad4 transcription factors in CMT-93 cells. Co-transfection experiments in 
the presence of pCMV-Smad2 (gray bars), pCMV-Smad3 (white bars) or pCMV-Smad4 (black bars) 
expression vectors. (C) Luciferase activity of Muc5ac promoter in HCT116-Smad4-/- (white bars) and 
in HCT116-Smad4+/+ (black bars) cells.
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In order to show whether the TGF-β responsive region that binds Smad4 is indeed 
regulated by Smad factors, we then performed co-transfection experiments in 
which Muc5ac-pGL3 deletion mutants were co-transfected with Smad4 alone or in 
combination with expression vectors encoding Smad2 or Smad3, that are co-factors 
of Smad4. As shown in Figure 6B, Smad2 induces Muc5ac promoter activity with 
the strongest effect on fragment –376/+3 (10 fold, gray bar). Smad3 transactivation 
of Muc5ac promoter is confined to the –376/+3 region of the promoter and is not 
as strong (4-5 fold activation, white bars, fragments –199/+3 and –376/+3). The 
transactivating effect of Smad3 is lost when co-transfected with longer fragments 
of the promoter (-1021/+3, -1171/+3). Smad4, as expected, strongly transactivates 
Muc5ac promoter activity throughout the sequence (12-22 fold activation, black 
bars). Co-transfection experiments in the presence of Smad2 and Smad4 or Smad3 
and Smad4 did not lead to synergistic activation of the promoter (not shown). The 
involvement of Smad4 in up-regulating Muc5ac transcription was then confirmed by 
comparing Muc5ac promoter activity in a cell line that either constitutively expresses 
active Smad4 (HCT116-Smad4+/+) or is mutated for Smad4 (HCT116-Smad4-/-) 
(Fig. 6C). The luciferase diagram shows that Muc5ac promoter activity (fragment 
–1021/+3) is three times more active in cells expressing Smad4 (black bar) compared 
with cells mutated for Smad4 (white bar). The same result was obtained with fragment 
–376/+3 (not shown).
From these studies, it can be concluded that Smad4 is an activator of Muc5ac 
transcription, that TGF-β responsive Smad4 binding sites are present throughout 
the promoter and that Smad2 and Smad3 factors do not act in synergy with Smad4 
to induce Muc5ac transcription.
Role of Sp1 and Sp3 in the regulation of Muc5ac promoter
Since we showed that Smad2 and Smad3 are not the partners of Smad4 
to activate Muc5ac transcription, we looked for other partners. Interestingly, when 
we looked at the location of the Smad4 binding sites in the promoter, we noticed 
that they were often either embedded in or neighboring Sp1 cis-elements and 
those transcription factors are known to synergize to activate transcription of many 
genes. Before testing the synergistic effect between Smad4 and Sp1, we studied the 
regulation of Muc5ac promoter by Sp1 and Sp3 since the proximal region is GC-rich 
and that Sp1/Sp3 are important regulators of mucin gene expression8.
EMSAs studies were performed with nuclear extracts from CMT-93 cells in which 
we checked the presence of Sp1 (96 kDa) and Sp3 (two isoforms, 100 and 60 kDa) 
proteins by western-blotting (Fig. 7A). Three double-stranded radiolabeled probes 
(Table II), each containing a putative Sp1 binding site (-113/-81, -57/-34) and CACCC 
boxes (-83/-56), were tested. Incubation of the -113/-81 probe with CMT-93 nuclear 
proteins did not produce any shift. Incubation with -57/-34 probe produced a strong 
retarded band but that could not be supershifted in the presence of anti-Sp1 or anti-
Sp3 antibodies (not shown). On the other hand incubation of -83/-56 probe (Fig. 7B), 
which contains CACCC box binding sites, with CMT-93 nuclear proteins produced 
three shifted complexes (lane 2, see arrows). Specificity of these complexes was 
confirmed by complete inhibition of complex formation when cold competition was 
performed with 50x excess of the cold probe (lane 3). Complex #1 was completely 
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supershifted upon addition of specific anti-Sp1 antibody in the reaction mixture 
(lane 4, SS Sp1) whereas complex #2 was specifically supershifted upon addition 
of anti-Sp3 antibody (lane 5, SS Sp3). No supershift was observed upon addition of 
irrelevant NF-κB p65 antibody (lane 6). In conclusion, Sp1 and Sp3 bind to the same 
cis-element located at –76/-65 within Muc5ac proximal promoter.
To study the role of Sp1 and Sp3 in regulating Muc5ac transcription, co-transfection 
experiments were carried out in CMT-93 cells in the presence of an expression 
vector encoding either Sp1 (pCMV4-Sp1, black bars) or Sp3 (pCMV4-Sp3, white 
bars) (Fig. 7C). Sp1 strongly transactivates both the proximal (fragments –199/+3 
and –376/+3, 8-9 fold activation) and distal (fragments –1021/+3 and –1171/+3, 
Figure 7. Regulation of Muc5ac promoter by Sp1 and Sp3 transcription factors in CMT-93 cells. 
Identification of an Sp1 cis-element in the promoter by EMSA. (A) Western-blotting of nuclear 
proteins prepared from CMT-93 cells. Prestained molecular weight markers (MWM). Immunostaining 
of the membrane with polyclonal PEP-2 anti-Sp1 (Sp1) and with polyclonal anti-Sp3 (Sp3) antibodies. 
(B) Identification of an Sp1 cis-element by EMSA. Nuclear extracts from CMT-93 cells were incubated 
with the -83/-56 radiolabeled DNA probe. Radiolabeled probe alone (lane 1). Incubation of -83/-56 
probe with CMT-93 nuclear proteins (lane 2), cold competition with x50 excess of cold probe (lane 
3), supershift analysis upon addition of anti-Sp1 (lane 4) or anti-Sp3 (lane 5) antibodies. Addition of 
irrelevant NF-κB p65 antibody (lane 6). DNA-protein complexes are indicated by an arrow on the left 
hand-side of the autoradiogram. Asterisks indicate the position of Sp1 (SS Sp1) and Sp3 (SS Sp3) 
supershifts. A longer exposure of the upper part of the same autoradiogram is shown at the bottom. 
(C) Co-transfection experiments in the presence of pCMV-Sp1 (black bars) or pCMV-Sp3 (white bars) 
expression vectors. Ref. refers to the normalized luciferase activity of the pGL3-deletion mutants of 
interest co-transfected with the empty expression vector pCMV4. Standard deviation represents the 
means of values obtained in triplicate in three separate experiments.
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10-15 fold activation) regions of the promoter. Addition of the 5’-UTR to the promoter 
construct –1171/+3 (=construct –1171/+132) inhibited the transactivating effect of 
Sp1. Sp3 only has a mild transactivating effect on the distal part of the promoter (2-3 
fold activation). Again, addition of the 5’-UTR inhibited that effect. Altogether, these 
studies indicate that Sp1 is a strong transactivator of Muc5ac promoter activity in 
CMT-93 cells.
Cooperation between Sp1 and Smad4 to activate Muc5ac promoter
Having shown that both Smad4 and Sp1 were strong activators of Muc5ac 
transcription in CMT-93 cells, we then undertook to look at their cooperative effect on 
the promoter. Co-transfection in the presence of Smad4 and Sp1 were performed on 
fragments –199/+3, -376/+3 and –1171/+3 (Fig. 8). No synergistic effect was seen 
on the shortest fragment –199/+3 (white bars). An additive effect was observed on 
the construct –376/+3 (black bars) whereas a synergistic transactivating effect was 
obtained on fragment –1171/+3 (gray bars). In conclusion, Sp1 appears to be the co-
factor of Smad4 to activate Muc5ac transcription and essential elements that convey 
the synergistic effect are localized within the -1171/-377 region of the promoter.
Discussion
 Organization, evolution, and regulation of expression of the four 11p15 mucin 
genes, MUC2, MUC5AC, MUC5B and MUC6 have been extensively studied over 
the past few years2, 7, 35. In situ hybridization and promoter functional studies have 
led the investigators to the conclusion that these mucin genes are tightly regulated 
at the transcriptional level8. They often harbor an altered profile of expression in 
human tumors of the respiratory, gastrointestinal and urogenital tracts2, 5, 6, 36 and such 
alterations (overexpression, repression, neoexpression) are usually characteristic 
of genes playing important roles in carcinogenesis. In order to study mucin gene 
regulation in animal models, isolation of the 5’-flanking regions including promoter of 
the murine counterparts are now mandatory.
In this paper, we have isolated and characterized the 5’-flanking region of the 
murine mucin gene Muc5ac including the promoter and first three exons/introns. 
Analysis and alignment of the first three exons with its human and rat counterparts 
Figure 8. Cooperation between Smad4 and 
Sp1 to transactivate Muc5ac promoter. 
Co-transfection experiments were performed 
in CMT-93 cells in the presence of pCMV-
Sp1, pCMV-Smad4 or both. Results are 
expressed as fold activation of the luciferase 
activity obtained in co-transfection with the 
expression vector encoding Smad4, Sp1 
or both compared with cells transfected 
with corresponding empty vector (Ref.). 
Standard deviation represents the means of 
values obtained in triplicate in three separate 
experiments.
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show a high degree of homology with rat Muc5ac (79%) whereas it is less with 
human MUC5AC (52%). First ATG is identical to rat Muc5ac (Oinuma, accession 
number AB042530), which adds four amino acid residues (MLHS) when compared 
to human MUC5AC N-terminal amino acid sequence33. The TATA box sequence 
(TACAAAA) is conserved throughout evolution since both mouse (this report) and 
human TATA boxes are identical33. The sequence of the TATA box in rat Muc5ac 
gene is not known. Overall, it can be stressed that the 5’-region of Muc5ac mucin 
gene is relatively well-conserved between human, mouse and rats and shows typical 
features of genes with cell-specific profile of expression. Indeed, in this report we 
found that expression of murine Muc5ac gene and protein was very specific and 
restricted to the surface epithelial cells of the gastric mucosa like what was previously 
described for rat Muc5ac37. No expression was found in trachea. This latter result is in 
contrast with expression territories in humans in which MUC5AC is expressed in the 
surface epithelium of stomach but also in goblet cells of the tracheobronchial tract9. 
This difference is most likely due to histological differences between rodents and 
humans, since the epithelium of their conducting airways mostly consist of ciliated 
cells (upper tract) and Clara cells (lower tract) whereas mucous cells remain rare38.
Analysis of the promoter nucleotide sequence immediately upstream of 
the TATA box (over the first 199 nucleotides) shows that it is GC-rich and bears 
numerous putative consensus Sp1 binding sites or CACCC boxes also known 
to bind transcription factors of the Sp family8. Consistent with a role in cancer for 
factors of the Sp family is their ability to be oncogenic themselves or to interact 
with oncogenes or tumor suppressors39. The high GC content of proximal region 
of promoters is a common feature in mucin genes as it was also found in human 
MUC2, MUC5AC, MUC5B and murine Muc2 promoters8, 20, 30, 40 and functional studies 
pointed out to an important role for the transcription factors of the Sp-family as mucin 
gene regulators. The fact that these cis-elements are conserved between mouse 
and human MUC5AC genes is also in favor of an important role for Sp1 in MUC5AC 
transcriptional regulation. Here, we confirmed that hypothesis by the means of 
co-transfection experiments in which we showed that Sp1 strongly transactivates 
the promoter of Muc5ac. Having previously shown that Sp3 interferes with Sp1-
mediated regulation of human MUC5AC promoter28, we studied its effect on murine 
Muc5ac promoter as well. Our results indicate that Sp3 is also a regulator of Muc5ac 
transcription but with a weaker effect. Since Sp1 and Sp3 are ubiquitously expressed 
in the cells and recognize the same DNA motif, it also implies that Sp1 and Sp3 will 
compete when they are both present in equimolar amounts in the cell.
Interestingly, Muc5ac promoter activity was repressed by 50% when pGL3 
constructs contained the 5’-UTR (33 nucleotides long) and part of the first exon. 
Analysis of the sequence indicated that an AP-1 and Sp1 binding sites are present 
within the 5’-UTR. Those factors are generally considered as activators of the 
transcription and could not be responsible for the repression observed. In close 
vicinity of the Sp1 binding site, was found a second Sp1 cis-element overlapping a 
YY1 binding site. YY1 possesses dual activity (repressor or activator) depending on 
the molecular context and is known to interact with Sp141 As it was recently shown for 
hamster Muc1 mucin gene42, YY1 may repress Muc5ac transcription via interactions 
with Sp1.
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Muc5ac promoter contains binding sites for Smad4 transcription factor 
throughout its sequence. Alignment of human33and mouse sequences (this report) 
of the promoters indicates that Smad putative sites are present in both genes but not 
at the same location. The response of the two genes to TGF-β is different and seems 
to depend on the cellular situation as it was recently shown that human MUC5AC is 
negatively regulated when nontypeable Haemophilus influenzae-infected cells are 
treated with TGF-β43. Smad transcription factors are activated by growth factors of 
the TGF-β family in a sequential manner18 and form either Smad2-Smad4 or Smad3-
Smad4 complexes that are translocated into the nucleus where they bind to the 
promoter of the target gene to activate transcription. However, once bound to the 
promoter, Smad4 may interact with other factors to activate transcription. Our results 
indicate that Muc5ac is a target gene of TGF-β. However, they also suggest that the 
pathway induced by TGF-β does not imply complex formation between Smad4 and 
Smad2 or Smad4 and Smad3. Apart from activating Smad factors, TGF-β is also 
known to activate Sp1 site-dependent transcription of its target genes, Smad factors 
are known to activate transcription through Sp1 sites and Sp1 interact with Smad4 
to induce transcription and this mechanism is TGF-β dependent39, 44, 45. The data 
presented in this manuscript are in favor of such a positive regulatory mechanism 
between Smad4 and Sp1 to explain the TGF-β-mediated upregulation of Muc5ac 
expression in cancer cells. Since TGF-β is a pleiotropic cytokine with diverse function 
during development, adult tissue homeostasis, carcinogenesis and inflammation46, 
47, it will be interesting in the future to study the correlation between TGF-β-mediated 
processes with that of Muc5ac expression and their consequences on epithelium 
homeostasis.
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If we were to better understand function and regulation of mucin genes in the 
intestine, this could lead to the discovery of potential therapeutic targets in epithelial 
diseases. Therefore, the overall aims as investigated in this thesis were:
1. To investigate the influence of changes in mucus production, more 
 specifically Mucin (Muc) 2, on the protective barrier function and 
 elementary intestinal physiology.
2. To gain insight into the complex transcription regulatory mechanism 
 of secretory mucins. 
Role of mucins in the intestine
As described in Chapter 1, the mucin Muc2 is the predominant secretory large 
intestinal mucin in mammals1-5. Produced by goblet cells in the entire intestine, Muc2 
is the most important compound of the mucus layer. As this layer is strategically 
positioned between the lumen and the epithelium, we hypothesized that it protects 
the intestinal cells against potential toxic and noxious agents present in the gut 
lumen. Further support for this hypothesis comes from studies showing decreased 
MUC2 synthesis in humans with inflammatory bowel disease (IBD)6-8. However, these 
clinical studies do not resolve the question whether these observed abnormalities in 
MUC2 synthesis are primary defects or whether they are secondary and induced by 
the inflammatory response. A major prerequisite for the development of colitis is the 
presence of bacteria in the colon. It has been convincingly shown that normal enteric 
bacteria can induce immune-mediated colitis in rodents with genetically engineered 
abnormalities in the immune system9-14. Muc2 provides a natural barrier between 
bacteria and the underlying colonic epithelium. Thus any change in quantity or 
structure of Muc2 could influence the effects of bacteria on the intestinal mucosa. 
 In Chapter 2 we studied the effects of the introduction of specific pathogen-
free, commensal bacteria on Muc2 synthesis and sulfation in germ-free, immuno-
compromised, interleukin (IL)-10 deficient (IL10-/-) mice. In germ-free state IL10-/- mice 
show no evidence of biochemical or histological inflammation10. We demonstrated 
that Muc2 synthesis was lower in the IL10-/- mice compared to wild type (WT) controls, 
even before bacterial colonization and the onset of inflammation. The inflammation in 
the IL10-/- mice after introduction of the enteric bacteria was characterized by thickening 
of the mucosa and a higher turnover of epithelial cells on account of increased 
proliferation in the crypts and apoptosis in the surface epithelium. In addition, as the 
colitis progressed from mild to severe in the IL10-/- mice, the colonic Muc2 sulfation 
decreased progressively. These quantitative and structural Muc2 aberrations in IL10-/- 
mice likely reduce the epithelium’s ability to cope with (nonpathogenic) bacteria and 
therefore may contribute to colitis susceptibility. The role of Muc2 in epithelial protection 
was further assessed in Chapter 3. We first characterized the colon of Muc2 deficient 
(Muc2-/-) mice and then challenged them luminally with dextran sulfate sodium, a 
colitis inducing agent. We showed that under specific pathogen-free conditions, loss 
of Muc2 in the intestine leads to mucosal thickening, increased proliferation, altered 
differentiation of epithelial cells and goblet cells, and superficial erosions in the colon. 
By challenging WT, Muc2 heterozygous and Muc2-/- mice with dextran sulfate sodium, 
we demonstrated that (partial) deficiency of Muc2 in the intestine predisposes to colonic 
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inflammation. These data provide evidence that changes in mucus composition, 
caused by Muc2 deficiency, leads to inflammation of the colon and that Muc2 can 
contribute to the onset and/or perpetuation of IBD. Considering that the severity of 
chronic intestinal inflammation is influenced by environmental, immunoregulatory, 
and epithelial factors, we investigated the protective capacities of Muc2 and IL10 in 
the intestine. To this aim we generated Muc2/IL10 double knockout (Muc2/IL10DKO) 
mice and tested whether combinations of defects in immunoregulatory and epithelial 
factors could exacerbate the pathogenesis of inflammation. To obtain insight into the 
protective capacities of Muc2 and IL10 in the intestine, we characterized the Muc2/
IL10DKO mice and compared their clinical symptoms and intestinal pathology to Muc2-
/- and IL10-/- mice of the same age (Chapter 4). Microscopic analysis of the colon 
of Muc2-/- mice showed abnormal morphology marked by thickening of the mucosa, 
flattening and ulceration of epithelial cells, general loss of architecture, increase of 
inflammatory cells, an increase in proliferation, and reduced cell differentiation in the 
colon as described in chapter 3. These abnormalities were even more pronounced 
in Muc2/IL10DKO mice of the same age. This indicates that absence of Muc2 in 
combination with changes in the immunological regulatory mechanisms, e.g. lack of 
IL10, leads to excessive uncontrollable inflammation of the colon, ultimately leading 
to the animal’s death. The Muc2/IL10DKO mouse clearly demonstrated that combined 
abnormalities in immunoregulatory and epithelial factors greatly accelerate and 
exacerbate the phenotype of colonic inflammation. Moreover, this study provided the 
evidence that the mucus layer in the intestine, more specifically the mucin Muc2, is 
pivotal in mucosal protection, suggesting that the mucus barrier is one of main factors 
for the genesis of colitis. 
 Another hypothesis involving Muc2 is the following: Muc2 also contributes 
to epithelial defense against other challenging factors, i.e. chemotherapy-induced 
damage. It is based on the finding that Muc2 protein expression was significantly 
increased during all phases of methotrexate (MTX)-induced damage in previous 
studies15, 16. To put this hypothesis to the test we challenged Muc2-/- mice with MTX. 
However, as described in Chapter 5, histological and biochemical analysis of the 
intestine of the Muc2-/- mice, showed that these mice were not more sensitive to 
MTX-treatment. As absence of Muc2, the structural component of the mucus layer, in 
Muc2-/- mice may lead to continuous exposure to luminal antigens (bacteria), this could 
unbalance cytokine production. The anti-inflammatory cytokine IL-10 has protective 
capacities in the intestine, and studies have shown that IL-10-/- mice are predisposed 
to develop chronic mucosal inflammation (chapter 2)10, 17, 18. IL-10 also protects the 
intestine from MTX-induced damage, seeing that IL10-/- mice develop more severe 
mucositis after MTX-treatment than their wild type littermates19. We confirmed that 
IL-10 was upregulated in these mice prior to MTX treatment, explaining why these 
mice did not show increased chemotherapy-induced mucositis. 
 The above-described studies confirm the importance of a healthy mucus layer. 
However, integrity of the mucus layer is also linked to availability of nutrients such 
as proteins, lipids, carbohydrates and essential amino acids within the intestine. For 
example, malnutrition and starvation alter the mucus layer by decreasing intestinal 
mucin synthesis20, 21. Further support for this hypothesis is that dietary restriction of 
threonine, one of the essential amino acids, has shown to impair intestinal mucin 
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synthesis22. We hypothesized that the gut’s high demand for dietary threonine, as 
reported by Schaart et al.23, is probably due to incorporation of the threonine into 
secretory mucins, mainly Muc2, which are rich in threonine residues. Therefore, as 
described in Chapter 6, we also investigated mucin involvement in the intestinal 
metabolism. We indeed demonstrated that a major fate of dietary threonine utilized 
by the intestine is its incorporation into Muc2. Furthermore, in the absence of Muc2, 
dietary threonine is mainly used for constitutive protein synthesis or becomes a 
substrate for oxidation. 
 In conclusion the first part of this thesis demonstrates a pivotal role for Muc2 
in the intestine. Both quantitative and structural aberrations in Muc2 in the intestine 
lead to abnormal morphology marked by thickening of the gut mucosa, flattening and 
ulceration of epithelial cells, general loss of architecture, increase of inflammatory 
cells, intensified proliferation, and lessening of cell differentiation in the colon. The 
change in proliferation and differentiation, and resulting inflammation of the colon 
most likely result from altered interaction of the epithelium with nonpathogenic 
bacteria due to deficiency in Muc2.
 Microbes in the intestine influence several aspects of epithelial differentiation. 
Altered differentiation in turn can influence nutrient absorption and processing 
by modulating expression of host genes in the intestine24, 25. Changes in mucus 
composition in the colon of the Muc2-/- and Muc2/IL10DKO mice probably lead to 
altered, maybe even less, colonization and therefore to altered intestinal physiology/
cell differentiation. The observed growth retardation in the Muc2-/-, Muc2/IL10DKO 
and, at a later age, IL10-/- mice could be attributed to the changes in colonization 
and thus altered intestinal physiology/cell differentiation. Multiple factors have 
been shown to affect growth in this situation, the most prominent of which are the 
presence and severity of inflammation and inadequate nutritional intake26-28. Not only 
intestinal damage, but also bacteria could affect nutritional uptake. Bacteria have 
been shown to be responsible for the conversion of many dietary substances into 
nutrients that can be absorbed and utilized by the host, as reviewed by Hooper 
et al29. Consequently, germ-free animals have less total body fat and need more 
caloric intake to maintain their body weight than conventionally raised animals30, 31. 
This can be explained by the fact that gut microbiota allow energy to be salvaged 
from otherwise indigestible dietary polysaccharides32. In addition, bacteria have 
shown to synthesize indispensable amino acids which are required and absorbed 
by the intestine33, 34. Furthermore, growth impairment was shown to be attributable 
to inflammation. Increased or altered bacterial exposure of the intestinal epithelium 
could also directly induce inflammatory cytokine production. Inflammatory cytokines in 
their turn are directly involved in mediating growth failure26, 27. The growth retardation 
seen in Muc2-/- and Muc2/IL10DKO mice is most likely attributable to a difference 
in microflora and inflammation rather than to the intestinal damage or nutritional 
uptake. This hypothesis is supported by the fact that these mice show no distinct 
pathology of the small intestine under unchallenged conditions (chapter 5) and that 
the absorption capacity of free threonine (chapter 6) was not impaired or different 
in the Muc2-/- mice compared to WT mice. Interesting would be however, to assess 
when the inflammation in the Muc2-/- and Muc2/IL10DKO mice is initiated. At 5 weeks 
of age both types of mice show inflammation of the colon, the severity dependent on 
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the mouse type. However, if the histology of these mice is already affected at birth, 
as Muc2 is expressed during embryonic development, or if the changes in histology 
are initiated during colonization, more specifically, sucking vs. weaning period of 
these mice remains to be investigated. 
 The increased proliferation and changes in both goblet cell and epithelial 
cell differentiation in the colon of the Muc2-/- , Muc2/IL10DKO and, at later age, IL10-/- 
mice might also stem from altered bacterial interaction with the epithelial cells of the 
intestine. This hypothesis is supported by a previous study showing that crypts in the 
colon of germ-free mice have a lower mitotic index and labeling index compared to 
conventional mice35. Bacteria and their products communicate with epithelial cells via 
pattern-recognition receptors, i.e. Toll-like Receptors (TLRs). These TLRs regulate 
gut immune responses to all kinds of bacterial interactions36. As reviewed by Cario37, 
each TLR binds distinct features present on different classes of microorganisms. For 
example, type TLR2 recognizes bacterial lipopeptides and lipoteichoic acid found in 
the cell walls of Gram-positive bacteria; TLR4 is a receptor for lipopolysaccharide, a 
cell wall component of Gram-negative bacteria; and TLR9 is activated by unmethylated 
CpgDNA motifs which are common on certain bacterial and viral genomes37. TLR4 
expression is increased in active human IBD and murine colitis38-40. Thus epithelial 
cells like goblet cells and enterocytes can detect (non)pathogenic bacteria and 
respond by altering gene expression. This may be the cause of the aberrant immune 
response seen in ulcerative and experimental colitis. Furthermore, a recent study 
has shown that IL10/MyD88 (a major adaptive protein essential for TLR-signaling) 
double knockout mice are resistant to spontaneous commensal induced colitis41. In 
this context, diminished Muc2 synthesis or absence of Muc2 may result in altered 
TLR signaling in epithelial cells, leading to changes in the different cell signaling 
pathways and thus possibly to increased proliferation and altered differentiation and 
immune responses. 
 Yet, this increase in proliferation and decrease in differentiation might also 
be direct responses to inflammation. De Koning et al. have suggested that during 
severe damage, the epithelium is preferentially involved with proliferation rather that 
differentiation, in order to restore intestinal barrier function42. This latter mechanism, 
however, does not explain why the expression of several intestinal specific markers 
is lower in the proximal colon of the Muc2/IL10DKO mice compared to the distal colon, 
whereas the inflammation and cell damage are the most severe in the distal colon 
of these mice. However, enterocyte-specific protein expression was shown to be 
downregulated in the entire colon during dextran sodium induced damage43. Loss of 
differentiation of the goblet cells and epithelial cells as described in the different colitis 
models above was characterized by a distinct change in expression of Muc4 (chapter 
4). Distinct changes in the mRNA expression levels of the mucins Muc1, -3 and -4 
in the distal colon during dextran sodium sulfate induced damage and regeneration 
were also observed (data not shown). Especially downregulation of Muc4 seemed 
to be a common factor for colonic damage, as investigated in chapter 4. Although 
there is clear evidence that these mucins play a role in cell-signalling44 related to 
growth, motility, differentiation and inflammation, the cause and consequence in 
change of expression and thus function of these mucins during colitis remains to be 
elucidated.  
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 The protective capacities of Muc2 during MTX-induced damage and 
regeneration remain to be investigated. The Muc2-/- mouse did not turn out to be 
the appropriate model to investigate this hypothesis as its immune system was out 
of balance prior to MTX-induced damage. In addition to protecting against intestinal 
inflammatory processes as described in chapters 2 and 4, IL-10 is also strongly 
implicated as having protective capacities in MTX-induced mucositis19. These data to 
a certain extent imply that the pathogenesis of mucositis is quite similar to that of IBD. 
Novel experimental therapies for IBD patients such as the application of IL-10-producing 
lactococci lactis may therefore provide attractive means to prevent mucositis45, 46. 
Furthermore, these bacteria might also upregulate Muc2 as other probiotic strains 
have shown to do47, 48. Specifically upregulating Muc2 in WT mice before MTX-
treatment might provide more evidence for a protective role of Muc2 against MTX-
induced mucositis. Furthermore, supplementing the intestine with serine, proline, and 
cysteine, which also represent major components of mucins, in addition to threonine 
may also enhance mucin synthesis, more specifically that of Muc2. This hypothesis 
is supported by data showing that in piglets between 80-90% of dietary threonine is 
utilized by the intestine23 and by chapter 6 of this thesis, which showed that threonine 
is incorporated into Muc2 and secreted in WT mice. A model that could elucidate the 
role of Muc2 in epithelial protection against MTX-induced damage in absence of IL-
10, would be to treat IL10/Muc2DKO mice with MTX. However, as described in chapter 
4, these animals show significant growth retardation, even compared to Muc2-/- mice, 
and die before reaching maturity. Regrettably it is not feasible, therefore, to expose 
these mice to MTX treatment. Another interesting experiment would be to evaluate 
the expression of Muc1, -3 and -4 during MTX-induced mucositis so as to verify 
whether the changes in expression during colitis as described in chapter 4 of this 
thesis are common phenomena during intestinal damage.   
 Another point that needs to be addressed is the difference in phenotype 
displayed by the Muc2-/- mice in these studies compared to a previous described 
study49. Velcich et al. showed that Muc2-/- mice developed adenomas from six months 
of age, progressing to invasive adenocarcinoma in the small intestine as well as rectal 
tumors at later age, albeit with no histological nor clinical signs of colitis at younger 
ages. The mice described by Velcich et al. had a mixed genotypic background (C57/
BL6-129SV), while in the current study, the knockout mice analyzed had a 129SV 
background only. Perhaps the phenotypic differences in the Muc2-/- mice can be 
attributed to differences in strain background and microbial environment as described 
for the IL10-/- mice50. However, the Muc2-/- 129SV mice might be at risk to develop 
cancer at an older age, in analogy to patients with IBD who are at increased risk of 
colorectal cancer51, but this likelihood was not assessed in this thesis. 
Regulation of mucin gene expression
Mucin gene expression is governed by complex regulatory mechanisms 
influenced by developmental and signal dependent transcription factors. The early 
expression of mucins before or during mucus cell, and more specifically goblet 
cell differentiation, indicates that they may be the targets of transcription factors 
responsible for those programs52. Muc2 is expressed early during embryonic 
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development of the intestine53, which suggests that Muc2 transcription is under the 
influence of transcription factors responsible for intestinal development and cell 
differentiation. In line with this hypothesis the human MUC2 mucin gene was found 
to be regulated by Cdx1 and Cdx2 transcription factors54, which are both involved in 
intestinal cell differentiation55. Having found binding sites for GATA and HNF factors 
in the promoter of Muc2, and seeing that Muc2 and these factors show spatio-
temporal restricted patterns of expression along the crypt-villus axis in the intestine, 
we set out to study the regulation of the promoter of mouse Muc2 by GATA-4/-5/-6 
and HNF-3α and -3β factors. As described in Chapter 7, GATA-4 was present in the 
nuclei of goblet cells in the small intestine. Furthermore, four GATA-4 cis-elements 
were identified in the promoter, and Muc2 promoter was efficiently activated when 
GATA-4 was overexpressed in the cells, with loss of transactivation when the binding 
sites were mutated or when a mutated form of GATA-4 was used. Overexpression 
of GATA-5 and GATA-6 also induced activity of Muc2 promoter. Altogether these 
results emphasize an important role for GATA factors as potent activators of Muc2 
expression in the intestine. Subsequently in Chapter 8, we initiated to study the role 
of HNF-3α and -3β factors in Muc2 regulation. We first showed localization of HNF-3α 
and HNF-3β in Muc2-expressing goblet cells early in the developmental stages 
of the intestine (embryonic day 17.5). Furthermore, we demonstrated that both 
transcription factors regulate Muc2 transcription and bind to the Muc2 promoter in 
vivo. Altogether these results identify Muc2 as a new target of HNF-3α and HNF-3β 
and point at an important role for these transcription factors in Muc2 expression in 
the intestine during development and goblet cell differentiation. Furthermore, mucin 
gene transcription has been shown to be influenced by a broad range of cytokines. 
Analysis of the Muc5ac promoter showed a high density of binding sites for factors 
essential for Transforming Growth Factor-β (TGF-β) signaling. TGF-β is a member of 
the superfamily of cytokines that affect a variety of cell types and elicit a wide array 
of cell-type-specific biological effects such as differentiation, migration, cell cycle 
arrest, adhesion, extracellular matrix production, and apoptosis56. TGF-β is also 
involved in gastritis and development of gastric cancer57, two pathologies that show 
altered MUC5AC expression. This knowledge led us to study Muc5ac regulation by 
TGF-β as described in Chapter 9. Our results indicate that Muc5ac is a target 
gene of TGF-β. However, they also suggest that the pathway induced by TGF-β 
does not only imply complex formation between Smad4 and Smad2 or Smad4 and 
Smad3. Apart from activating Smad factors, TGF-β is also known to activate Sp1 
site-dependent transcription of its target genes; Smad factors are known to activate 
transcription through Sp1 sites; and Sp1 interacts with Smad4 to induce transcription, 
which mechanism is TGF-β dependent58-60. The data presented in chapter 9 are in 
favor of such a positive regulatory mechanism between Smad4 and Sp1 to explain 
the TGF-β-mediated upregulation of Muc5ac expression in cancer cells. 
 These studies give us insights into the regulation pathways of the mucin 
genes Muc2 and Muc5ac, however, these regulation pathways are not exclusive. For 
example, GATA-4 is expressed in the small intestine where Muc2 is also expressed. 
However, Muc2 is also highly expressed in the colon whereas GATA-4 is not. This 
shows that GATA-4 alone is not sufficient for the cell-specific transcriptional activation 
of Muc2. In addition, GATA-4 inducible knockout mice show increased Muc2 
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production. This can be accounted for, however, by a 50% increase of goblet cells61. 
Consistent with an expansion of secretory goblet cells, Math-1, a known activator of 
the secretory cell fate62, 63, was induced in the jejunum of GATA-4 mutant mice. This 
suggests that GATA-4 does not only regulate Muc2 expression on a transcription 
level, but may also be involved in the choice of intestinal epithelial cell fate. The Notch 
pathway specifies cell fate through feedback amplification of relative differences 
in cellular levels of Notch and its ligand Delta64. Cells that produce large amounts 
of Notch induce expression of transcription factors, such as Hes-165. Hes-1 is a 
transcriptional repressor, and therefore cells that express the Hes-1 gene remain 
precursor (enterocyte) cells. Math-1 is a downstream target of Hes-1, therefore 
controlling initial choice of cell fate. In cells in which Delta expression levels are high, 
Hes-1 expression is blocked, and Math-1 expression is induced. Expression of Math-
1 allows precursor cells to choose whether to become goblet cells, Paneth cells or 
enteroendocrine cells. Nevertheless, the regulatory role of GATA-4 on the Math-1, 
Hes-1 transcription factors in this signaling pathway remains to be investigated.
 Furthermore, it would be interesting to asses expressions of these different 
transcription factors during intestinal damage in order to gain insight into Muc2 
regulation. A study described by de Koning et al.42, showed diminished GATA-4, Cdx-2 
and HNF-1 expression during most severe damage of the intestine after MTX-
treatment and restoration of expression of these factors during regeneration. This 
suggests that the epithelium in the intestine is preferentially involved with proliferation 
rather than with differentiation during severe damage, but needs cell differentiation to 
restore intestinal barrier function during regeneration. Data by Verburg et al.15 showed 
that there was indeed downregulation of Muc2 mRNA during MTX-induce intestinal 
damage, corresponding with the diminished expression of transcription factors as 
described above. However, they also showed that despite the low levels of Muc2 
mRNA there was an increase in Muc2 protein levels, suggesting the involvement of 
post-transcriptional regulatory mechanisms that enhance Muc2 secretion in order 
to preserve Muc2 barrier function. There is no indication for a negative regulatory 
mechanism among the transcription factors studied. For an expression gradient 
along the small intestine has been identified in which GATA-4 expression decreases 
from proximal to distal, and HNF-1α and –β expression as well as Cdx-2 expression 
increase from proximal to distal small intestine66. This shows that downregulation of 
one factor does not automatically lead to downregulation of others. 
 General regulatory mechanisms may be involved, of through which 
developmental transcription factors target intestinal-specific genes expression. The 
four secretory mucins, Muc2, Muc5ac, Muc5B and Muc6 are clustered on chromosome 
7. In addition, they are all expressed by tissues that derive from the primitive gut53, 67 
in which Cdx2, GATA and HNF also play an important role during the development 
(chapters 8 and 9 of this thesis and 68-71). In line with this hypothesis, apart from 
the Muc2 promoter that appears to be activated by Cdx254, GATA-4,-5 and 6 (this 
thesis, chapter 7) as well as  members of the HNF-3 family (this thesis, chapter 8), 
several other intestine-specific gene expressions, such as intestinal lactase-phlorizin 
hydrolase and sucrase isomaltase expression, have been shown to be controlled by 
Cdx-1/-2, HNF-1/-3 and GATA-4/-5/-672-77. 
 Interestingly, a recent publication showed that HNF-4 activity was downregulated 
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by tumor necrosis factor alpha (TNF-α) via a nuclear factor kappa B (NF-κB) dependent 
pathway78. As both TNF-α and NF-κB were found to be upregulated in ulcerative 
colitis patients79-81, NF-κB might also affect other families of transcription factors, 
more specifically the HNF family, during inflammation. In line with this finding, another 
recent publication showed transdifferentation of cells (by upregulation of HNF-3α 
 and -β) into distinct epithelial cell types to repair airway epithelium after injury82. These 
findings imply the workings of general mechanisms between endoderm tissues aimed at 
regeneration through upregulation of transcription factors involved in differentiation. 
 As described in chapter 9, TGF-β can induce Muc5ac transcription. Previous 
studies using epithelial cells showed that TGF-β can also mediate Muc2 transcription83. 
TGF-β is upregulated in patients with IBD84, however its signaling was found to 
be impaired85, 86. In addition to decreased SMAD-3 phosphorylation, SMAD-7, an 
antagonist of the TGF-β pathway, appeared to be upregulated in the affected areas of 
the intestinal mucosa of these patients, thus blocking TGF-β signalling85. Interferon 
gamma, a proinflammatory cytokine, has proved an important mediator in enhancing 
SMAD-7 production87 and may thus contribute to the uncontrolled inflammation seen 
in patients with IBD. Therefore, the physiological role of TGF-β signaling on Muc2 
transcription in IBD patients remains to be investigated. 
 Muc2 may also be directly involved in proliferation and differentiation 
of epithelial cells. Studies, as described in chapters 8 and 9, show that Muc2 
expression is under the control of transcription factors responsible for programs of 
cell differentiation in the intestine. This provides another argument in favor of Muc2 
involvement in goblet cell differentiation along the crypt-villus axis. More evidence 
supporting this hypothesis comes from intensified proliferation in the small intestine 
of Muc2-/- mice as described by Velcich et al.88, and in the Muc2-/-129SV mice as 
the mice age (our unpublished observations). Thus, next to the fact that Muc2 is 
crucial for epithelial protection and as such is part of the innate defense mechanism 
in the intestine, this molecule might also be important in the regulation of epithelial 
homeostasis (e.g., epithelial proliferation and differentiation). 
General future perspectives 
The findings from this thesis clearly point at a pivotal role for Muc2 in maintaining 
intestinal homeostasis. A next crucial step would be to unravel the mechanisms 
behind the development of inflammation in the absence of Muc2. Signaling profiling 
studies (i.e. TLRs) could be performed to identify molecules that i) initiate/perpetuate 
inflammation, ii) regulate epithelial proliferation, and iii) regulate epithelial differentiation. 
Furthermore, the fusion of germ-free and gnotobiotic technology, functional genomics 
and quantative PCR would make it possible to use the Muc2-/- and WT mouse 
models to quantify the impact of the microbial population on cell homeostasis, gene 
expression and subsequent barrier function of the gut. In addition, these models would 
enable evaluation of the roles of pre- and probiotics in intestinal protection, and more 
specifically mucin production. Cumulatively, these data would give more information 
about microbes, genes and signaling pathways involved in intestinal inflammation, 
possibly leading to identification of potential therapeutic targets.
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De rol van mucines in de darm
Zoals beschreven in Hoofdstuk 1 is het eiwit mucine 2 (Muc2) de meest 
voorkomende secretoire mucine in de dikke darm van zoogdieren. Muc2 
wordt geproduceerd in slijmbeker-cellen – ook wel goblet-cellen genoemd 
– in de gehele darm, en is de belangrijkste component van de mucuslaag. Deze 
mucuslaag is strategisch gesitueerd tussen de darmholte en het epitheel (cellen 
die de darmoppervlakte bekleden). Onze hypothese is dat deze mucuslaag de 
darm(wand)cellen beschermt tegen mogelijk schadelijke stoffen in de darmholte. De 
resultaten van voorgaande studies ondersteunen deze hypothese; zo is aangetoond 
dat mensen met chronische ontstekingen aan de dikke darm (bijvoorbeeld Colitis 
Ulcerosa) een verlaagde productie van Muc2 hebben. Dit zijn echter klinische 
studies, die geen antwoord geven op de vraag of deze verlaagde Muc2 synthese 
een primair gebrek is, of indirect een gevolg is van een ontstekingsreactie. Een 
belangrijke oorzaak van colitis, een ontsteking van de dikke darm, is de aanwezigheid 
van bacteriën in de darm. Zo kunnen normale darmbacteriën bij knaagdieren met 
een genetische aanpassing in het afweersysteem colitis veroorzaken. Muc2 zorgt 
voor een natuurlijke barrière tussen bacteriën en de epitheelcellen. Veranderingen 
in de structuur van Muc2 of in de aangemaakte hoeveelheden zouden daarom de 
(schadelijke) uitwerking van bacteriën op het darmslijmvlies kunnen beïnvloeden. 
Wanneer we beter zouden weten wat de functie van mucine-genen in de 
darm is en hoe deze gereguleerd worden, zouden we kunnen komen tot nieuwe 
behandelmethoden voor darmziektes. Met als doel om een beter begrip van deze 
materie te krijgen, richtte dit promotieonderzoek zich in grote lijnen op:
1. De invloed van een verlaagde productie van mucine, specifiek 
 Muc2, op de barrièrefunctie en de fysiologie van de darm.
2. De mechanismen die het lichaam gebruikt om de hoeveelheid 
 mucines te regelen. 
In Hoofdstuk 2 werd bij kiemvrije (steriele) interleukine-10 deficiënte muizen 
(IL10-/-; deze muizen kunnen geen IL-10 maken) onderzocht wat de gevolgen zijn van 
het inbrengen van specifieke niet-schadelijke en natuurlijk voorkomende bacteriën 
op de aanmaak en structuur van Muc2. IL-10 is een eiwit dat het lichaam aanmaakt 
om ontstekingsreacties te dempen. IL10-/- muizen krijgen een ontsteking in de darm 
als ze aan (normale, niet-schadelijke) bacteriën worden blootgesteld. Deze IL-10-/- 
muizen vertoonden echter onder kiemvrije omstandigheden geen biochemische of 
histologische kenmerken van ontstekingsreacties in de darm. We zagen dat nog vóór 
het inbrengen van bacteriën en dus vóór het mogelijke ontstaan van een ontsteking, 
de hoeveelheid Muc2 die in de darm van de IL10-/- muizen werd aangemaakt lager 
was dan bij ’gewone’ wild-type (WT) controlemuizen. De ontsteking bij de IL10-/- 
muizen na de introductie van darmbacteriën, kenmerkte zich door verdikking van het 
darmslijmvlies, een groter aantal zich delende cellen in de crypten en meer celdood 
bij de oppervlaktecellen van de darm. Met het verloop van de ontsteking van mild 
naar ernstig, was er ook een verandering in de structuur c.q. opbouw van Muc2 
te zien. Door deze kwantitatieve en structurele veranderingen van Muc2 bij IL10-/- 
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muizen waren de epitheelcellen van de darm minder goed in staat zich tegen (niet-
schadelijke) bacteriën te beschermen. Het resultaat is een mogelijke verhoogde 
gevoeligheid voor colitis. 
De rol van Muc2 bij de bescherming van de darm werd verder uitgediept in 
Hoofdstuk 3. Na karakterisering van de dikke darm van Muc2-deficiënte (Muc2-/-) 
muizen (deze muizen maken geen Muc2 aan) kregen ze dextraan sulfaat sodium 
toegediend, een stof die colitis veroorzaakt . Dit werd ook gedaan bij Muc2 
heterozygote muizen (deze hebben één gen van het Muc2 in plaats van twee) en 
WT muizen. Het tekort/gebrek aan Muc2 in de darm van deze muizen veroorzaakt, 
zelfs onder normale omstandigheden, verdikking van het darmslijmvlies, een groter 
aantal zich delende cellen, verandering in de differentiatie van epitheel- en goblet-
cellen, en schade aan de epitheelcellen in de dikke darm. De proef met dextraan-
sulfaat sodium toonde aan dat de Muc2-/- en de Muc2 heterozygote muizen, die een 
gebrek of een tekort hadden aan Muc2 in de darm, gevoeliger waren voor colitis dan 
de WT muizen. Deze proeven bewijzen dat veranderingen in de samenstelling van 
de mucuslaag als gevolg van minder of géén Muc2, leiden tot een ontsteking van de 
dikke darm. Ook lieten ze zien dat te weinig of géén Muc2 kan bijdragen tot inductie 
en verergering van een chronische vorm van ontsteking. 
In de wetenschap dat de ernst van chronische ontstekingen van de dikke darm 
samenhangt met omgevingsfactoren (o.a. bacteriën), maar ook met eigenschappen 
van het epitheel (epitheliale factoren) en het afweersysteem, deden we onderzoek 
naar de beschermende capaciteiten van Muc2 en IL10 in de darm. Speciaal hiervoor 
werden Muc2/IL10 dubbel knock-out muizen (Muc2/IL10DKO) gefokt. Bij deze muizen 
keken we of een combinatie van defecten in het afweersysteem en epitheliale 
factoren, het ziekteverloop van de ontsteking zou kunnen verergeren. Om inzicht te 
krijgen in de beschermende capaciteiten van Muc2 en IL10 in de darm, vergeleken 
we de klinische symptomen en darmpathologie van de Muc2/IL10DKO muis met die 
van Muc2-/- en IL10-/- muizen (Hoofdstuk 4). Microscopische analyse van de dikke 
darm van de Muc2-/- muis liet een abnormale vorm en structuur zien. We zagen 
een verdikking van het darmslijmvlies, afplatting en verzwering van epitheelcellen, 
algeheel verlies van structuur, een groter aantal cellen die betrokken zijn bij 
ontsteking, meer celdeling en minder celdifferentiatie, zoals beschreven in hoofdstuk 
3. Deze afwijkingen waren nog sterker bij Muc2IL10DKO muizen van dezelfde leeftijd. 
Dit wijst er op dat afwezigheid van Muc2 in combinatie met veranderingen in het 
afweermechanismen, bijvoorbeeld gebrek aan IL10, leidt tot een buitensporige, 
oncontroleerbare ontsteking van de dikke darm, uiteindelijk leidend tot de dood 
van het dier. Deze studie geeft aan dat de mucuslaag in de darm, meer specifiek 
de mucine Muc2, een kernrol speelt in de bescherming van de darm, en dat de 
mucusbarrière waarschijnlijk één van de belangrijkste factoren is voor het ontstaan 
van colitis. 
Een andere hypothese over Muc2 luidt als volgt: Muc2 draagt bij tot de 
bescherming van darmcellen tegen bijvoorbeeld de schadelijke gevolgen van 
chemotherapie (mucositis). Deze hypothese is gebaseerd op een eerdere studie 
die aantoonde dat methotrexaat (MTX) de Muc2 eiwitexpressie significant verhoogt. 
Om deze hypothese te kunnen bewijzen, werden Muc2-/- muizen behandeld met 
MTX. Zoals beschreven in Hoofdstuk 5, bleek uit histologische en biochemische 
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analyse van de dunne darm dat de Muc2-/- muizen niet gevoeliger waren voor 
behandeling met MTX. Afwezigheid van Muc2 kan bij Muc2-/- muizen kan leiden 
tot een continue blootstelling aan bacteriën in de darmholte, wat de productie van 
cytokines – boodschapperstoffen van het afweersysteem –   uit balans kan brengen. 
De ontstekingsremmende cytokine IL-10 vertoont beschermende eigenschappen in 
de darm. Verschillende studies hebben aangetoond dat IL10-/- muizen gevoeliger 
zijn voor de ontwikkeling van chronische ontstekingen (hoofdstuk 2). De Koning et 
al., toonden ook aan dat IL10-/- muizen na behandeling met MTX een zwaardere 
vorm van mucositis ontwikkelen dan WT muizen. Dit bewijst dat IL-10 de darm tegen 
MTX-geïnduceerde schade beschermt. In Muc2-/- muizen was IL-10 verhoogd nog 
vóór behandeling met MTX. Dit geeft een verklaring waarom deze muizen geen 
verhoogde chemotherapie-geïnduceerde mucositis vertoonden. 
De bovenstaand beschreven studies bevestigen het belang van een gezonde 
mucuslaag. Bovendien is een perfecte conditie van de mucuslaag ook afhankelijk 
van de beschikbaarheid van voedingsstoffen, zoals eiwitten, vetten, koolhydraten en 
essentiële aminozuren in de darm. Ondervoeding (zowel kwalitatief als kwantitatief) 
verlaagt de mucineproductie in de darm, en tast hiermee de mucuslaag aan. Verder 
is aangetoond dat te weinig threonine, een essentieel aminozuur, in de voeding 
de mucineproductie in de darm vermindert. Onze hypothese is dat de hoge vraag 
naar threonine van de darm uit de voeding, zoals beschreven in Schaart et al., 
waarschijnlijk te wijten is aan het feit dat threonine wordt gebruikt voor de opbouw 
van secretorische mucines, voornamelijk Muc2. Daarom werd in Hoofdstuk 6 de 
betrokkenheid van mucines bij het metabolisme van de darm onderzocht. Er kon 
inderdaad aangetoond worden dat veel threonine uit de voeding in de darm in Muc2 
wordt opgenomen. Als er geen Muc2 aanwezig is wordt het vooral gebruikt voor de 
onderhoudseiwitsynthese of als substraat voor oxidatie. 
Samengevat laat het eerste deel van dit proefschrift zien dat kwantitatieve en 
structurele veranderingen in Muc2 in de darm uitwerking heeft op de celdeling en 
differentiatie, met als gevolg ontsteking. Dit bewijst dat Muc2 een kernrol speelt in de 
beschermende mucuslaag van de darm. 
Regulatie van mucine-genexpressie
De aanmaak van alle eiwitten geschiedt d.m.v. transcriptie (dit gebeurt in 
de celkern: aanmaak van RNA complementair aan één van de DNA-strengen) en 
translatie (vertaling van RNA codes tot specifieke ketens aminozuren, de voorlopers 
van eiwitten). De promotor is dat deel van het gen dat de werking (expressie) van het 
gen reguleert. De transcriptie van mucine-genen wordt aangestuurd door complexe 
regelmechanismen, onder invloed van ontwikkelings- en signaalafhankelijke 
transcriptiefactoren. Deze factoren binden aan de promotor-regio van het gen. 
Muc2 wordt al vroeg tijdens de embryonale ontwikkeling van de darm tot expressie 
gebracht. Dit suggereert dat de Muc2-transcriptie beïnvloed wordt door bepaalde 
transcriptiefactoren die verantwoordelijk zijn voor de ontwikkeling en celdifferentiatie 
van de darm. In overeenstemming met deze hypothese werd in eerdere 
onderzoeken gevonden dat het Muc2 mucine–gen bij de mens wordt gereguleerd 
door Cdx1 en Cdx2 transcriptiefactoren. Deze Cdx-factoren zijn beide betrokken bij 
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de celdifferentiatie van de darm. Na mogelijke bindingsplaatsen voor GATA- en HNF-
factoren op de Muc2-promotor te hebben gevonden en na gezien te hebben dat Muc2 
en deze factoren slechts beperkt tot uiting komen in de crypte-villus as van de darm, 
onderzochten we de regulering van de Muc2 promotor door GATA-4/-5/-6, HNF-3α 
en HNF-3β transcriptiefactoren bij de muis. Zoals beschreven in Hoofdstuk 7, was 
GATA-4 aanwezig in de kernen van de goblet-cellen in de dunne darm. Bovendien 
werden er vier GATA-4 cis-elementen geïdentificeerd in de promotor. Een 
overexpressie van GATA-4 in cellijnen leidde tot activatie van de Muc2–promotor. Dit 
werd echter ongedaan gemaakt wanneer de bindingsplaatsen gemuteerd werden of 
wanneer een gemuteerde vorm van GATA-4 gebruikt werd. Ook kon overexpressie 
van GATA-5 en GATA-6 leiden tot activiteit van de Muc2-promotor. Deze resultaten 
tonen aan dat GATA-factoren belangrijke en krachtige activatoren zijn van de Muc2-
expressie in de darm. 
Vervolgens werd in Hoofdstuk 8 de rol van HNF-3α en -3β factoren op de Muc2-
regulatie bestudeerd. HNF-3α en 3β factoren werden gelokaliseerd in goblet-cellen, 
die Muc2 tot expressie brengen, vroeg in de ontwikkeling van de darm (embryonale 
dag 17.5). Bovendien werd aangetoond dat de beide transcriptiefactoren Muc2-
transcriptie reguleren en zich kunnen binden aan de Muc2-promotor. Het blijkt dus dat 
Muc2 eveneens een doelwit is van HNF-3α en 3β, en dat  deze transcriptiefactoren 
een belangrijke rol spelen bij de Muc2-expressie in de zich ontwikkelende darm 
tijdens goblet-cel differentiatie. Ook werd aangetoond dat de mucine-gentranscriptie 
onder invloed staat van een breed spectrum van cytokines. Analyse van de 
Muc5ac-promotor liet een hoge dichtheid van bindingplaatsen zien voor factoren 
die essentieel zijn voor de signalering van Transforming Growth Factor-β (TGF-β). 
TGF-β behoort tot een superfamilie van cytokines die  diverse celtypes aangrijpt 
en een scala aan celspecifieke biologische effecten reguleert, zoals differentiatie, 
migratie, tijdelijk stopzetten van de celdeling, adhesie, extracellulaire-matrixproductie 
en celdood. Ook is TGF-β betrokken bij gastritis (ontsteking van het maagslijmvlies) 
en de ontwikkeling van maagkanker, twee ziektebeelden die ook een veranderde 
Muc5AC expressie laten zien. Deze bevindingen leidden tot een onderzoek naar de 
regulering van Muc5ac door TGF-β, zoals beschreven in Hoofdstuk 9. De resultaten 
toonden aan dat het Muc5ac-gen een doelwit is van TGF-β. Bovendien lijkt het 
aannemelijk dat de signaleringsroute, geïnduceerd door TGF-β, niet alleen een 
complexe formatie is van Smad4 en Smad2 of van Smad4 en Smad3. Los van het 
activeren van Smad-factoren, staat TGF-β ook bekend om het kunnen activeren van 
Sp1-afhankelijke transcriptie. De bevindingen in hoofdstuk 9 duiden op de werking 
een positief regelmechanisme tussen Smad4 en Sp1 dat de TGF-β-gemedieerde 
verhoging van Muc5ac expressie in kankercellen zou kunnen verklaren. 
Samenvattend, we hebben aangetoond dat Muc2 gereguleerd wordt door 
transcriptiefactoren, in het bijzonder GATA en HNF3, die betrokken zijn bij de 
ontwikkeling en celdifferentiatie van de darm. Bovendien werd aangetoond dat 
TGF-β de transcriptie van het secretoire mucine-gen Muc5ac, kan verhogen in 
kankercellijnen. Dit suggereert dat de mucine-genexpressie hoogstwaarschijnlijk 
onder invloed staat van de homeostase-status van de darm. De onderzochte 
signaalroutes zijn echter niet exclusief en andere routes moeten in de toekomst nog 
verder uitgediept worden. 
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Algemene toekomstperspectieven
De bevindingen in dit proefschrift laten een duidelijke kernrol zien voor Muc2 
bij de handhaving van de homeostase in de darm. Een volgende belangrijke stap 
zou het ontrafelen van het mechanisme achter de ontwikkeling van de ontsteking 
in de afwezigheid van Muc2 zijn. Signaal-profielstudies zouden kunnen dienen om 
moleculen te identificeren die i) ontstekingen initiëren en verergeren, ii) epitheliale 
proliferatie reguleren en iii) epitheliale differentiatie reguleren. Bovendien zouden 
er nieuwe onderzoekstechnieken ingezet kunnen worden. Te denken valt aan 
kiemvrije en gnotobiotische technologie, waarbij dieren gebruikt worden die specifiek 
gekoloniseerd zijn met, voor de onderzoeker bekende, één of meer bacteriestammen, 
functionele genomics en kwantitatieve PCR (polymerase chain reaction). Door deze 
gecombineerd toe te passen kunnen we Muc2-/- en WT muismodellen gebruiken 
om na te gaan wat de impact is van de microbiële populatie op de celhomeostase, 
de genexpressie en vervolgens de barrièrefunctie van de darm. Tevens kunnen we 
dan inzicht krijgen in de rol van pre- en probiotica bij de bescherming van de darm, 
en meer specifiek de productie van mucine. Al met al zou de informatie die dan 
beschikbaar komt over microben, genen en signaleringsroutes die betrokken zijn bij 
ontstekingen van de darm, kunnen leiden tot nieuwe behandelmethoden. 
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Chapter 2 Figure 3. Histochemistry of BALB/c and IL10-/- proximal colon. Tissue sections were 
prepared from the proximal colon of BALB/c and IL10-/- mice in germ-free (GF) conditions and at 7 
days after the introduction of SPF normal enteric bacteria (Bacteria). The tissue sections were stained 
histochemically with hematoxylin and eosin (Panels A-D), AB/PAS (Panels E-H), or HID/AB (Panels 
I-L). The arrows in Panels E-G indicate PAS-positive goblet cells in the upper half of the crypts. The 
arrowheads in Panels I-K indicate HID-positive goblet cells in the upper half of the crypts. Sections 
were stained immunohistochemically for the presence of Muc2 protein, using a polyclonal anti-murine 
Muc2 antiserum (Panels M-P). All micrographs were recorded at the identical magnification of 200x.
Chapter 3 Figure 4. Protein 
expression in the distal colon. 
Goblet cells were stained for (A 
and B) Muc2 and (C and D) Tff3. 
As an enterocyte marker villin was 
used (E and F). A, C, and E, are 
sections representing tissue from 
the distal colon of WT animals and 
B, D, and F, represent tissue from 
the distal colon of Muc2-/- animals, 
respectively. Inserts in C and D 
show a close-up of a goblet cell in 
WT and Muc2-/- mice, respectively. 
Insert in E shows a close-up of 
normal villin expression by WT 
enterocytes. F shows loss and 
redistribution (arrow heads) of 
villin expression by the epithelial 
cells of Muc2-/- mice.
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Chapter 3 Figure 7. Effects of DSS treatment on disease activity score (DAI) and histology. (A) 
Relative changes in the DAI of WT (black bars), Muc2+/- (stippled bars) and Muc2-/- (white bars) DSS-
treated mice. To be able to calculate percentage weight loss, WT, Muc2+/- and Muc2-/- animals were 
compared to their individual body weight prior to the DSS-administration. Error bars reflect the SEM 
of the changes of the DAI score on each day. Days of DSS/water treatment are indicated as arrows 
under the x-axis. (DAI Muc2-/- vs. WT  #P<.001 all time points; DAI Muc2-/- vs. Muc2+/- P<.001 up to day 
6, aP<.01 day 7 and bP<.05 day 8; DAI WT vs. Muc 2+/- day 7 and 8 P<.05) (B) Histology scores as 
determined according to Rath el al 21 determined for WT vs. Muc2+/- mice (aP<.001,  *P<.05). Error bars 
reflect the SEM. (C) Representative sections of the distal colon on day 2 and day 8 after the start of 
the DSS-administration of WT, Muc2+/- and Muc2-/- mice.
Color Plates 221
Chapter 4 Figure 2. Colonic morphology the WT and Muc2/IL10DKO mice. Representative sections 
of the colon are depicted at 5 weeks of age (A-C; proximal colon, D-H; distal colon). A-B; E-F represent 
H&E stainings whereas C-D; G-H represent AB-PAS stainings. A and C, and E and G represent 
proximal colon and distal colon, respectively of the WT mice. B and D, and F and H represent proximal 
colon and distal colon, respectively of the WT  mice.  The insert in H shows a close-up of goblet cells in 
the crypts of Muc2/IL10DKO mice. The asterisks represents a lower magnification of the distal colon.
Chapter 4 Figure 4. Tff3 expression in colon. 
Tff3 was expressed by goblet cells in the 
proximal colon of (A) WT mice, but was virtually 
absent in the proximal colon of (B) Muc2/IL10DKO 
mice. In the distal colon, Tff3 was present in 
the goblet cells of (C) WT mice, but in larger 
numbers compared to the goblet cells of the (D) 
Muc2/IL10DKO mice. 
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222 Chapter 5 Figure 4. MTX-induced changes in the small intestine in WT and Muc2-/- mice. 
Morphology of the jejunum of WT (A,C,E,G) and Muc2-/- (B,D,F) mice on days 2 (A-B), 3 (C-D), 4 (E-
F) and 6 (G) after MTX-treatment. On day 2, morphology of WT and Muc2-/- mice was mildly affected 
and characterized by mild crypt loss and epithelial flattening. On days 3 and 4, intestinal damage was 
more severe, showing increased crypt loss on day 3 and epithelial flattening and villus atrophy on 
days 3 and 4. Crypt regeneration was seen on day 4, but was more pronounced in the Muc2-/- mice 
compared to WT mice. On day 6, the intestinal morphology of the WT mice had started to regenerate 
as evidenced by higher numbers of well-formed crypts and villi. (H)Crypt and (I) villus lengths of WT 
and Muc2-/- littermates before and after MTX-treatment. Both groups showed significant villus atrophy 
and crypt elongation after MTX-treatment. Significant differences were seen on day 2; Muc2-/- mice 
showed more villus atrophy, but less elongation of crypt length compared to WT mice. On day 3, villus 
atrophy was comparable in both groups, but still minimal differences were seen in crypt length. In the 
regenerative phase, day 6, WT mice showed an increase in villus and crypt length compared to control 
littermates. Bars are expressed in Mean ± SEM.
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Chapter 7 Figure 1. Expression of GATA-
4 transcription factor in mouse small 
intestine by immuno-histochemistry. Alcian 
blue staining was performed as described in 
the material and methods section. GATA-4 
immunostaining was carried out on the same 
section of mid jejunum of an adult mice using 
a specific antibody for GATA-4. Sections were 
counterstained with haematoxylin. Inset : close-
up of one GATA-4 expressing goblet cell.
Chapter 8 Figure 1.  Spatio-temporal 
expression of HNF-3α and HNF-3β in the 
mouse small intestine. HNF-3β expression 
was observed in (A) the pseudostratified 
epithelium at E15.5, and in the intervillus cells 
and goblet cells along the villi at (B) E17.5. 
HNF-3α and -3β staining, respectively of (C-
D) E18.5 (E-F) P1.5 and (G-H) adult small 
intestine. Inserts of G and H show a close-up 
of a goblet cell stained with HNF-3α and -3β, 
respectively and counterstained with Alcian 
Blue. Magnification in A-D and E-H are equal, 
respectively, bar representing 75µm.

